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In a nutshell:
Prevention of cardiovascular disease (CVD) comprises one of the biggest healthcare 
challenges in modern Western society (1). Tremendous efforts have been made to 
discover new risk markers beyond the well-known traditional Framingham risk factors in 
order to identify individuals at high risk of a future occurrence of a CVD event (2). Perhaps 
even greater efforts have been made to evaluate drug treatment therapies to prevent 
CVD events in such individuals (3-6). Both at the population level (i.e. is a preventive 
intervention beneficial to a group of individuals, against acceptable costs for society?), 
and at the individual level (for which specific individual can we expect a preventive 
intervention to be beneficial?), decision modelling can provide significant insights into 
these complex decision problems, when trial-based evidence is either lacking, takes too 
much time or is infeasible. 
To elaborate on that:
Approximately one out of every three deaths is attributable to cardiovascular disease 
which makes it the number 1 cause of death throughout the world (1). WHO statistics 
revealed that CVD killed 17.5 million people in 2012 -of these, 7.4 million died of 
ischaemic heart disease, the remaining 6.7 million died of stroke (7). A number of 
-commonly well known, modifiable physiological and behavioural risk factors -such as 
high blood pressure, increased levels of cholesterol and smoking, have been identified 
and it has been established that they play a causal role in the aetiology of the disease 
(8). Targeting individuals by using these risk factors and preferentially modifying them in 
individuals with unfavourable levels of these factors, can reduce the future risk of CVD 
within these individuals, even if they do not have overt symptoms of the disease yet or 
have ever experienced a CVD event before.
In general, prevention can be achieved by either shifting the distribution of a modifiable 
risk factor for a population as a whole or targeting and treating the individuals with 
the highest levels of the risk factor -as described by Geoffrey Rose (9). As efficacious 
and efficient some population based strategies sometimes may seem -exemplified by 
the projected reduction in deaths attributable to CVD by reducing the daily intake of 
salt (10), their effectiveness sometimes fades in the face of implementation in reality (11). 
Correspondingly, most guidelines on prevention of CVD in Western societies incorporate 
some form of an individualized risk-based approach (12-16). As an elaborate example, 
initiation of statins is currently recommended if the future risk of CVD surpasses the 
(rather arbitrarily picked) threshold of 7.5% within 10 years. Below that level, initiation 
of statins is only recommended if the level of low density lipoprotein cholesterol (LDL) is 
exceedingly high. In the case of statins, most side effects are considered fairly mild, and 
serious side effects rare (17). Considering aspirin, however, there is a clear trade-off. On 
the one hand it reduces the risk of future heart disease and ischemic stroke, while at the 
same time it increases the risk of a -possibly fatal, episode of major bleeding (18). In this 
case, a precise and correct estimate of the net benefit of the preventive intervention in 
an individual-weighing both the potential gain in life expectancy due to a lower risk of 
heart disease and ischemic stroke, and the potential decrease in life expectancy due to 
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higher risk of major bleeding, is of utmost importance. The main determinant of this net 
benefit is the risk of the CVD event one tries to prevent. For years, the Framingham risk 
factors -calendar age, smoking status, total cholesterol level, systolic blood pressure, 
use of anti-hypertensive medication and diabetes mellitus status, have been used to 
estimate the risk of a future CVD event (2, 19-21) and are incorporated in risk scores used in 
guidelines as mentioned before. These risk factors are well established, used worldwide 
and are relatively easy and inexpensive to obtain. 
During the last decades, ‘novel’ or ‘non-traditional’ markers of future cardiovascular risk 
have become available, and allow for detection of subclinical atherosclerotic disease or 
provide measures of general systemic inflammation. These novel risk markers have been 
shown to improve the prediction of future CVD risk beyond the traditional Framingham 
risk factor based scores (3). It has even been shown that -dependent on the distribution 
of the novel risk marker and the concordant distribution in traditional risk factors within 
a certain population, the estimated future risk of CVD within individuals changes based 
on the additional information in the novel risk marker, to the extent that a number of 
these individuals will now surpass a risk-based threshold used in prevention guidelines 
as mentioned before, compared to the ‘old’ or ‘current’ situation in which only the 
traditional risk factors were used. Improved classification of an individual’s future CVD 
risk suggests that -by using the novel marker, we would be better able to estimate 
an individual’s net benefit of initiating preventive treatment, and by doing so more 
adequately inform a patient about whether or not to initiate therapy based on his or her 
unique characteristics. But the improvement in (correct) classification due to a novel risk 
marker in itself is not sufficient to prove that we actually should use it (22). Some of the 
novel risk markers are costly or bear harms in itself, i.e. due to an associated radiation 
induced increased risk of future cancer as a result of the technical modality used to 
obtain the result of a novel risk marker. The challenge at hand is to evaluate the impact of 
using novel risk markers, from the perspective of a decision maker. The latter can be the 
government of a country, which has to decide if it should implement a novel risk marker 
as a screening instrument in order to prevent CVD in its population. It’s not enough to 
project the number of CVD events avoided, as by lowering the risk for a single cause of 
death, another ‘competing’ cause of death is given the opportunity to take its place (23). 
Some events will cause a chronic state with reduction in quality of life, some events will 
induce lifelong substantial increases in medical expenditures. All of these aspects have 
to be evaluated simultaneously in order to correctly inform a decision maker. 
The one facing the decision can also be an individual sitting in front of a practitioner’s 
desk, who may not be interested in novel risk markers, but wants to know what he or 
she is expected to gain from the (currently, traditional risk factor based) recommended 
initiation and continuation of taking medication such as statins daily for the rest of his 
or her life. If a patient brings his own preferences and characteristics into the equation, 
it may not be sufficient to inform the individual patient’s decision on averaged, 
population-level results. 
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Ideally, clinical trials would inform us about the optimal decision in both cases. But -in 
an attempt to address the value of novel risk markers at the population-level decision, 
trials typically cover a relatively short period of follow up and include a limited number 
of trial arms, due to feasibility issues. For the decision at the individual level, the number 
of possible combinations of an individual patient’s characteristics and preferences will 
be limitless, and therefore impossible to evaluate in a trial setting. By synthesizing all 
available information on all relevant parameters -including distributions of traditional 
and novel risk markers and their correlations within a population, treatment effects of 
cardio-protective medication, risks of competing events, and by extrapolating short 
term results, decision modelling can overcome the boundaries of trial-based studies. 
In this thesis, strategies for the primary prevention of cardiovascular disease, based on 
risk assessment and early detection of subclinical cardiovascular disease, were evaluated 
by such decision models. 
In order to adequately synthesize evidence and evaluate interventions based on 
cardiovascular risk assessment, we studied 1) the (individualized) underlying truth 
in decision models, based on long-term CVD risk predictions and their improvement 
using novel risk markers; 2) the validity of and critical assumptions underlying decision 
models and their relation to the outcome of such models and finally; 3) the comparative 
effectiveness and cost-effectiveness of guiding preventive (medical) treatment based 
on risk-stratification using both established risk scores and novel risk markers.
More specifically, in chapter 2, the comparative effectiveness and cost-effectiveness 
of computed tomography screening for coronary artery calcium -one of the promising 
novel risk markers for CVD, was studied using a population level decision model based 
on Rotterdam Study data (24). Chapter 3 addressed the validity of a previously developed 
individual level simulation model to investigate the effects of modifying cardiovascular 
disease risk factors on the burden of CVD: the Rotterdam Ischemic heart disease and 
Stroke (RISC) model (25). In chapter 4, we evaluated the influence of using different 
methods of modelling statin treatment effectiveness on the outcomes of a decision 
model. In chapter 5, we used the RISC model to predict personalized lifetime benefits of 
statin therapy in asymptomatic individuals. In Chapter 6 we analysed the performance 
of long-term Framingham cardiovascular disease predictions (21) in the Rotterdam 
Study, taking into account competing risks and the additional disentangling of CVD 
into coronary heart disease and stroke separately. Using similar methodology, Chapter 
7 studied the separate prediction of intracerebral hemorrhage and ischemic stroke – 
again taking into account competing risks. 
Focussing on the United States general population using data from the National Health 
and Nutrition Examination Survey (NHANES) -a cross-sectional study designed to 
be a representative sample of the U.S. general population, Chapter 8 dealt with the 
evaluation of the added predictive value of four novel risk markers of CVD beyond the 
Framingham based risk scores, using a new micro-simulation model. In Chapter 9 this 
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model was extended to compare the cost-effectiveness of these four novel risk markers 
for screening asymptomatic individuals in the U.S. population. Chapter 10 evaluated 
the trade-off between future CVD risk and the disutility of lifelong daily medication in 
the comparative effectiveness and cost-effectiveness of initiating statin therapy for the 
primary prevention of CVD events. Finally, in Chapter 10 the main findings of this thesis 
were summarized. We additionally discussed the methodological issues that have been 
raised in these research projects and provided future perspectives for further research. 
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AbstRACt 
Objectives: The aim of this study was to assess the (cost-) effectiveness of screening 
asymptomatic individuals at intermediate risk of coronary heart disease (CHD) for 
coronary artery calcium with computed tomography (CT).
Background: Coronary artery calcium on CT improves prediction of CHD.
Methods: A Markov model was developed on the basis of the Rotterdam Study. Four 
strategies were evaluated: 1) current practice; 2) current prevention guidelines for 
cardiovascular disease; 3) CT screening for coronary calcium; and 4) statin therapy for all 
individuals. Asymptomatic individuals at intermediate risk of CHD were simulated over 
their remaining lifetime. Quality-adjusted life years (QALYs), costs, and incremental cost-
effectiveness ratios were calculated.
Results: In men, CT screening was more effective and more costly than the other 
3 strategies (CT vs. current practice: 0.13 QALY [95% confidence interval (CI): 0.01 to 
0.26], $4,676 [95%CI: $3,126 to $6,339]; CT vs. statin therapy: 0.04 QALY [95%CI : 0.02 
to 0.13], $1,951 [95%CI : $1,170 to $2,754]; and CT vs. current guidelines: 0.02 QALY 
[95%CI: 0.04 to 0.09], $44 [95%CI: $441to$486]).The incremental cost-effectiveness 
ratio of CT calcium screening was $48,800/QALY gained. In women, CT screening was 
more effective and more costly than current practice (0.13 QALY [95%CI: 0.02 to 0.28], 
$4,663 [95%CI: $3,120 to $6,277]) and statin therapy (0.03 QALY [95%CI: 0.03 to 0.12], 
$2,273 [95%CI: $1,475 to $3,109]). However, implementing current guidelines was 
more effective compared with CT screening (0.02 QALY [95%CI: 0.03 to 0.07]), only a 
little more expensive ($297 [95%CI: $8 to $633]), and had a lower cost per additional 
QALY ($33,072/QALY vs. $35,869/QALY). Sensitivity analysis demonstrated robustness 
of results in women but considerable uncertainty in men.
Conclusions: Screening for coronary artery calcium with CT in individuals at intermediate 
risk of CHD is probably cost-effective in men but is unlikely to be cost-effective in women. 
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IntRoduCtIon
In asymptomatic individuals, primary prevention of coronary heart disease (CHD) is 
often based on the predicted 10-year risk of a CHD event. The Framingham risk factors 
are widely adopted for this purpose (1-2). Guidelines on cardiovascular disease (CVD) 
prevention recommend advice on a healthy lifestyle (e.g. smoking cessation, regular 
physical activity)) for individuals with a low CHD risk (<10%, 10-year risk) supplemented 
by statins, anti-hypertensives, and sometimes aspirin for individuals at high CHD 
risk (>20%, 10-year risk) (3-5). In individuals at intermediate risk (10-20%, 10-year risk) 
the decision to treat with drugs is generally only recommended when either serum 
cholesterol or blood pressure levels are above a defined threshold. In this group, 
performing a non-invasive test may be able to identify those who could benefit from 
more aggressive treatment. Coronary artery calcium on computed tomography (CT), 
quantified by the CT coronary calcium score, is such a test (6-7). 
Recent studies have demonstrated that the CT calcium score is a strong predictor of 
CHD risk, independent of the Framingham risk factors (7-16). In fact, more than half of 
the individuals originally classified at intermediate risk, based on the Framingham risk 
factors, are reclassified to the high (>20%) or low (<10%) risk category when the calcium 
score is taken into account (7,17). Accordingly, these individuals should be treated more 
aggressively (high risk) or less aggressively (low risk). The reclassification to another 
risk category suggests that using CT may be beneficial but reclassification by itself 
is insufficient evidence to justify implementation (18-19). Studies, ideally clinical trials, 
demonstrating comparative effectiveness and cost-effectiveness are necessary.
In the absence of clinical trials showing the benefit of CT screening, an extensive 
evaluation of CT coronary calcium scoring using observational data is warranted (20). 
The objective of this study was to assess the comparative effectiveness and cost-
effectiveness of screening an asymptomatic elderly population at intermediate risk for 
CHD for coronary calcium with CT.
Methods 
We developed a Markov decision model using TreeAge for Health Care (TreeAge Pro 2009 
– TreeAge Software Williamstown MA) to analyze relevant strategies in asymptomatic 
elderly individuals at intermediate risk for CHD. The model structure, model parameters, 
and data sources are briefly described here. Details of the modeling assumptions and 
parameter estimation are given in a technical appendix. 
501599-L-bw-van Kempen
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Model structure
The following four strategies were considered (Figure 1):
Stayed in 
Intermediate Risk
– statin if LDL >160 mg/dl (4.14 mmol/l)
– anti-hypertensives if SBP >140 mmHg  
CT Coronary 
calcium 
Screening 
– statin if LDL >130 mg/dl (3.37 mmol/l)
– anti-hypertensives if SBP >140 mmHg  
– statin in all
– anti-hypertensives in all
– aspirin if men
Current 
Guidelines No additional intervention modeled 
Current 
Practice
– statin if LDL >130 mg/dl (3.37 mmol/l)
– anti-hypertensives if SBP >140 mmHg  
 – statin in all
– no further intervention modeled
  Statin therapy
Reclassied to
Low Risk
Reclassied to
High Risk
Decision for an individual at
intermediate risk for CHD
Figure 1. Schematic representation of the four alternative strategies for an individual at intermediate 
risk for CHD
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(1) ‘Current practice’. This strategy reflects the incidence of CHD and non-CHD events 
of individuals at intermediate risk without any additional preventive intervention, 
as observed in the Rotterdam Study and is used as the reference strategy. Some 
individuals were treated at baseline with statins, anti hypertensive medication or 
aspirin by their general practitioners, which is considered to be reflected in the 
observed incidence of CHD and stroke, 
(2) ‘Current guidelines’. This strategy, based on fully implementing the most recent 
guidelines on primary prevention of CHD for individuals at intermediate risk 
for CHD, implies giving lifestyle advice to all, statin therapy when baseline low 
density lipoprotein (LDL) cholesterol exceeds 130 mg/dL (3.37 mmol/l) (4), and 
anti-hypertensive medication when baseline systolic blood pressure exceeds 140 
mmHg (5). In a sensitivity analysis, we lowered the LDL threshold to 100 mg/dL (2.59 
mmol/L) 
(3) ‘CT calcium screening’. In this strategy a CT scan was performed to determine the 
coronary calcium score and the 10-year CHD risk was recalculated based on the 
Framingham risk factors and the calcium score combined. Consequently, a number 
of individuals will be reclassified to the high risk or low risk category. Individuals 
reclassified to the low risk category received life style advice and pharmacological 
treatment if systolic blood pressure was above 140 mm Hg (21) and/or plasma 
LDL levels were >160 mg/dL (4.14 mmol/l) (4). Individuals who remained in the 
intermediate risk category were treated as recommended for individuals at 
intermediate risk, similar to strategy 2. Individuals reclassified to the high risk 
group received lifestyle advice, statin therapy, and anti-hypertensive medication, 
irrespective of their baseline cholesterol and blood pressure levels. In addition, 
men received low dose aspirin (80-100 mg daily). For both the current guidelines 
and CT calcium screening strategy, we assumed that individuals who used any of 
the three drugs at baseline, would continue to use them.
(4) ‘Statin therapy’. For this strategy we assumed that everyone not currently on a 
statin would receive a moderate dose statin and was otherwise managed according 
to ‘current practice’. Although initiating statins in all individuals is not always 
considered feasible in all situations, it puts the CT calcium screening strategy into 
a broader perspective, between the least aggressive strategy (‘current practice’) 
and fairly aggressive strategy (‘statin therapy’), providing a range of possibilities 
for an individual at intermediate risk of CHD (20). Conceptually, an even more 
aggressive strategy would be to treat everyone not only with statins, but also with 
anti-hypertensives and aspirin (in men). In a sensitivity analysis we substituted the 
statin therapy strategy with this ‘aggressive medical treatment’ strategy.
For each of the four strategies, the model kept track of quality of life, costs and time 
spent in one of the following health states: (a) well; (b) post CHD event; (c) post-major 
bleeding; (d) post stroke event; (e) post stroke event & CHD event; (f ) post stroke & 
major bleeding ; (g) post CHD event & major bleeding; (h) post CHD event & stroke event 
& major bleeding (i) CHD or stroke death; and (j) non-CHD or non-stroke death. Each 
simulated individual started out in the ‘well’ state. Age- and gender-specific probabilities 
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of non-CHD death, fatal- and non-fatal MI, fatal- and non-fatal major bleeding due to 
aspirin use, fatal and non-fatal stroke and lethal cancer due to radiation, determined 
the transition to the other states during each annual cycle. The time horizon was the 
remaining lifetime of the simulated individuals. 
A CHD event was defined as any of the following outcomes: non-fatal myocardial 
infarction, coronary artery bypass graft, percutaneous coronary intervention, and CHD 
mortality. In sensitivity analysis we repeated the analysis using ‘hard’ CHD events as 
outcome, consisting of non-fatal myocardial infarction and CHD mortality. Stroke was 
defined as ischemic, hermorrhagic or undefined stroke on cerebral CT. Major bleeding 
due to aspirin therapy (defined as extra cranial hemorrhage leading to substantial 
disability) was modelled as a secondary event.
Following a CHD event, stroke event or a major bleeding episode, individuals moved 
to the ‘post-CHD-event’, ‘post stroke event’ or ‘post-major bleeding’ state, respectively, 
or the combined states if two or all three events occurred. Following a major bleeding 
episode, we assumed that aspirin therapy would be discontinued. In the case of a non-
fatal CHD or stroke individuals would be allocated medical treatment for secondary CVD 
prevention. Non-CHD deaths included fatal cancer due to radiation associated with CT 
scanning. 
Data sources
Effectiveness of treatment, cost data, and transition probabilities were retrieved from 
the literature and from primary data collection and summarized in table 1 with their 
data sources (17, 22-34).
Rotterdam Study and event rates 
From 1997 onwards, 2028 participants in the Rotterdam Study underwent CT to 
determine their coronary calcium score and were subsequently followed for 9.2 years 
(median) (12, 17, 35). Primary care physicians were blinded for the findings on CT. Inter- 
and intra-observer agreement on calcium scoring has been found to be excellent (36). 
Two regression models were developed to predict the 10-year risk of CHD based on 
the Framingham risk factors (prediction model 1) and based on Framingham plus the 
coronary calcium score (prediction model 2) (17). The Framingham risk factors included 
were: age, systolic blood pressure, anti-hypertensive medication, total and HDL-
cholesterol, diabetes and current smoking (4). More than 50% of the individuals classified 
as Framingham intermediate-risk were reclassified to either high- or low-risk when CT 
coronary calcium was added as risk factor and the C-statistic increased significantly from 
0.72 to 0.76 (17). The net improvement in reclassification was found to be 0.14 (P<0.01).
After excluding individuals who had a history of CHD or stroke prior to the CT coronary 
calcium scan, we used the baseline Rotterdam Study data and the two prediction models 
to: (1) determine the baseline characteristics of the target population, (2) determine 
the proportion of Framingham intermediate-risk individuals reclassified to low- and 
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high-risk when the coronary calcium score was added. Of all individuals reclassified to 
the low, intermediate or high risk category, we observed how many of them actually 
suffered from a CHD or stroke event using survival analysis stratified by sex (Table 1). 
Probabilities of having a non-CHD event were calculated on the basis of age-and sex-
specific mortality rates from national life tables of the general population (37). Life-
expectancy was adjusted for quality-of-life using mean health-related quality-of-life 
weights based on literature data (Table 1) (32). 
Effectiveness of treatment
The benefit of statin and anti-hypertensive treatment on CHD and stroke incidence was 
obtained from meta-analyses, and considered equal for men and women (24, 30). Based 
on a recent update, there is evidence that elderly men benefit from aspirin therapy in 
primary prevention of CHD. For elderly women there remains considerable controversy (3). 
Therefore, aspirin treatment for primary prevention was, when applicable, only modeled 
in men (38).
Treatment adherence is an important determinant of treatment benefit (39). While we 
used intention-to-treat-based relative risk reductions based on clinical trials, which 
take into account adherence, the adherence rate in a population-based intervention 
is less than that achieved in the controlled setting of a trial. Based on expert opinion, 
we assumed adherence to treatment in our population to be 70% of the adherence in 
the original trials for the reference case analysis and explored a range of 20 – 100% in a 
sensitivity analysis. 
For secondary prevention and primary prevention in high risk individuals, statins, anti-
hypertensive medication, and, in men, aspirin therapy are combined. Wald et al (40) 
estimated the effect of combining medication for CHD prevention but their approach 
does not account for possible synergy or dyssynergy between the drugs (41). Instead, 
we estimated the effect of combining drugs by multiplying the individual relative risks 
and multiplying the product by a synergy factor, which we varied in sensitivity analyses 
between 0.9 and 1.10, 0.9 implying synergy, 1.0 implying independent effects, and 1.10 
implying dyssynergy (see Technical Appendix for details). The range in the synergy 
factor was chosen such that a combination of drugs was at least as effective as a single 
component of the combination of the same drugs.
Since we considered a population at intermediate risk, we accounted for the fraction of 
individuals that used (a combination of ) statins, aspirin, or anti-hypertensive medication 
at baseline. An individual using statins at baseline, but with LDL cholesterol levels >160, 
>130 and >90 mg/dL for the low, intermediate and high risk category respectively, was 
assumed to switch to a higher dose or more potent statin. The same was assumed for an 
individual using anti-hypertensives at baseline and systolic blood pressure levels >140, 
>140, and >120 mm Hg for the three risk categories respectively. 
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We assumed that all individuals in the Rotterdam Coronary Calcium Study received 
lifestyle advice consistent with current primary care practice and that therefore the 
observed CHD and stroke event rates reflected this intervention.
Adverse Effects
Hemorrhagic stroke due to aspirin therapy was accounted for in the odds ratio’s of 
net treatment benefit for stroke from the meta-analysis. Extra cranial major bleeding 
due to aspirin therapy was modeled explicitly as a secondary event using probabilities 
based on a recent meta-analysis (23). Myopathy and hepatitis were modeled based on 
a meta analysis of the adverse effects of statins (42). Based on a recent modeling study 
by Pletcher et al (43), we calculated the expected costs and disutilities of a myopathy 
and hepatitis episode, including costs for associated complications such as hospital 
admission, workup and mortality, weighted by the probability of complications. 
Costs
Costs incorporated in the model included health-care costs and non-health-care costs 
and were assessed from the societal perspective for the U.S. (Table 1). All costs were 
converted to the year 2010 using the consumer price indices.
Health-care costs included costs of diagnostic procedures, costs for personnel, materials, 
equipment, costs for medication, costs for health care resource use in subsequent 
years after an event, and overhead. The costs for a non-contrast cardiac CT were based 
on healthcare reimbursement rates in 2009. Medication costs were based on pricing 
information from the 2009 Red Book (33), which were comparable with current prices for 
statins, anti-hypertensives, and aspirin. Based on baseline LDL cholesterol, we assumed 
that 30% of our population would need a potent and more expensive statin such as 
Rosuvastatin or Atorvastatin, and the remaining 70% could do with a generic statin 
such as Simvastatin. For antihypertensive medication we assumed that everyone would 
need at least a thiazide, combined with either an angiotensin II receptor blocker, ACE 
inhibitor or calcium channel blocker in 60% of individuals (44). Medication costs were 
only accounted for in adherent individuals. In a sensitivity analysis we used generic 
prices for statins and anti-hypertensives, estimated to be $ 160 yearly for generic statins 
and $300 for antihypertensives (33). For both strategy 2 and 3, we accounted for the costs 
of obtaining the Framingham risk factors by a general practitioner, including laboratory 
costs. Event-related costs included the costs of hospitalization, diagnostic workup, 
interventions, and rehabilitation during the first year after an event and was assumed 
to reflect the average cost following a non-fatal myocardial infarction, coronary artery 
bypass graft or percutaneous coronary intervention (31, 34, 45-46). Non-health care costs 
included travel costs and patient time costs. 
Analysis
All authors agreed on the model structure and data input prior to performing the 
analyses to ensure an objective and unbiased analysis. 
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Important baseline characteristics such as lipid levels, blood pressure and medication 
use, were determined for the cohort of individuals at intermediate risk, stratified by 
sex. The number of individuals using a statin, anti hypertensive or aspirin under each 
strategy was determined. Quality-adjusted life years (QALYs), life time costs, incremental 
cost-effectiveness ratios (i.e., additional costs divided by QALYs gained), and net health 
benefit (QALYs minus (costs / willingness-to-pay)) were calculated for all strategies. To 
take into account time preference, future costs and effectiveness were discounted at the 
currently recommended U.S. discount rate of 3% for both costs and effectiveness (47-48). To 
take into account second order uncertainty, 100,000 independent samples were drawn 
from each of the input parameter distributions, generating outcome distributions 
for QALYs and costs for each strategy. Calculations were done for men and women 
separately. 
Strategies were first ordered according to increasing cost. A strategy was considered 
dominated if another strategy was both more effective and less costly. A strategy was 
considered extended dominated if another strategy achieved more effectiveness at a 
lower incremental cost-effectiveness ratio. After eliminating dominated and extended 
dominated strategies, the incremental cost-effectiveness ratios were calculated as the 
difference in mean lifetime costs divided by the difference in mean QALYs for each 
strategy compared to the next best non-dominated strategy. We considered 50,000 U.S. 
dollar per QALY gained as a commonly accepted threshold for the societal willingness-
to-pay threshold for primary prevention (49-51) and varied it between 15,000 and 100,000 
dollar in sensitivity analyses. For the reference case analysis we analyzed the model with 
input parameters as given in Table 1.
Extensive one-way, two-way, multi-way, and probabilistic sensitivity analyses were 
performed using plausible ranges of the parameter values. In particular, we explored 
model sensitivity to drug costs, aspirin therapy in women, and the relative risk of an 
event with aspirin therapy. As some clinicians would be reluctant to withhold therapy 
from an individual who starts out with a predicted risk of 11% (putting him originally at 
intermediate risk), and after inclusion of coronary calcium a revised risk of 9% (putting 
him at low risk), we explored the effect of an alternative assumption in which treating 
individuals reclassified to the 5%-10% risk category as individuals with intermediate 
risk (10-20%), and checked whether the optimal decision would change. Reclassification 
probabilities for this assumption are presented in Table 4 in the technical appendix.
As the 2004 guidelines on the initiation of statin therapy include an optional cutoff 
value of 100 mg/dl for individuals at intermediate risk, we did an additional analysis 
using this cutoff value in the ‘current guidelines’ strategy and the ‘CT calcium screening’ 
strategy for the individuals who remained in the intermediate risk group. 
Probabilistic sensitivity analysis was performed using the outcome distributions of 
100,000 Monte Carlo simulations (52). We calculated the probability that CT screening 
was cost-effective compared to current practice, current guidelines and statin therapy 
strategies for varying willingness-to-pay thresholds, which yielded acceptability curves. 
501599-L-bw-van Kempen
Cost-effectiveness of CT Coronary Calcium | 27
Results 
Reference case analysis
Review of the baseline characteristics of the cohort at intermediate risk demonstrated 
that women were older than men and had less favorable risk factor levels apart from 
smoking and calcium scores (Table 2). In men, implementing current guidelines for all 
individuals at intermediate risk, led to a steep increase in the number of statin and anti 
hypertensive users (from 12% to 75% and 23% to 64%) compared to current practice 
(Table 5 in the technical appendix). In women, a similar pattern was observed (from 
15% to 87% and 52% to 84%) (Table 6 in the technical appendix). Implementing the CT 
screening strategy results in slightly fewer statin users compared with implementing 
current guidelines in both men (69% vs 75%) and women (41% vs 87%). In men, statin 
users with either current practice or CT screening had a higher expected 10 year risk 
of CHD compared to non-users (Table 7 in the technical appendix). This difference 
disappeared between users and non-users with current guidelines. In women, this was 
only the case for CT screening (Table 8 in the technical appendix).
In men (Table 3a), CT calcium screening was more effective and more costly compared to 
current practice (QALY-gain: 0.13 [95%CI 0.01;0.26], cost-increase: $4,676 [95%CI 3,126 ; 
6,339]), more effective and more costly than statin therapy (QALY-gain: 0.04 [-0.02;0.13], 
cost-increase: $1951 [1170 ; 2754]) and more effective but slightly more costly than 
current guidelines (QALY-gain: 0.02 [-0.04;0.09], cost-increase: $44 [-441 ; 486]). The cost 
effective plane in figure 2a shows that in men, current guidelines is extended dominated 
by CT screening, as the latter leads to a higher expected quality adjusted life expectancy 
against a lower incremental cost effectiveness ratio. The incremental cost effectiveness 
ratio of statin therapy is $30,278 per QALY and for CT calcium screening it is $48,800 per 
QALY gained (Table 3a). 
In women (Table 3b), CT screening was more effective and more costly than current 
practice (QALY-gain: 0.13 [0.02;0.28]; cost-increase $4,663 [3,120 ; 6,277]), more effective 
and more costly than statin therapy (QALY-loss: 0.03 [-0.03 ; 0.12], cost-savings: $2273 
[1475 ; 3109]) and less expensive but also less effective compared to current guidelines 
(QALY-loss: 0.02 [-0.03 ; 0.07], cost-savings: $297 [-8 ; 633]). The cost effective plane 
in Figure 2b shows that in women, CT screening is extended dominated by current 
guidelines, as the latter leads to a higher expected quality adjusted life expectancy 
against a lower incremental cost effectiveness ratio, and therefore, CT screening is not 
considered cost-effective in women. 
Sensitivity analysis
In men, at a willingness-to-pay threshold of $50,000 per QALY, a slight dyssynergy 
between drugs would change the optimal decision from CT screening to statin therapy 
(Table 4a). This shift would also occur if treatment adherence dropped below 58%, the 
effect of aspirin therapy on CHD was less protective, the cost of a CT rose above $200 
or the risk of radiation induced cancer increased more than ten-fold. In women, the 
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optimal strategy changed from ‘current guidelines’ to statin therapy in case of a slight 
dyssynergy between drugs, and strong protective effects of aspirin on the incidence 
of CHD and/or stroke (Table 4b). Using generic drug prices made the CT screening 
more cost-effective in men with an ICER of $24,675 / QALY whereas in women current 
guidelines became more cost effective with an ICER of $21,140 / QALY. Substituting the 
statin therapy strategy with the aggressive medical treatment strategy did not change 
the optimal decision in men. In women the optimal decision switched from current 
guidelines to aggressive medical treatment. 
Table 2. Baseline characteristics of study population with initial risk of CHD between 10-20%
Variable Men (n=329) Women (n=247)
Age, years 70 (66 – 73) 74 (71 – 78)
Body mass index, kg/m2 26.5 (24.8 – 28.7) 28 (25 – 31)
Systolic blood pressure, mmHg 144 (131 – 155) 149 (135 – 161)
Diastolic blood pressure, mmHg 78 (70 – 85) 76 (69 – 82)
Total cholesterol, mg/dl 
 (mmol/l)
222 (201 - 240)
 5.7 (5.2 – 6.2)
240 (217 – 232)
6.2 (5.6 – 6.8)
HDL cholesterol, mg/dl 
 (mmol/l)
46 (33 – 63)
1.2 (1.1 – 1.4)
50 (39 - 54)
1.3 (1.1 – 1.4)
LDL cholesterol, md/dl 
 (mmol/l)
146 (124 – 165)
3.75 (2.42 – 5.1 )
158 (135 – 178)
4.1 (2.63 – 5.62)
Cholesterol lowering medication (%) 52 (11.9%) 44 (17.1%)
Anti Hypertensive medication(%) 87 (22.5%) 117 (45.5%)
Anti thrombotic agents (%) 97 (20.4%) 43 (16.7%)
Smokers (%)
 Never
 Current
 Former
29 (9%)
70 (21%)
230 (70%)
124 (50%)
33 (13%)
90 (36%)
Diabetes Mellitus 19 (5.8%) 42 (17.0%)
Calcium score (%) 
 0
1-100
101-400
401-1000
>1000
11 (3%)
122 (37%)
79 (24%)
64 (20%)
53 (16%)
16 (7%)
104 (42%)
65 (26%)
37 (15%) 
25 (10%)
Categorical variables are presented as absolute number (percentage). Continuous values are expressed as mean (inter quartile range).
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Figure 2b. Cost effectiveness plane for the base case analysis in women. 
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Probabilistic sensitivity analysis demonstrated that in men CT screening was cost-
effective compared to current practice in the majority of simulations if the willingness 
to pay threshold was above $50,000 (Figure 3a). In women, even at higher willingness 
to pay thresholds, CT calcium screening would be cost effective in less than 20% of the 
simulations (Figure 3b). 
dIsCussIon
In this study we evaluated the comparative effectiveness and cost-effectiveness of 
CT coronary calcium screening within the framework of current CVD prevention 
guidelines. In men, the incremental cost effectiveness ratio for CT screening was just 
below the willingness-to-pay threshold of $50,000 per QALY and small changes in 
assumptions changed CT screening from being cost-effective to not cost-effective. 
Some of the assumptions could be considered plausible, such as a slight dyssynergy 
between drugs, or a treatment adherence lower than 60%, whereas others were more 
extreme (for example, a more than 10-fold increase in radiation risk). The uncertainty in 
optimal decision was further illustrated by the acceptability curves, which showed that 
in a minor but substantial proportion of the simulations, CT screening was not cost-
effective. However, using generic drug prices the ICER for CT screening dropped and the 
result was more robust in sensitivity analysis. 
In women CT screening was not found to be cost-effective, even after using a wide 
range of varying assumptions, which included assumptions more favourable to the 
CT calcium screening strategy by treating individuals in the higher end of ‘low risk’ (5-
10% risk) more aggressively, and using more treat-prone LDL thresholds. The difference 
in the optimal decision between men and women can be explained by the fact that 
compared to men, more women were reclassified to the low risk group leading to less 
aggressive treatment. Furthermore, within the low risk group, the observed risk of CHD 
is higher in women than in men, so the foregone benefit with less aggressive treatment 
is higher in women. The benefit of CT screening is obtained in the high-risk group, where 
individuals are treated more aggressively compared to current guidelines for treatment 
of intermediate-risk individuals. Since fewer women were reclassified to high-risk, the 
potential benefit of CT screening is lower than in men. The balance is further shifted 
due to the fact that aspirin is prescribed in men at high risk, but not in women due to 
controversy regarding its efficacy in primary prevention of CHD. 
The ATP-IV guidelines, which will be published soon, are expected to recommend more 
aggressive statin treatment than the current statin treatment guidelines. Our statin 
therapy strategy can be considered quite aggressive and is likely to be similar to the 
antcipated ATP-IV recommendation, ensuring future applicability of our results. Of note, 
when we compared CT screening with an even more aggressive treatment strategy, as 
we did in the sensitivity analysis with the ‘medical treatment’ strategy, CT screening 
remained cost effective in men. This implies that CT screening does not simply put more 
individuals on treatment, but allocates treatment to individuals who are expected to 
benefit most.
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A number of cost-effectiveness papers on CT coronary calcium scoring have previously 
been published but differed from our study in the strategies, target population 
considered or they dichotomized the calcium score rather than including the score in a 
risk prediction. These studies found that cost effectiveness of CT screening was highly 
sensitive to the population screened and downstream costs (53-55). The relatively high 
incremental cost effectiveness ratio we found for CT screening in men is comparable 
with results of other cost-effectiveness studies on interventions for primary prevention 
of CHD such as the study by Pletcher et al (43). Generalizability of our findings is further 
supported by comparable reclassification data on coronary calcium found by Polonsky 
et al in the Multi-ethnic study of atherosclerosis (7). 
Our results should be interpreted in the light of the limitations. First, we focused on 
individuals at intermediate risk, which implied individuals were on average older than 
69 years of age. Screening for coronary calcium could potentially have value in other 
subgroups but we explicitly chose to investigate CT screening in the intermediate risk 
group as advocated by recent guidelines and current consensus. Second, the time 
horizon in our analysis was the remaining lifetime. Therefore, we had to extrapolate the 
incidence of CHD beyond the available 10-year data, but few simulated individuals lived 
beyond 15 years. Finally, although we stratified by sex, further stratification by different 
combinations of baseline risk factors was not possible due to a limited sample size.
As with all models of screening and diagnostic tests, the differences between the four 
strategies in terms of quality adjusted life expectancy were small. Even though in 
women, the results seem robustly unfavourable for the CT calcium screening strategy, 
the residual uncertainty reflected in the acceptability curves indicates that further 
research might be beneficial. In men the results indicated that CT screening was cost-
effective in the majority of simulations. Nevertheless, in a substantial proportion of 
simulations in men, current guidelines or statin therapy was optimal compared to CT 
screening, indicating that further research is necessary. 
In conclusion, screening for coronary artery calcium with CT is probably cost-effective in 
men at intermediate risk of CHD. For women at intermediate risk for CHD, CT screening 
does not appear to be cost effective. 
teChnICAl AppendIx
Model
Figure 1a to 1d show the cycle tree of the Markov model, with all states and possible 
transitions between them. Within a cycle, the incidence of one type of event did not 
exclude the possibility of another type. 
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Figure 3a. Acceptability curve in men. For varying willingness-to-pay thresholds, the proportions of 
simulations that demonstrated cost-effectiveness for each strategy are indicated. 
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 20000 40000 60000 80000 10000
Willingness to Pay in US dollars
Pr
ob
ab
ili
ty
 C
os
t_
Ef
fe
ct
iv
e
Current Practice
Current Guidelines
CT Screening
Statin Therapy
Figure 3b. Acceptability curve in women. For varying willingness-to-pay thresholds, the proportions 
of simulations that demonstrated cost-effectiveness for each strategy are indicated.
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CHD incidence
The probability of incident CHD was determined by first converting observed 10 year 
probabilities p to average rates r per time unit t (equation (1)). 
r = –ln(1 – p)
t
 (1)
Zhich was assumed to be constant over time and extrapolated beyond 10 years. This 
assumption was validated by observing the fairly constant rate over a 10-year follow-up 
period (Figures 2 and 3). Subsequently, the calculated rate was converted to an annual 
probability, by:
p = 1 – e-r (2)
Adjusting for efficacy of Treatment
Drug treatment efficacies, in terms of Relative Risks (RR) were obtained from meta 
analyses and considered the relative risk in incidence of CHD (any of the following 
outcomes: non-fatal myocardial infarction, CABG, PCI, and CHD mortality) or stroke 
(ischemic, hemorrhagic or unspecified) compared to placebo. The relative risk of a 
certain treatment or intervention was assumed to be constant over time. 
Derived annual probabilities of CHD and stroke respectively, were multiplied by the RR 
of the appropriate strategy.
Pafter_treatment = Punadjusted • Rstrategy (3)
Adjusting the treatment efficacies for treatment adherence, baseline prevalence and 
treatment goals.
The model incorporates 3 basic drug treatments: statins, anti-hypertensives and aspirin, 
each with their own specific treatment goals. In order to estimate the combined effect, 
we made the following assumptions:
(1) An individual already on statins at baseline who had not reached the treatment 
goal, i.e. >160 (4.92), >130 (3.37) and >90 (2.50) mg/dL (mmol/l) for the low, 
intermediate and high risk category respectively, was assumed to switch to a 
higher dose or more potent statin, and assigned half of the reduction in risk based 
on a full dose given to a non-user.The same holds for an individual using anti-
hypertensives at baseline and SBP >140, >140, >130 mm Hg respectively. 
(2) When a combination of drugs was assigned, the net effect of the drugs together on 
risk reduction was assumed to be the product of the individual RR’s, times a factor 
for potential (dys)synergy, SF, where .90 < SF <1.10. This range was chosen to make 
sure that a combination of 2 or 3 drugs was at least as effective as the effect of a 
single drug. For the base case analysis we used a synergy factor of 1. When 2 drugs 
were jointly taken, the joint effect was corrected with SF. When 3 drugs were jointly 
taken, the joint effect was corrected with SF2.
501599-L-bw-van Kempen
Cost-effectiveness of CT Coronary Calcium | 37
The RR of each strategy was corrected for adherence and baseline prevalence of 
statin, anti-hypertensives and aspirin use. To simplify, the adherence for aspirin, anti-
hypertensives and statin or any combination of them was considered to be equal.
For the individuals reclassified to the low risk group in the CT screening strategy, the 
RR’s for both CHD and stroke (RR1) were determined by:
 (4)
Where C equals the percentage of therapy adherent individuals and f equals a fraction 
sub-indexed by: 
LDL+ indicates LDL >160 mg/dL (4.92 mmol/l); LDL- indicates LDL ≤160 mg/dL 
(4.92 mmol/l),
LDLU indicates statin use at baseline ; LDLN indicates no use at baseline,
BP+ indicates SBP >140 mm Hg ; BP- indicates SBP <140 mm Hg,
BPU indicates anti-hypertensives use at baseline ; BPU indicates no use at baseline,
RRStatin equals the relative risk of CHD (stroke) for someone taking statins versus placebo, 
RRantiH equals the relative risk of CHD (stroke) for someone taking anti-hypertensives vs 
placebo,
SF equals the synergy factor discussed earlier.
The baseline fractions of f for strategy I are given in Table 1.
For the current guidelines strategy, consisting of both statins and anti-hypertensives 
when indicated, and the individuals reclassified to the intermediate risk group in the CT 
screening strategy, the RR’s for both CHD and stroke (RR2) were determined by 
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 (4)
Where C equals the percentage of therapy adherent individuals and f equals a fraction 
sub-indexed by: 
LDL+ indicates LDL >130 mg/dL (3.37 mmol/l); LDL- indicates LDL ≤130 mg/dL 
(3.37 mmol/l),
LDLU indicates statin use at baseline ; LDLN indicates no use at baseline,
BP+ indicates SBP >140 mm Hg ; BP- indicates SBP <140 mm Hg,
BPU indicates anti-hypertensives use at baseline ; BPU indicates no use at baseline,
RRStatin equals the relative risk of CHD (stroke) for someone taking statins versus placebo, 
RRantiH equals the relative risk of CHD (stroke) for someone taking anti-hypertensives vs 
placebo,
SF equals the synergy factor discussed earlier.
The baseline fractions of f for strategy II are given in Table 2.
For the individuals reclassified to the high risk group in the CT screening strategy, the 
RR’s were determined by:
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 (5)
All sub-indexes are similar to the ones used in (4), except for
RRasp which is the relative risk of incident CHD for someone taking aspirin vs placebo, 
AU indicates aspirin use at baseline ; AN indicates no use,
LDL+ indicates LDL >90 mg/dL (2.5 mmol/l); LDL- indicates LDL ≤90 mg/dL (2.5 mmol/l),
BP+ indicates SBP >130 mm Hg ; BP- indicates SBP <130 mm Hg
Note that aspirin is only prescribed in males. Fractions of f for strategy III are given in 
Table 3.
Secondary prevention
In high-risk individuals, the risk of a recurrent CHD event was assumed to be 1.5-
fold higher than their risk of a primary CHD event (22). In low- and intermediate-risk 
individuals, the risk of a recurrent CHD event was assumed to be similar to the risk of a 
primary CHD event in high-risk individuals. Treatment for secondary prevention of CHD 
and stroke was assumed to be similar to the medical treatment of high-risk individuals/
secondary prevention of CVD. 
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Major bleeding rate
We modeled the excess rate of major bleeding due to the use of aspirin in males. From 
the most recent meta analysis, the bleeding rate in the placebo group was converted 
to a yearly probability PMajorBleeding. The annual probability of excess major bleeding 
PExcessMajorBleeding was calculated by:
PExcessMajorBleeding = (R –1) • PMajorBleeding (6)
where RR equals the relative risk of major bleeding for males taking aspirin compared 
to placebo.
Death due to radiation
A recent simulation study estimated the lifetime attributable risk (LAR) of cancer from a 
single CT Coronary Calcium scan. We divided the LAR by the expected remaining lifetime 
of our cohort, and used this as approximation for the annual cancer risk due to radiation. 
Making this simplifying assumption led to slight overestimation of the radiation risk but 
since the risk is extremely low, it’s influence will be negligible. 
.
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Figure 1a. Schematic presentation of the Markov simulation model. The cycle tree of each health 
state is presented.
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Figure 1b. Second part of Markov model. The cycle tree of each health state is presented.
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Figure 1c. Third part of Markov model. The cycle tree of each health state is presented.
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Figure 1d. Fourth part of the schematic presentation of the Markov simulation model. 
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Figure 2. Probability of CHD in year t for men, conditional on survival up until beginning of year t. For 
each risk category (low, intermediate and high), both the probability calculated assuming a constant 
hazard rate and the Weibull distribution are drawn.
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Figure 3. Probability of CHD in year t for women, conditional on survival up until beginning of year 
t. For each risk category (low, intermediate and high), both the probability calculated assuming a 
constant hazard rate and the Weibull distribution are drawn.
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Table 1. Fractions of different combinations of statin use, anti-hypertensives use, LDL-level and SBP 
level at baseline, stratified by sex, used in the CT screening strategy for individuals reclassified to the 
low risk category.
Fraction Men Women
LDL >160 mg/dl 0.11 0.13
SBP >140 mmHG
No Statin 
No anti-hypertensives
LDL >160 mg/dl 0.02 0.10
SBP >140 mmHG
No Statin 
anti-hypertensives use
LDL >160 mg/dl 0.10 0.17
SBP <140 mmHG
No Statin 
–*
LDL >160 mg/dl 0.00 0.01
SBP >140 mmHG
Statin use 
No anti-hypertensives
LDL >160 mg/dl 0.00 0.01
SBP >140 mmHG
Statin use
anti-hypertensives use
LDL >160 mg/dl 0.00 0.01
SBP <140 mmHG
Statin use
–*
LDL <160 mg/dl 0.29 0.19
SBP > 140 mmHG
–*
No anti-hypertensives
LDL <160 mg/dl 0.10 0.22
SBP > 140 mmHG
–*
anti-hypertensives use
LDL < 160 mg/dl 0.39 0.17
SBP <140 mmHG
–*
–*
*Irrespective of statin and anti-hypertensives use respectively
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Table 2. Fractions of different combinations of statin use, anti-hypertensive use, aspirin use, LDL-
level and SBP level at baseline, stratified by sex, used in the ’current guidelines’ strategy, and for the 
individuals reclassified to the intermediate risk category in the CT screening strategy.
Fraction Men Women
LDL >130 mg/dl 0.24 0.23
SBP >140 mmHG
No Statin 
No anti-hypertensives
LDL >130 mg/dl 0.09 0.22
SBP >140 mmHG
No Statin 
anti-hypertensives use
LDL >130 mg/dl 0.30 0.26
SBP <140 mmHG
No Statin 
–*
LDL >130 mg/dl 0.04 0.02
SBP >140 mmHG
Statin use 
No anti-hypertensives
LDL > 130 mg/dl 0.02 0.02
SBP > 140 mmHG
Statin use
anti-hypertensives use
LDL >130 mg/dl 0.01 0.04
SBP <140 mmHG
Statin use
–*
LDL <130 mg/dl 0.13 0.07
SBP > 140 mmHG
–*
No anti-hypertensives
LDL <130 mg/dl 0.06 0.08
SBP > 140 mmHG
–*
anti-hypertensives use
LDL <130 mg/dl 0.12 0.04
SBP <140 mmHG
–*
–*
*Irrespective of statin and anti-hypertensives use respectively
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Table 3. Fractions of different combinations of statin use, anti-hypertensive use, aspirin use, LDL-level 
and SBP level at baseline, stratified by sex, used in the CT coronary calcium screening strategy for 
individuals reclassified to the High risk category.
Fraction Men Women
–* 0.50 0.33
–*
No Statin 
No anti-hypertensives
No Aspirin
–* 0.14 0.07
–*
No Statin 
No anti-hypertensives
Aspirin use
–* 0.04 0.19
SBP >130 mmHG
No Statin 
Anti-hypertensives use
No Aspirin
–* 0.04 0.04
SBP >130 mmHG
No Statin 
Anti-hypertensives use
Aspirin use
–* 0.05 0.19
SBP <130 mmHG
No Statin 
Anti–hypertensives use
No Aspirin
–* 0.01 0.04
SBP <130 mmHG
No Statin 
Anti-hypertensives use
Aspirin use
LDL >90 mg/dl 0.09 0.02
–*
Statin use
No Anti-hypertensives 
No Aspirin
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Table 3. Continued
Fraction Men Women
LDL >90 mg/dl 0.04 0.02
–*
Statin use
No Anti-hypertensives 
Aspirin use
LDL >90 mg/dl 0.06 0.04
SBP >130 mmHg
Statin use
Anti-hypertensives use
No Aspirin
LDL >90 mg/dl 0.01 0.04
SBP >130 mmHg
Statin use
Anti-hypertensives use
Aspirin use
LDL >90 mg/dl 0.03 0.00
SBP <130 mmHg
Statin use
Anti-hypertensives use
No Aspirin
LDL >90 mg/dl 0.00 0.04
SBP <130 mmHg
Statin use
Anti-hypertensives use
Aspirin use
LDL <90 mg/dl 0.00 0.02
–*
Statin use
No Anti-hypertensives
No Aspirin
LDL <90 mg/dl 0.00 0.00
–*
Statin use
No Anti-hypertensives
Aspirin use
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Table 3. Continued
Fraction Men Women
LDL < 90 mg/dl 0.00 0.00
SBP > 130 mmHg
Statin use
No Anti-hypertensives
No Aspirin
LDL <90 mg/dl 0.00 0.00
SBP >130 mmHg
Statin use
No Anti-hypertensives
Aspirin use
LDL <90 mg/dl 0.00 0.00
SBP <130 mmHg
Statin use
Anti-hypertensives use
No Aspirin
LDL <90 mg/dl 0.00 0.00
SBP <130 mmHg
Statin use
Anti-hypertensives use
Aspirin use
*Irrespective of statin and anti–hypertensives use respectively
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Table 4. Reclassification for <5%,5-20% and >20% for the low, intermediate and high risk category.
Parameters Base-case value men† Base-case value women†
Probabilities and Characteristics of Reclassification groups
Total: 329 Total: 247
Individuals Reclassified to alternative low risk group (<5%)
N (%) 37 (12%) 40 (16%)
Observed 10-year CHD Risk 0.03 0.03 (0.04, 0.16)
Observed 10-year stroke Risk 0.09 0.06 (0.04, 0.16)
Individuals reclasified to alternative intermediate risk 
(5-20%) group#
N(%) 212 (64%) 153 (62%)
Observed 10-year CHD Risk 0.09 0.14
Observed 10-year stroke Risk 0.05 0.14
Individuals Reclassified to alternative high risk group 
(>20%)
N(%) 80 (24%) 54 (22%)
Observed 10-year CHD Risk 0.30 0.23
Observed 10-year stroke Risk 0.16 0.14
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AbstRACt
Background: We developed a Monte Carlo Markov model designed to investigate the 
effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD. 
Internal, predictive, and external validity of the model have not yet been established.
Methods: The Rotterdam Ischemic Heart Disease and Stroke Computer Simulation (RISC) 
model was developed using data covering 5 years of follow-up from the Rotterdam 
Study. To prove 1) internal and 2) predictive validity, the incidences of coronary heart 
disease (CHD), stroke, CVD death, and non-CVD death simulated by the model over 
a 13-year period were compared with those recorded for 3,478 participants in the 
Rotterdam Study with at least 13 years of follow-up. 3) External validity was verified 
using 10 years of follow-up data from the European Prospective Investigation of Cancer 
(EPIC)-Norfolk study of 25,492 participants, for whom CVD and non-CVD mortality was 
compared. 
Results: At year 5, the observed incidences (with simulated incidences in brackets) of 
CHD, stroke, and CVD and non-CVD mortality for the 3,478 Rotterdam Study participants 
were 5.30% (4.68%), 3.60% (3.23%), 4.70% (4.80%), and 7.50% (7.96%), respectively. At 
year 13, these percentages were 10.60% (10.91%), 9.90% (9.13%), 14.20% (15.12%), and 
24.30% (23.42%). After recalibrating the model for the EPIC-Norfolk population, the 
10-year observed (simulated) incidences of CVD and non-CVD mortality were 3.70% 
(4.95%) and 6.50% (6.29%). All observed incidences fell well within the 95% credibility 
intervals of the simulated incidences. 
Conclusions: We have confirmed the internal, predictive, and external validity of the 
RISC model. These findings provide a basis for analyzing the effects of modifying 
cardiovascular disease risk factors on the burden of CVD with the RISC model.
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IntRoduCtIon
Decision models are being increasingly used to guide decisions on medical interventions 
in healthcare (1-3). Both for healthcare policy-makers who have to make decisions for 
specific populations and weigh both benefits and costs, and for a general practitioner 
facing a medical decision for a particular patient, decision models can provide valuable 
information to aid the decision at hand. Empirical and trial-based studies on (cost-)
effectiveness of medical interventions often evaluate a limited number of strategies, 
and typically cover a limited period of follow-up. Decision modeling can overcome 
these limitations by synthesizing the available information and extrapolating short-
term study results, providing policy-makers with information on expected long-term 
outcomes and accompanying uncertainties (4). However, because decision models are 
based on a necessarily simplified representation of the underlying disease and the 
intervention being studied, the validity of the model is not automatically guaranteed. 
Earlier research has shown that importance of model validation before the results of a 
simulation study can be used for medical decisions (5-8).
Three types of validity have been described. With internal validation, the output of the 
model is compared with the data that was used to build the model (9, 10). Although model 
output and data are inherently dependent on each other with this type of validation, 
internal validity is a necessary condition, and provides an indication of how well the 
model output represents the data. Whereas the follow-up period in observational 
studies and clinical trials is necessarily limited, medical decisions often require long-
term outcomes. A common approach is to extrapolate the results of a simulation model 
beyond the period on which it was originally based. The validity of a model with regard 
to its accuracy to simulate results beyond the original timeframe is called ‘predictive’ 
or ‘prospective’ validity (11, 12), and constitutes the second form of validity. In evaluating 
predictive validity, the model output is compared with data from the new follow-up 
period, which has become available after the model was developed. The extent to which 
the results of a model can be applied to other populations different from the original 
one is the third form of validity, external validity (9, 10). Because potential differences 
between populations affect many of the parameters used in a model, external validity is 
a more rigorous test of model validity than the other two validity measurements. 
The objective of this study was to assess the internal, predictive, and external validity 
of the Rotterdam Ischemic Heart Disease and Stroke Computer Simulation (RISC) model 
(13). The RISC model was designed to investigate the effects of modifying cardiovascular 
disease (CVD) risk factors on the CVD burden in a general population. The model is 
based on data from the Rotterdam Study, a cohort follow-up study of 7,983 adults aged 
55 years and older. Validation of the RISC model is required before the results produced 
by the model can be used for decision-making.
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Methods
The model
The RISC model is a Monte Carlo state-transition model (schematically presented in 
Figure 1) with six states: 1) the CVD death state, 2) the non-CVD death state, 3) the 
coronary heart disease (CHD) state, 4) the stroke state, 5) the CHD and stroke state, and 
6) the well state (being alive without CHD or stroke). The model simulates incident CVD 
events in individuals with and without previous CVD based on risk-actor-dependent 
transition probabilities, using Cox regression equations. 
Other death
CVD death
StrokeWell CHD CHD & Stroke
Figure 1. Schematic presentation of the Rotterdam Ischemic Heart Disease and Stroke Computer 
Simulation (RISC) model. 
CHD = coronary heart disease, CVD = cardiovascular disease. Arrows indicate transitions between the health states
Individual risk-factor profiles are modeled and tracked over time. Incident CVD events 
are counted using tracker variables during the period of simulation. CHD is defined as: 
acute myocardial infarction (International Classification of Diseases, 10th edition (ICD-10) 
code I21), percutaneous transluminal coronary angioplasty (PTCA) and coronary artery 
bypass graft (CABG). Stroke is limited to non-hemorrhagic and unspecified strokes (ICD-
10 codes I63, I64). Cardiovascular death is defined as mortality due to hypertensive 
diseases (ICD-10 codes I10 to 15), ischemic heart disease (ICD-10 codes I20 to I25), 
sudden cardiac death (ICD-10 codes I46, I49), congestive heart failure (ICD-10 code I50), 
cerebrovascular disease (ICD-10 codes 160 to 167), other arterial disease (ICD-10 codes 
501599-L-bw-van Kempen
Validation of the RISC Model | 63
I70 to I79), or sudden death (ICD-10 code R96). Non-cardiovascular death is defined as 
mortality due to all other causes (all other ICD-10 codes). The model was built using 
TreeAge software (version Data Professional release 2009; TreeAge Software, Inc., 
Williamstown, USA). Detailed information about the model has been given in an earlier 
publication (13) (see also Additional file 1). 
Ethics approval 
In the RISC model, the risk-factor profiles and transition probability functions were based 
on data from the Rotterdam Study population. The Rotterdam Study was originally 
approved by the institutional review board of the Erasmus Medical Center and by the 
review board of The Netherlands Ministry of Health, Welfare and Sports (14). 
Data sources 
This population consisted of 7,983 respondents from a random sample of adults aged 
55 years and older, who were recruited between 1990 and 1993 and were residing 
in Ommoord, the Netherlands. Of these 7,983 respondents, 6,871 both visited the 
research center and signed an informed consent document. These individuals were 
followed up from 1990 to 2000; the follow-up consisted of three physical examinations 
with interviews, and the surveillance of hospital admissions, death registries, and 
other available medical sources ensured accurate follow-up of death and clinical 
manifestations of CVD. 
In 3,501 of the participants, all important characteristics for prediction of CVD were 
known, and the RISC model is based on 5-year follow-up data from these 3,501 
individuals. The risk factors considered for the transition probability functions were 
age, sex, smoking status, systolic and diastolic blood pressure, body mass index, waist-
to-hip ratio, ankle-brachial index; levels of plasma glucose, plasma total cholesterol, 
high-density lipoprotein (HDL) cholesterol, and plasma creatinine; family history of 
CVD, presence of hypertension (blood pressure over 160/90 or use of anti-hypertensive 
medication) or diabetes mellitus; manifestations of intermittent claudication, angina 
pectoris, atrial fibrillation or transient ischemic attacks; and prevalent CVD. Details about 
the assessment of these risk indicators have been described in earlier publications (15). 
The Cox regression equations that described the state-transition probabilities were 
centered around the mean of the risk factors of these 3,501 participants. This enabled 
the analysis of populations other than the original one, by substituting the centered 
cumulative baseline hazard and the average values of the risk factors by the values from 
the other population(s). 
Simulation of parameter uncertainty
The RISC model allows for the evaluation of parameter uncertainty (16). The majority of 
the parameter uncertainty in the model stems from the β-coefficients underlying the 
transition probability functions, and these β-coefficients are potentially dependent on 
each other. To model the uncertainty of the coefficients, 100 bootstrap samples of the 
study population were drawn. All the transition probability functions were fitted for 
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every bootstrap sample, resulting in 100 sets of linked transition probability functions, 
which allowed for the dependency between them. The transition probabilities were 
based on Cox regression equations, and parameter uncertainty around the baseline 
hazards of the CVD events, CVD death, and non-CVD death was also included.
Simulation of heterogeneity
The RISC model was designed to simulate individuals who each had a unique risk-
factor profile for CVD (17). Model outcomes are expected to be different for individuals 
with high-risk profiles (older age, male, high blood pressure, high lipid levels, diabetes 
mellitus) than for those with more favorable profiles. To allow for differences in outcomes 
resulting from individual differences in risk-factor profiles (that is, heterogeneity), we 
used the RISC model to simulate different individuals one at a time. 
Simulation of the history for each individual
The risk factors used in the RISC model reveal trends over time. As an example, total 
cholesterol levels were found decline with age in the Rotterdam Study. To take these 
trends in risk factors over time into account, each risk-factor profile for a particular 
individual was updated every 5 years during their simulated life in the model, based 
on the trends seen during the first 5 years in the Rotterdam Study. Therefore, the 
development of the risk factors needed to be tracked over time. 
Events occurring during an individual’s simulated life could influence the occurrence 
of other events. As an example, a CHD event increases the risk of dying in subsequent 
years. All cardiovascular events in the RISC model were therefore tracked and linked 
to the transition probabilities. The inclusion of variables used to track CVD events and 
changes in risk factors over time for each individual required the simulation of each 
individual multiple times to account for stochastic uncertainty (17).
Internal and predictive validation
From our cohort of 3,501 individuals from the Rotterdam Study on which the RISC model 
was based, we selected 3,478 who had at least 13 years of follow-up as of 1 January 2007. 
The remaining subjects were lost to follow-up because they had moved out of the area 
or had discontinued their participation. We calculated the cumulative incidences for 
total mortality, CVD mortality, non-CVD mortality, CHD, and stroke as defined previously 
for the 13-year period of follow-up (beginning of year 1 until end of year 13). We then 
compared this with the simulated cumulative incidences of the same events during the 
1st year until the end of the 13th year by the RISC model. We furthermore stratified the 
analyses for the internal and predictive validity for CVD mortality by tertiles of age for 
the 3,501 participants, and for men and women separately. We choose CVD mortality 
because it is one of the most important clinical outcomes, and there would be enough 
events for it in each stratum to obtain stable results. 
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External validation
For the external validation, we used data from the EPIC-Norfolk study (18), which is a 
prospective population study of 25,663 men and women aged 45 to 79 years old residing 
in Norfolk, UK. This study had been approved by the Norwich District Health Authority 
ethics committee, and all participants gave signed informed consent (18). Participants 
were originally recruited from age and gender registers of general practices in Norfolk 
as part of the 10-country collaborative EPIC study designed to investigate dietary and 
other determinants of cancer. Additionally, characteristics including anthropometry, 
blood pressure, and lipid levels were obtained for the assessment of determinants of 
other diseases. For the baseline survey from 1993 to 1997, participants completed a 
detailed health and lifestyle questionnaire and attended a clinic visit. All participants 
were followed up and mortality, linked to the UK Office of National Statistics, was 
recorded. Participants admitted to hospital were identified by their unique National 
Health Service number by data linkage with the East Norfolk Health Authority (ENCORE) 
database, which identifies all hospital contacts throughout England and Wales for 
Norfolk residents. 
The EPIC data did not contain all variables used in the RISC model. In particular, the 
following information was not readily available: ankle-brachial index, serum glucose 
levels, and a history at baseline of angina pectoris, atrial fibrillation, intermittent 
claudication, or transient ischemic attack. Consequently, we imputed the missing data 
in the EPIC dataset based on the multiple variables that were available (19). All major risk 
factors such as age, sex, cholesterol levels, and blood pressure were available and did 
not need to be imputed.
We used EPIC-Norfolk mortality data from 1993 until 31 March 2008. From the 25,663 
participants, we selected 25,492 who had a follow-up of at least 10 years. For the external 
validation, we calculated the cumulative incidence of CVD and non-CVD mortality in the 
EPIC dataset. We compared this with the simulated cumulative incidences of the same 
events after year 1 until year 10 by the RISC model, using the 25,492 EPIC profiles as 
input. 
We did not calculate or simulate CHD and stroke events in the external validation, 
because the EPIC study did not document CABG and PCI events and furthermore, non-
fatal events were only recorded if the patient was hospitalized. In the Rotterdam Study, 
both CABG and PCI were counted as CHD events, and all CHD and stroke events were 
recorded whether or not the patient was hospitalized, making the definition of CHD and 
stroke inherently different between the two cohorts (20, 21).
Statistical analysis
Important baseline characteristics for the baseline 3,478 Rotterdam Study participants 
and 25,492 EPIC participants were calculated and tabulated to evaluate their differences.
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To take into account parameter uncertainty, the heterogeneity of the participants, and 
the stochastic uncertainty, we performed a three-level simulation (16, 17). We calculated the 
mean and distribution around the mean of the cumulative incidences by drawing from 
100 second-order sets of linked β-coefficients from the state-transition probabilities 
and values for the baseline hazards of the events (outer simulation loop for parameter 
uncertainty). For each set of linked β-coefficients and baseline hazards, we consecutively 
simulated 2,000 randomly drawn risk-factor profiles from the 3,478 Rotterdam profiles 
for the internal and predictive validation. and 2,000 from the 25,492 EPIC profiles for 
the external validation (middle simulation loop for heterogeneity). For each profile, 200 
random walks were simulated, needed for the tracking of the individual cardiovascular 
histories (microsimulation, inner simulation loop for stochastic uncertainty). This implies 
100 × 2,000 × 200 runs per analysis. We did not model any particular intervention or 
treatment in this study; only the observed history (current practice) was simulated for 
purposes of validation. For the stratified analyses we aggregated on the individual level 
(n = 3,501× 200 × 100 runs per analysis). 
For the internal and predictive validation, we determined the average simulated 
cumulative incidences of CVD death, non-CVD death, CHD, and stroke for the 13-year 
period. For the external validation, we determined the average simulated cumulative 
incidences of CVD death and non-CVD death for year 1 until year 13. Because the 
Rotterdam Study and EPIC-Norfolk population are potentially different with respect 
to the distribution of risk factors and incidence of CVD, we subsequently recalibrated 
the RISC model by substituting the centered cumulative baseline hazards and mean 
values of the risk factors from the original model based on the Rotterdam data with 
the corresponding ones from the EPIC-Norfolk cohort (22). We then ran again 2,000 
randomly drawn participants from the 25,492 EPIC participants. 
For all cumulative incidences, we calculated the 2.5% and 97.5% percentiles of the 
variation around the average incidences (credibility intervals) from the RISC simulations, 
to quantify the influence of parameter uncertainty. We compared the observed with the 
simulated incidences for all events.
Results
Compared with the Rotterdam Study, the the EPIC-Norfolk study participants were 10 
years younger on average, and there were more men in the EPIC-Norfolk study (Table 1). 
On average, EPIC participants had lower total cholesterol levels and higher HDL levels 
(Table 1). The number of Rotterdam Study participants with a history of CVD at baseline 
exceeded that of the EPIC participants. 
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Table 1. Baseline characteristics of the risk factors used in the Rotterdam Ischemic Heart Disease 
and Stroke Computer Simulation (RISC) model for the 3,478 Rotterdam study participants and 25,492 
European Prospective Investigation of Cancer (EPIC)-Norfolk study participants.a 
Variable RISC (n = 3,478) EPIC (n = 25,492)
Age 69.0 (62 to 75) 59.2 (51 to 67)
Male subjects, % 39% 45%
Smoker
Never 34.5% 46.0%
Former 41.9% 42.3%
Current 23.6% 11.7%
BMI 26.3 (23.8 to 28.5) 26.3 (23.7 to 28.4)
WHR 0.91 (0.84 to 0.97) 0.86 (0.78 to 0.93)
Systolic BP 140.0 (124 to 155) 135.5 (122.5 to 146.5)
Diastolic BP 74.1 (66 to 82) 82.5 (74.5 to 89.5)
Hypertension 36.4% 29.9%
Total cholesterol 6.67 (5.8 to 7.4) 6.19 (5.4 to 6.9)
HDL cholesterol 1.34 (1.1 to 1.5) 1.41 (1.1 to 1.6)
Glucoseb 6.93 (5.5 to 7.5) 6.67 (5.5 to 7.3)
Creatinine 82.5 (72 to 91) 86.7 (76 to 97)
Diabetes mellitus 10.7% 12.2%
Angina pectorisb 10.4% 9.2%
Atrial fibrillationb 2.5% 2.9%
Intermittent claudication b 2.1% 1.5%
TIAb 5.1% 4.8%
CVD 17.8% 4.3%
Family history of MI 16.3% 18.4%
Family history of CVD 23.0% 23.3%
Abbreviations: BMI = body mass index, BP = blood pressure, CVD = cardiovascular disease, MI = myocardial infarction, TIA = transient 
ischemic attack, WHR = waist-to-hip ratio.
aAverage values and inter-quartile ranges (brackets) are given for continuous variables, while categorical variables are given as 
percentages. 
bIndicates imputed risk factors for the EPIC-Norfolk dataset.
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Figure 2. Cardiovascular disease (CVD) mortality during 13 years of follow-up. The first 5 years refer to 
the internal validation, the remaining years to the predictive validation. Simulated versus observed 
values for the Rotterdam Study data
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Figure 3. Non-cardiovascular disease (CVD) mortality during 13 years of follow-up. The first 5 years 
refer to the internal validation, the remaining years to the predictive validation. Simulated versus 
observed values for the Rotterdam Study data
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Figure 4. Coronary heart disease (CHD) events during 13 years of follow-up. The first 5 years refer to 
the internal validation, the remaining years to the predictive validation. Simulated versus observed 
values for the Rotterdam Study data
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Figure 5. Stroke events during 13 years of follow-up. The first 5 years refer to the internal validation, 
the remaining years to the predictive validation. Simulated versus observed values for the Rotterdam 
Study data
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Figure 6. Cardiovascular disease (CVD) mortality during 10 years of follow-up. Simulated versus 
observed values for the European Prospective Investigation of Cancer (EPIC)-Norfolk data
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Figure 7. Non-cardiovascular disease (CVD) mortality during 10 years of follow-up. Simulated versus 
observed values for the European Prospective Investigation of Cancer (EPIC)-Norfolk data
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Figure 8. Cardiovascular disease (CVD) mortality during 10 years of follow-up in the recalibrated 
model. Simulated versus observed values for the European Prospective Investigation of Cancer (EPIC)-
Norfolk data 
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Figure 9. Non-cardiovascular disease (CVD) mortality during 10 years of follow-up in the recalibrated 
model. Simulated versus observed values for the European Prospective Investigation of Cancer (EPIC)-
Norfolk data
501599-L-bw-van Kempen
72 | Chapter 3
Internal and predictive validation
During the 13 years of follow-up, 367 CHD events, 343 stroke events, 494 CVD deaths, 
and 846 non-CVD deaths occurred in the 3,478 Rotterdam Study participants, The 
cumulative incidences of CVD and non-CVD mortality during the13 years of follow-up 
for the Rotterdam Study participants were compared with the incidences generated 
by the RISC model (Figure 2, Figure 3). The observed values, both during the first 5 
years (internal validation) and for the extrapolated period (predictive validation), were 
consistent with the simulated ones. The cumulative incidences of CHD and stroke 
events during the 13-year follow-up were compared with the incidences generated by 
the RISC model (Figure 4, Figure 5). The observed values were again consistent with the 
simulated events. For the cumulative incidences of CVD mortality, stratified by tertiles 
of age, for men and women respectively, the observed values were also consistent with 
the simulated values (see Additional file 1, Figure S2, Figure S3).
External validation and recalibration
During the 10-year follow-up of the 25,492 EPIC-Norfolk participants, 943 CVD deaths 
and 1,661 non-CVD deaths occurred. The cumulative incidence of CVD and non-CVD 
mortality during the 10-year follow-up of the 25,492 EPIC participants were compared 
with the incidences generated by the RISC model, using the EPIC-Norfolk profiles as 
input (Figure 6, Figure 7). The observed values were within the 95% credibility intervals 
of the simulated values, but the RISC model overestimated the incidences for all years, 
for both CVD and non-CVD mortality. We then estimated the cumulative incidences 
of CVD and non-CVD mortality, after substituting the centered cumulative baseline 
hazards and average values of the risk factors with those based on the EPIC data, which 
recalibrated the model (Figure 8, Figure 9). After this recalibration, the observed CVD 
and non-CVD mortality incidences matched the simulated incidences from the RISC 
model.
dIsCussIon
In this study, we evaluated the internal, predictive, and external validity of the RISC 
model. The simulated cumulative incidence of CVD and non-CVD deaths, CHD events, 
and strokes adequately represented the data during the original follow-up period of 
5 years on which the RISC model was based. Extrapolation of the simulated results 
beyond this period proved to be valid for 13 years of follow-up, the maximum length 
that we analyzed in this paper. Although the results of the RISC model overestimated 
the CVD and non-CVD mortality compared with the observed 10-year incidences in the 
EPIC-Norfolk population, recalibrating the model with the cumulative baseline hazards 
and mean values of the risk factors substantially improved performance.
Other decision models used to evaluate preventive and treatment strategies for CVD 
have been well established. A recent review by Unal et al identified forty-two such 
models, of which six major ones have been described in detail (23). Although some of the 
501599-L-bw-van Kempen
Validation of the RISC Model | 73
forty-two models reported assessment of validity, most did not. Of the six major models, 
three have not been validated (24-26), two models had information on internal validity 
reported (27, 28), and an external validation had been performed fo two models (29, 30). 
In the present study, the predictive validity of the RISC model was tested against follow-
up data for more than twice the length of the period on which the model was originally 
based. The fact that the observed and simulated incidences matched closely even when 
extrapolated beyond the original data makes it plausible to expect projections beyond 
13 years to be valid as well. The trends in risk factors over time and their effects on 
the incidence of events, which are jointly modeled in the RISC model, seem to provide 
a valid basis to extrapolate results, without the need to recalibrate the model for the 
Rotterdam Study population. We furthermore showed the robustness of the internal 
and predictive validity by providing results for the stratified analyses by tertiles of age 
and sex. As for the external validation, the EPIC-Norfolk population was on average 
younger and healthier than the Rotterdam Study population. It was to be expected 
that an unadjusted model, using the baseline hazards and mean of the risk factors from 
the Rotterdam Study, would overestimate the observed incidences in the EPIC-Norfolk 
study. In the recalibrated model, we updated only the baseline cumulative hazards of 
the events and the mean values of the risk factors, a method very commonly used when 
applying models to other populations than that for which the model was originally 
developed in (22, 31). This result suggests that the relative strengths of the associations of 
the risk factors with the incidence of the events in the RISC model are the same for both 
the EPIC-Norfolk population and Rotterdam Study. The resulting external validity of the 
RISC model after this adjustment strongly supports this assumption.
Our analysis does have some limitations. The RISC model was designed to investigate 
the effects of modifying cardiovascular risk factors on the burden of CVD in the middle-
aged and older general population. We validated the model in the EPIC-Norfolk data, 
which included people aged from 45 years upwards. Although most current guidelines 
on the primary prevention of CVD mostly start at the age of 45 years and older, some do 
(or in the future potentially will), suggest that CVD prevention should begin at an earlier 
age Whether the RISC model also performs well in a younger population remains to be 
determined. The RISC model is intended to be used for projections during the remaining 
lifetime of an individual. The model proved to be valid for projections during 13 years 
of follow-up, and for most older people this is sufficiently long to cover their remaining 
lifespan. For younger people, this is less likely, and model extrapolation beyond this 
period therefore has to be made, which currently has not been validated. Because the 
Rotterdam Study is ongoing, and longer follow-up data are being collected, we will be 
able to test whether this additional extrapolation is valid as well. 
A number of risk factors used for the RISC model were not documented in the EPIC-
Norfolk study. To make the EPIC-Norfolk dataset suitable for the RISC model, we 
imputed missing data based on the correlations between the missing risk factors and 
the documented variables. These correlations stemmed from the Rotterdam Study data, 
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thereby introducing dependency between the (imputed) EPIC-Norfolk data and the RISC 
model. However, the major traditional risk factors such as age, sex, cholesterol level, 
and blood pressure were available in EPIC. The prevalence of a number of missing risk 
factors such as atrial fibrillation and intermittent claudication were low in the Rotterdam 
Study data on which the RISC model was developed, and the incremental value beyond 
the traditional risk factors of the other variables, such as the ankle-brachial index, has 
been found to be limited (32). It is therefore less likely that the imputation influenced the 
external validity in favor of concordance. Although the EPIC-Norfolk dataset contains 
information on (hospitalized) patients with MI, the RISC model simulates CHD as a 
combined endpoint, including CABG and PCI. This is consistent with most clinical trials 
using similar combined endpoints. The design of the RISC model therefore did not allow 
for direct comparison of simulated MIs as a sole endpoint. Although acute MI is the 
major component of CHD, both CABG and PCI interventions are inherently different 
from acute MIs, and we therefore did not externally validate CHD events in the EPIC 
dataset. 
At the time of this paper, we did not have datasets other than EPIC-Norfolk at our 
disposal to perform additional external validation. The fact that the RISC model, after 
updating the model with the baseline hazards and mean values for the risk factors 
from EPIC, proved to be valid for the EPIC-Norfolk cohort, does not automatically imply 
that it will be valid in other populations as well. The EPIC-Norfolk cohort was younger 
on average, and included more men than the RISC cohort. However, the fact that the 
cohort was different with regard to these important risk factors, and yet RISC still 
provided valid results, does make a strong case that the model will be valid for other 
cohorts as well. We do intend to validate the model with other data as they become 
available. Both the Rotterdam Study and the EPIC-Norfolk study were population-based 
studies and included individuals regardless of pre-existing risk-factor profiles or disease 
status. Although risk-factor distributions of the study participants might in principle 
be different from the populations they intend to represent, it is very likely that the 
RISC model is valid for most western European populations in general after adjusting 
for baseline hazards. A simpler model with a reduced set of parameters, excluding the 
less common ones such as atrial fibrillation and ankle-brachial index, would possibly 
allow for a more rapid validation process in other populations. In an ongoing effort to 
optimize our model, we also intend to make efforts to simplify our current model.
We modeled and validated the cardiovascular histories of the participants of the 
Rotterdam Study and EPIC-Norfolk cohort as they were observed; that is, without any 
interventions. Although the results with regard to this validity seem promising, the RISC 
model will be used to evaluate interventions for the primary prevention of CVD. In that 
case, the validity of the model to evaluate an intervention depends not only on the 
observed CVD history, but also on the extent to which other structural assumptions are 
made, such as modeling the treatment effect of an intervention (33). A more extensive 
framework of model validation proposed by Kopec et al (34) also includes between-
model comparisons, and comparisons of evidence from examining the consequences 
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of model-based decisions. Between-model comparisons are specifically useful when 
analyzing certain interventions compared with the natural history of the disease, as we 
did in the current analysis. Being a simplifying abstraction of reality, a model will be 
valid with regard to some (but not necessarily all) mechanisms or relationships seen 
in real life. Assumptions made to assure that particular mechanisms are characterized 
can cause the model to be less valid with regard to other possible mechanisms. This 
makes the modeling of complex interrelationships more of an art than an exact science. 
For each particular decision problem, it is important to determine the assumptions to 
which each approach is sensitive, determine the appropriateness of these assumptions, 
and judge the relevance of the model sensitivity to them in the context of the decision 
problem and the forthcoming decisions that will result from it.
ConClusIons
This study shows that the RISC model accurately predicts mortality and CVD events 
during the period of 5 years on which it is based (internal validity) and during an extended 
follow-up period up for 13 years (predictive validity). In addition, after recalibration, it 
accurately predicts mortality in the EPIC-Norfolk cohort as well (external validity). These 
findings provide a basis to generalize results from the RISC model. 
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teChnICAl AppendIx
In this Appendix, we provide additional information on the RISC model and analyses.
RISC Model 
The RISC model is a Monte Carlo state-transition model (schematically presented in 
Figure S1) with six states: 1) the CVD death state, 2) the non-CVD death state, 3) the 
Coronary Heart Disease (CHD) state, 4) the Stroke state, 5) the CHD and Stroke state 
and 6) the Well state (being alive without coronary heart disease or stroke). The model 
simulates incident CVD events in individuals based on risk factor dependent transition 
probabilities, using Cox regression equations. Individual risk factor profiles were 
modeled and tracked over time. The model was built in TreeAge (version 2009, TreeAge 
Software, Inc., Williamstown, USA).
Probabilities for the transitions between the six health states were based on six 
multivariable Cox regression equations. The development of these equations was 
described in a previous article on the RISC model (1). The first equation estimated the 
cumulative hazard from the Well state to the CHD state and from the Stroke state to the 
CHD & Stroke state. The second equation estimated the cumulative hazard from the Well 
state to the Stroke state and from the CHD state to the CHD & Stroke state. In developing 
these models, censoring was performed for an incident stroke and CHD respectively. In 
both equations, previous CHD and/or stroke were included as a covariable. The third 
and fourth equations estimated the 6-months cardiovascular mortality rate (case-
fatality) after a CHD and stroke event respectively. Six-month case-fatalities were used 
as proxies for the immediate fatality rates of these events. The probability of dying 
from a fourth CHD event and third stroke event were assumed to be 100%. The fifth 
and sixth Cox regression equations estimated the cumulative hazards of the remaining 
CVD mortality, which is caused by other causes than CHD or stroke (see Table S1 for 
equations). For extrapolation to a lifelong follow-up, follow-up time was divided into 
5-year intervals and a cycle length of one year was chosen. The first 5 years, baseline 
values of covariables were used together with the one-year cumulative hazards 
from the Cox models for each cycle. For the remaining follow-up, the same baseline 
one-year cumulative hazards were used, but values of the covariables were updated 
every 5 years by using multiple linear regression for continuous variables and logistic 
regression for dichotomized variables. From the outcomes of the logistic regression 
equations regarding dichotomized variables, binomial distributions were created. Every 
5 year period during follow-up, presence (1 or 0) of the dichotomized variables was 
derived from these distributions. Cumulative hazards of fatal and non-fatal events were 
separately weighted for their total cumulative hazards to ascertain that all probabilities 
for respectively cardiovascular and non-cardiovascular mortality vs. survival and stroke 
and CHD events vs. disease-free survival summed to one. For each transition, cumulative 
hazards were converted to probabilities by exponentiation. Occurrences of events and 
duration in each health state were stored using Monte Carlo tracker variables to allow 
for the calculation of incidences of the different events. These tracker variables are 
variables used to count the occurrences of a state transition representing an event in 
TreeAge.
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Figure S1. Schematic presentation of RISC model.
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Figure S2. CVD mortality during 13 years of follow-up. Simulated vs observerd values per tertile of age 
in men for the Rotterdam Study data
Figure S3. CVD mortality during 13 years of follow-up. Simulated vs observerd values per tertile of age 
in women for the Rotterdam Study data
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AbstRACt
Purpose: Modeling studies which evaluate statin treatment for the prevention of 
cardiovascular disease (CVD) use different methods to model the effect of statins. The 
aim of this study was to evaluate the impact of using different modeling methods on 
the optimal decision found in such studies.
Method:  We used a previously developed and validated Monte Carlo-Markov model 
based on the Rotterdam Study (RISC model). The RISC model simulates coronary heart 
disease (CHD), stroke, cardiovascular death and death due to other causes. Transition 
probabilities were based on 5-year risks predicted by Cox regression equations, 
including (amongst others) total and HDL cholesterol as covariates.
 
In a cost-effectiveness analysis of implementing the ATP-III guidelines we evaluated the 
impact of using three different modeling methods of statin effectiveness: (I)  Through 
lipid level modification: statins lower total cholesterol and increase HDL, which through 
the covariates in the Cox regression equations leads to a lower incidence of CHD and 
stroke events; (II) Fixed risk reduction of CVD events:  statins  decrease the odds of CHD 
and stroke with an associated odds ratio which is assumed to be the same for each 
individual; (III) Risk reduction of CVD events proportional to individual change in LDL 
Cholesterol: the relative risk reduction with statin therapy on the incidence of CHD and 
stroke was assumed to be proportional to the absolute reduction in LDL-cholesterol 
levels, for each individual. The probability that the ATP-III strategy was cost-effective, 
compared to usual care as observed in the Rotterdam study, was calculated for each of 
the three modeling methods for varying willingness-to-pay thresholds. 
 
Result: Incremental cost-effectiveness ratios for the ATP-III strategy compared with the 
reference strategy were 56,642 euro/QALY, 21,369 euro/QALY and 22,131 euro/QALY for 
modeling method I, II and III respectively. At a willingness-to-pay of 50,000 euro/QALY, 
the probability that the ATP-III strategy was cost effective was about 40% for modelling 
method I, and more than 90% for both method II and III. Differences in results between 
the modeling methods were sensitive to both the time horizon modeled and age 
distribution of the target population.
Conclusion:  Modeling the effect of statins on CVD through the modification of lipid 
levels produced different results and associated uncertainty than modeling it directly 
through a risk reduction of events. This was partly attributable to the modeled effect of 
cholesterol on the incidence of stroke.
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IntRoduCtIon
As the burden of cardiovascular disease (CVD) is still increasing globally, the primary 
prevention of CVD is more important than ever. Most Western populations are ageing, 
and given limited health care resources, research in CVD prevention should evaluate 
not only effectiveness but also cost-effectiveness. Randomized clinical trials in this area 
are scarce and a number of recent papers have used simulation models to analyze the 
cost-effectiveness of preventive interventions for CVD (1-11). Frequently, the intervention 
in these studies consisted of statin treatment for asymptomatic individuals, often based 
on the third report of the expert panel on detection, evaluation, and treatment of high 
blood cholesterol in adults (ATP-III) (12). 
As in all modeling studies, assumptions have to be made for the relationship between 
the disease of interest and the intervention proposed (1-2, 5-6, 8, 10, 13). The assumptions made 
differed between the reviewed simulation models. Some authors modeled the effect of 
statin therapy through the modification of lipid levels (2, 8, 14-18), others used observed risk 
reductions from trials (9, 19-21), or used a combination of lipid level changes and observed 
risk reductions (1). A natural question arises when optimizing effectiveness and cost-
effectiveness of statin therapy: does making different structural model assumptions 
about the treatment effect of a statin change the decision about statin initiation? If so, 
a decision maker, faced with the results from a modeling study, should interpret the 
conclusion in light of these assumptions. 
As the ATP-III guidelines are frequently studied with decision models, it provides a 
suitable decision analytic example to illustrate the use of different modeling methods 
of statin effectiveness (12). The purpose of this study was to evaluate the impact of 
using different methods of modeling statin treatment effectiveness on the lifetime 
effectiveness and cost-effectiveness of implementing the ATP-III guidelines.
Methods
To evaluate the impact of using different methods of modeling treatment effectiveness 
of a statin, we used the previously developed Rotterdam Ischemic Heart Disease & 
Stroke Computer Simulation Model (RISC model). The model will be briefly outlined, 
after which three different modeling methods of statin effectiveness will be described, 
applied to the RISC model. Finally the decision problem used to evaluate the different 
modeling methods will be outlined.
The model
The RISC model is a Monte Carlo state-transition model (schematically presented in 
Figure 6 of the technical appendix) with six states: (1) the CVD death state, (2) the non-
CVD death state, (3) the coronary heart disease (CHD) state, (4) the Stroke state, (5) the 
CHD and Stroke state and (6) the Well state (being alive without coronary heart disease 
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or stroke). The model simulates incident CVD events in individuals based on risk factor 
dependent transition probabilities, using Cox regression equations. Individual risk 
factor profiles were modeled and tracked over time. The model was built in TreeAge 
(version 2009, TreeAge Software, Inc., Williamstown, USA). Detailed information about 
the model is given in an earlier publication (22) and technical appendix. 
The Rotterdam Study
In the RISC model the risk factor profiles and transition probability functions were based 
on data from the Rotterdam study population (23). This population consisted of 7983 
respondents from a random sample of adults aged 55 and older that were recruited 
between 1990 and 1993 and residing in Ommoord, the Netherlands. Of these 7983 
respondents, 6871 individuals both visited the research center and signed an informed 
consent. Individuals were followed from 1990 to 2000 and follow-up consisted of three 
physical examinations with lifestyle interviews and surveillance of hospital admissions, 
death registries and other available medical sources, ensuring accurate follow-up of 
death and clinical manifestations of CVD. 
In 3501 individuals all important characteristics to predict CVD were completely 
known. The RISC model was based on data from these 3501 individuals. The risk factors 
considered for the transition probability functions were age, sex, smoking status, systolic 
and diastolic blood pressure, diabetes mellitus, plasma glucose level, body mass index, 
waist to hip ratio, plasma cholesterol and HDL-cholesterol level, plasma creatinine level, 
family history of CVD, ankle-brachial systolic blood pressure index, manifestations of 
intermittent claudication, angina pectoris, atrial fibrillation or transient ischemic attacks 
and prevalent CVD. Details about the assessment of these risk indicators are described 
in earlier publications (23). We define a CVD event as any of the following events: a fatal or 
non-fatal myocardial infarction, coronary artery bypass grafting (CABG), percutaneous 
coronary intervention (PCI), fatal or non fatal ischemic or unspecified stroke, or death 
due to heart disease, cerebrovascular disease or other arterial disease. 
Modeling statin effectiveness
In this study, three methods of modeling statin effectiveness applied to the RISC model 
were evaluated:
 
(I) Through lipid level modification: clinical trials have shown that statins increase HDL-
cholesterol, and decrease both total cholesterol, triglycerides and LDL-cholesterol 
(24). In the RISC model, both total cholesterol and HDL-cholesterol are included in 
the Cox regression equations describing the hazards of a (fatal or non-fatal) CHD 
event (myocardial infarction, percutaneous transluminal angioplasty, or coronary 
artery bypass graft intervention), the 6-month case-fatality rate after a stroke event, 
and other cardiovascular mortality (CVD related mortality, not due to a fatal CHD 
or stroke event within 6 months). Table 1 provides an overview of the hazard rate 
ratios for both total and HDL cholesterol underlying the transition probabilities 
for these 3 events. In accordance with earlier research (25), the total incidence of 
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stroke is unchanged by total and HDL-cholesterol – only the fraction of fatal events 
is reduced. This method of modeling statin effectivenss assumes that the statin-
induced reduction in total cholesterol and increase in HDL cholesterol, causes a 
decrease in the hazard rates for cardiovascular related events via the Cox regression 
equations, and lowers the annual probabilities of having such events in the model, 
compared with not taking statins. Based on the most recent meta-analysis by 
Brugts et al (24), we assumed an average 15.7% reduction in total cholesterol from 
baseline when using statins and a 3.1% increase in HDL.
Table 1. Hazard rate ratios in transition probabilities relating to Total cholesterol and HDL cholesterol.
Transition probability Hazard rate ratio per 1 mmol/L 
increase in Total cholesterol  
[95% confidence interval]**
Hazard rate ratio per 1 mmol/L 
increase in HDL cholesterol  
[95% confidence interval]****
CHD event¶ 1.22 [1.13 1.36] 0.30 [0.18 0.44]
Stroke event§ n/a n/a
6 month fatality rate after a CHD 
event
n/a n/a
6 month stroke case fatality rate 0.78 [0.62 0.93] Age 60 – 0.14†
Age 65 – 0.26†
Age 70 – 0.46†
Age 75 – 0.86†
Age 80 – 1.56†
Other CVD mortality± 1.01 [0.99 1.03] n/a
* Anual transition probabilities
** Hazard rate ratio > 1 indicates that a 1 mmol/L increase in Total or HDL cholesterol increases the specific probability
¶ A CHD event is defined as fata or non-fatal myocardial infarction, CABG or PCI
§ A stroke event is defined as a fatal or non-fatal ischemic or unspecified stroke event
± Other CVD mortality is defined as mortality due to heart disease, cerebrovascular disease or other arterial disease, not due to a fatal 
CHD or stroke event within 6 months
† HDL cholesterol included as variable on its own and as interaction term with age. An increase in HDL cholesterol lowers this hazard 
up until age 76, and increases the hazard for individuals aged 77 and over
n/a: not applicable, i.e. total cholesterol or HDL-cholesterol was not included in the regression equation underlying the specific state 
transition probability
(II) Fixed risk reduction of CVD events: based on the same meta-analysis, clinical trials 
have shown an average reduction in the incidence of a first fatal or non-fatal 
myocardial infarction (OR 0.7 95%CI [0.61 0.81]) and first fatal or non-fatal stroke 
event (OR 0.81 95%CI [0.71 0.93]) (24). Directly applying these odds ratio’s to the 
annual odds of a first fatal or non-fatal myocardial infarction and fatal or non-fatal 
stroke, lowers the incidence of having such events in the model, compared with 
not taking statins. We assumed that the case-fatality rate following a CHD or stroke 
event remained unchanged. 
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(III) Risk reduction of CVD events proportional to individual change in LDL cholesterol: 
the third modeling method assumes that the statin induced reduction in LDL 
cholesterol is an indicator of the risk reduction that can be expected from statin 
therapy. Given an individual’s baseline LDL cholesterol, the expected absolute 
reduction in LDL cholesterol in mmol/L was calculated, based on the same meta-
analysis as used in methods 1 and 2 which demonstrated an average relative 
reduction in LDL of 23.7% (24). Based on another source, the risk reduction in the 
incidence of first fatal or non-fatal myocardial infarction was estimated to be 0.23 
per mmol/L LDL reduction, and 0.17 for first fatal or non-fatal stroke (26). Multiplying 
each individual’s baseline LDL level (mmol/L) with the relative reduction in LDL and 
with the risk reduction per mmol/L LDL reduction, we obtained each individual’s 
estimated risk reduction under statin therapy. Applying these individual risk 
reductions to the annual probabilities of a first non-fatal myocardial infarction 
and first fatal or non-fatal stroke, lowers the incidence of having such an event in 
the model, compared with not taking statins. This method differs from method I, 
because it does not affect the beta-coefficients in the state-transition probabilities 
but affects the probabilities of incident myocardial infarction and stroke similarly 
as method II. It does differ from method II, as the risk reduction is not fixed for each 
individual, but depends on the individual’s baseline LDL level. 
Decision Problem
To illustrate the impact of using the three different methods, the cost-effectiveness 
of applying the ATP-III guidelines (12) to the Rotterdam study population, compared to 
current practice without implementing the ATP-III guidelines (reference strategy). For 
simplicity we assumed that the individuals in the Rotterdam study did not use statins 
at baseline. For the ATP-III guidelines strategy, we assumed that an individual would be 
assigned a statin if one of the following were true:
(1) The predicted 10-year risk for a hard CHD event, based on the Framingham risk 
score (27) would be lower than 10%, and baseline LDL cholesterol would exceed 
160 mg/dL
(2) The predicted 10-year Risk based on the Framingham risk score would be between 
10 and 20%, and baseline LDL cholesterol would exceed 130 mg/dL
(3) The predicted 10-year Risk based on the Framingham risk score would be 20% or 
higher, and baseline LDL cholesterol would exceed 100 mg/dL
(4) An individual had experienced a previous CVD event at baseline
(5) An individual had been diagnosed with diabetes at baseline
We did not explicitly model the exact dosage and type of statin given to an individual, 
but assumed that the statin type and dose would match those covered in the meta-
analyses (24, 26) used. We used tracker variables to model myopathy and hepatitis, two 
of the most important side effects of statins, and used hazard rate ratios to model the 
increased risk of these events due to statin use based on a meta-analysis of side effects (28). 
We modeled the associated decrease in quality of life and costs of both events (2). For the 
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purpose of this study, adherence to statin treatment was assumed to be equivalent to 
that obtained in the studies included in the meta-analysis.
Table 2 provides an overview of the most important parameter values with regard to 
probabilities, costs and utilities. Parameter distributions were determined directly from 
its source, or additional assumptions were made. 
Table 2. Important model parameters and assumptions. 
Model assumptions
Parameter Base case – 95%CI Distribution Reference
Statin cost per year 300 euro”  (33) 
% decrease total cholesterol with statin 15.7 [15.0 16.6] beta (34)
% decrease LDL cholesterol with statin 23.7 [22.7 25.6] beta (35)
% increase HDL cholesterol with statin 3.1 [2.7 3.5] Beta  (24)
Odds ratio non fatal and fatal myocardial infarction  
with statin
0.70 [0.61 0.81] lognormal  (24)
Odds ratio non fatal and fatal stroke with statin 0.81 [0.71 0.93] lognormal  (24)
Relative risk reduction per mmol/L decrease in 
LDL cholesterol on non fatal and fatal myocardial 
infarction with statin
0.77 [0.74 0.8] lognormal  (24) 
 Relative risk reduction per mmol/L decrease in LDL 
cholesterol on non fatal and fatal stroke with statin
0.83 [0.78 0.88] lognormal  (24)
5 year risk of myopathy episode with statin 0.002 binomial  (26)
Hazard rate ratio of a myopathy episode during  
one year with statin use
6.15 [5.19 7.3] (men) 
; 2.97 [2.36 3.74] 
(women)
gamma (26) 
Cost of myopathy* 238 euro - (28)
QALY loss myopathy* 0.18 -  (28)
5 year risk of hepatitis episode with statin 0.014 binomial  (2,28)
Hazard rate ratio of a hepatitis episode during one year 
with statin use
1.53 [1.41 1.66] gamma (2,28) 
Cost of hepatitis* 116.5 euro - (28)
QALY loss hepatitis* 0.0429 -  (28)
* Number given is a one time decrease in quality adjusted life years and a one time cost penalty for one episode of myopathy or 
hepatitis. Details of these numbers are provided in the technical appendix
“ Assumed use of generic statins
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Analysis
For each of the 3501 individuals, the 10-year Framingham risk score, based on the original 
paper from 1998, was calculated (27). Important baseline variables were calculated, 
stratified by three risk categories: low (10 year Framingham risk <10%), intermediate 
(10-20%) and high (>20%). Individuals with a history of CVD or diabetes at baseline 
were considered to be at high risk. Quality-adjusted life years (QALYs), life time costs, 
incremental cost-effectiveness ratios (i.e., additional costs divided by QALYs gained) 
were calculated for the ATP-III strategy and reference strategy, for all three modeling 
methods separately. To take time preference into account, future costs and effectiveness 
were discounted at the currently recommended U.S. discount rate of 3% for both costs 
and effectiveness (29). Strategies were first ordered according to increasing cost. A 
strategy was considered dominated if another strategy was both more effective and 
less costly. A strategy was considered extended dominated if another strategy achieved 
more effectiveness at a lower incremental cost-effectiveness ratio. After eliminating 
dominated and extended dominated strategies, the incremental cost-effectiveness 
ratios were calculated as the difference in mean lifetime costs divided by the difference 
in mean QALYs for each strategy compared to the next best non-dominated strategy. 
A three-level simulation was performed. The first loop consisted of 1000 parameter 
drawings, including the joint distributions of the beta coefficients from the Cox 
proportional hazards equations, representing parameter (second order) uncertainty. 
The second loop consisted of a fixed subset of 200 randomly drawn individuals from the 
3501 individuals, each with their own risk profile, representing heterogeneity. Average 
values of the baseline characteristics for these 200 individuals were not significantly 
different from those of the 3501 individuals. The third and final loop consisted of 100 
random walks (stochastic uncertainty) which was necessary because multiple tracker 
variables were used in the model (30). For each of the three modeling methods, we 
calculated the probability that the ATP-III strategy was cost-effective, for a range of 
willingness-to-pay thresholds, generating acceptability curves. 
In order to get more insight into possible differences between the modeling methods 
with regard to the ICERs, we determined intermediate outcomes such as the age of 
death, the percentage of all deaths due to CVD and non-CVD causes, and the percentage 
of individuals with incident CHD, stroke and total incident CVD.
Sensitivity analysis
As the first method directly affects both the hazards of CVD events and other CVD 
mortality, and includes an interaction with age and HDL cholesterol in one of the 
transition probabilties, the potential differences in outcomes between the three 
methods are anticipated to be sentitive to the time horizon modeled, as well as the age 
range of the population simulated. In a sensitivity analysis, we checked whether the 
results would be different when using a follow up of 5, 10, 15 and 20 years. In another 
sensitivity analysis, we stratified the analysis by age groups. We ran the (lifetime) 
simulation with individuals who belonged to the first, second, third and fourth age 
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quartile, respectively. We calculated the ICER of implementing ATP-III vs the reference 
strategy, and the probability that the ATP-III stratey was cost-effective, for each of the 
modeling methods in each subgroup and a willingness-to-pay of 50,000 euro.
Results
Base case analysis
Important baseline characteristics of the 3501 individuals from the Rotterdam Study, 
stratified by the Framingham risk score categories can be found in Table 3. As expected, 
on average risk factor profiles were less favourable for individuals in higher risk categories. 
The incremental cost-effectiveness ratio’s of the ATP-III strategy compared with the 
reference strategy for the three different modeling methods were 56,642 euro/QALY, 
21,369 euro/QALY and 22,131 euro/QALY, respectively (Table 4). Acceptability curves 
(Figure 1) show that for a willingness-to -pay between 30,000 and 60,000 euro/QALY, 
the ATP-III guidelines strategy had a less than 50% probability of being cost-effective 
using modeling method I, but more than 85% probability of being cost-effective using 
modeling method II or III.
Table 3. Baseline characteristics of the 3501 individuals of the Rotterdam Study. Mean values and 
standard devations between brackets.
Variable Low Risk N= 1400 Intermediate Risk N = 1058 High Risk* N = 1043
Age, Years 66 (7.90) 71 (8.15) 72 (9.78)
Men (%) 3% 55% 66%
Glucose level (mmol/L) 6.11 (1.31) 6.57 (1.35) 7.86 (2.81)
BMI 25.9 (4.74) 27.9 (3.92) 26.8 (2.77)
Total Cholesterol (mg/dL) 257.6 (42.4) 252.0 (49.4) 262.4 (44.3)
HDL Cholesterol (mg/dL) 57.7 (14.8) 54.6 (17.9) 45.7 (15.6)
LDL Cholesterol (mg/dL) 169.3 (36.5) 167.7 (43.7) 181.6 (36.5)
Waist to hip ratio 0.85 (0.07) 0.98 (0.09) 0.94 (0.08)
Systolic Blood Pressure (mm Hg) 129 (17) 140 (17) 149 (18.6)
Diagnosed with Hypertension (%) 10% 39% 55%
Diagnosed with Diabetes Mellitus 
(%)
- - 28%
*Includes individuals with a history of CVD or Diabetes at baseline. 
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Table 4. Average costs, QALYs and incremental cost-effectiveness ratio’s (ICER) for the reference 
strategy and the ATP-III strategy calculated with each modeling method. The ICER comparing ATP-III 
with the reference strategy is presented for each modeling method.
  Cost (Euro) [95%CI] QALY [95%CI] ICER (Euro/QALY)
Reference Strategy¶ 10,230 
[9,623 10,942]
9.35
[8.97 9.75]
 
I. Through Lipid Level Modification 12,942
[12,321 13,599] 
9.40
[9.02 9.80]
56,642
II. Fixed Risk Reduction 12,702
[12,046 13,396]
9.47
[9.09 9.87]
21,369
III. Risk Reduction proportional to LDL 12,736
[12,135 13,739]
9.47
[9.09 9.87]
22,131
¶ Reference strategy consists of the current practice in the Rotterdam Study without implementing the ATP-III guidelines
Intermediate outcomes
The age at death increased with the ATP-III strategy compared to the reference strategy 
and was the highest for method II and III (Table 5). Of all deaths, the percentage from 
CVD decreased with ATP-III and as a consequence, the non-CVD causes of death 
increased slightly, which was the most prominent with methods II and III. Incident CHD 
and CVD decreased with ATP-III, but the decrease was larger with modeling method II 
and III compared to method I. The incidence of stroke decreased with method II and III, 
but increased slightly with method I. 
Sensitivity analysis
The four selected groups based on age-quartiles were on average 59, 65, 71 and 81 years 
of age. Figure 2 shows that the incremental cost-effectivess of the ATP-III guidelines 
declined when older populations were simulated compared with younger ones, for 
method II and III, but increased for method I. Figure 3 shows that an increase in follow-
up duration decreased the ICER of the ATP-III strategy in general, but the decline was 
larger with method I compared to II and III.
The probability that the ATP-III strategy is cost-effective declines when older populations 
are simulated with method I, while it increases slightly with method II and III (Figure 4). 
Longer follow-up was associated with a higher probability that the ATP-III strategy is 
cost effective for all three methods (Figure 5). 
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Table 5. Intermediate outcomes for the base case analysis for each of the three modeling methods.
 
Age at 
death
% that died 
from CVD 
cause
% that died 
from other 
cause
% with 
incident 
CHD
% with 
incident 
Stroke
% with 
incident 
CVD
Reference Strategy 86.6 38.1 61.9 13.6 19.4 20.7
ATP-III: I. Through Lipid Level 
Modification
86.7 37.7 62.3 11.2 19.6 19.4
ATP-III: II. Fixed Risk Reduction 86.8 36.9 63.1 10.4 17.1 18.3
ATP-III: III. Risk Reduction 
proportional to LDL
86.8 36.9 63.1 10.7 17 18.1
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Figure 1. Acceptability curves showing the probability that the ATP-III strategy is cost effective for 
each of the three modeling methods, for a range of willingness-to-pay values. 
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Figure 2. Incremental Cost-Effectiveness Ratio’s for the four age-quartiles, for modeling method I, II 
and III. 
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Figure 3. Incremental Cost-Effectiveness Ratio’s for the four different follow-up durations, for modeling 
method I, II and III.
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Figure 4. Probabilities that the ATP-III strategy is cost-effective given a willingness-to-pay of 50,000 
Euro / QALY, for the four age-quartiles, for each of the three modeling methods.
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Figure 5. Probabilities that the ATP-III strategy is cost-effective given a willingness-to-pay of 50,000 
Euro / QALY, for the four different follow-up durations, for each of the three modeling methods.
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dIsCussIon
In this study, we evaluated the consequences of using different modeling methods of 
statin treatment effectiveness on the cost-effectiveness of implementing the ATP-III 
guidelines for the primary prevention of cardiovascular disease. We found that different 
modeling assumptions about the effect of statin therapy affected the results such that 
the optimal decision would change. For willingness-to-pay thresholds of 30,000 – 60,000 
euro/QALY, modeling methods II and III would lead to the conclusion that the ATP-III 
guidelines are cost-effective, whereas using method I would lead to the conclusion that 
the ATP-III guidelines are not cost-effective. 
These results were not obvious a priori as the three methods influence different 
events compared to another. Modeling method I leads to a lower probability of CHD, 
the 6-month case-fatality rate after a stroke (a conditional probability) and other 
cardiovascular mortality. Methods II and III lower the incidence of CHD and stroke as 
well, but do not affect the latter two probabilities. An indirect effect was present on 
the incidence of stroke with model I: since the hazard rate ratio of incident stroke is 
unchanged with statins with method I and as a result of competing risks in the model, an 
increase in the incidence of stroke was observed compared with this method compared 
to the reference strategy. As strokes are an important determinant of cardiovascular 
disease, these differences between the modeling methods partly explain the QALY and 
cost disadvantage for method I compared to II and III.
Two important sensitivity analyses showed how age and the decision time-frame 
influenced our findings. For individuals aged 77 and over, a statin-induced increase in 
HDL cholesterol would lead to an increase in the hazard of stroke mortality due to the 
interaction with age (Table 1). This can partly explain the steep increase in the ICER of 
the ATP-III with this method, observed in Figure 2. The steeper decline in ICER of the 
ATP-III with method I when follow-up is extended from 5 to 10 years can be explained 
by the fact that a substantial part of the effect of statin treatment with this method is 
obtained through the reduction in other CVD mortality. The probability of CVD mortality 
is higher after a non-fatal CVD event and non-fatal CVD events accumulate with a longer 
follow-up. 
Are these findings generalizable to other models than the RISC model and would a 
similar difference between method I vs II/III have been found? Several investigators 
have modeled the treatment effect of a statin similar to method I (2, 8, 14-18). These models 
are, just like the RISC model, based on risk factor dependent transition probabilities 
with total and HDL-cholesterol as lipid-based risk factors (15-18). The treatment effect of 
statins was, similar to method I, modeled through these risk factors and accompanying 
regression coefficients. While the magnitude of the beta coefficients of total and HDL-
cholesterol may differ from those in the RISC model, it is highly likely that similar 
associations between cholesterol risk factors and CHD and stroke events would have 
been found. More specifically, other data supports the lack of an association between 
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total cholesterol, HDL cholesterol and incident stroke (25), but did find a trend for HDL 
cholesterol on fatal stroke. Thus, any simulation model based on risk factor dependent 
transition probabilities based on observational data, that would incorporate stroke 
events, would likely be subject to the same phenomenon as observed with modeling 
method I in the RISC model. It would be interesting to see if models using a method 
similar to method I would report worse cost-effectiveness ratios of statin interventions 
than models using a method similar to method II or III. However, the papers we looked 
into were too heterogeneous with regard to the exact statin-based intervention to 
make a meaningful comparison. 
With regard to the possible mechanisms underlying the treatment effect of statins, 
other authors have suggested that statins have a cardioprotective effect beyond the 
improved lipid levels (31-32). This would suggest a preference for methods II and III, 
which directly model the relation between statin therapy and outcomes and capture 
the (potential) effects on events beyond lipid lowering. However, the validity of a 
model only partly depends on the structural modeling of the treatment effect. Being 
a simplifying abstraction of reality, a model will be valid with regard to some (but not 
necessarily all) mechanisms or relationships as observed in real life. Assumptions made 
to assure that particular mechanisms are characterized can cause the model to be less 
valid with regard to other possible mechanisms. For example, if the decision problem 
requires that the modeled reduction in incident CHD and stroke corresponds to the 
same reduction as observed in trials, the resulting reduction in fatal total CVD events 
produced by this model is unlikely to match the observed reduction in fatal total CVD 
events in the same trials if no further adjustments or assumptions are introduced. This 
makes the modeling of complex interrelationships more of an art than an exact science. 
For each particular decision problem it is important to determine which assumptions 
each approach is sensitive to, determine the appropriateness of these assumptions, 
and judge the relevance of the model sensitivity to them in the context of the decision 
problem studied. Rather than determining the validity of the three methods against 
some arbitrary chosen ‘’gold standard’’, we demonstrated how the different methods 
currently used in practice can affect the results and alter the conclusions of a decision 
analysis. 
Our study bears some limitations. The state transition probabilities in the RISC model did 
not include LDL cholesterol as a covariate. Similarly, the original Framingham risk score 
and the European SCORE function, do not include LDL cholesterol as well. Instead, they 
include HDL and total cholesterol, as does the RISC model. Although we demonstrate 
large differences in results, our study does not provide information on which modeling 
method is optimal. The complex interplay between various aspects of Markov decision 
models, including competing risks and extrapolation to lifetime events, make it 
practically impossible to say beforehand which method would be preferable in terms 
of model validity. The only proper way to find out is to perform a thorough validation 
analysis, both internal and external, before a simulation model is used to evaluate a 
decision problem.
501599-L-bw-van Kempen
100 | Chapter 4
In our analysis, we evaluated the ATP-III treatment scenario. Although our results could 
be different for other statin treatment scenario’s – such as pure risk-based treatment 
interventions, it is likely that such scenarios are subject to the same effects of modeling 
treatment effectiveness. Though we explicitly looked into the effect of statins, other 
interventions targeting risk factors or intermediate outcomes in primary prevention of 
cardiovascular disease such as smoking cessation, weight loss and blood pressure are 
likely to be subject to the same phenomenon. Smoking status, systolic and diastolic 
blood pressure, and weight-related risk factors such as BMI or waist-to-hip ratio are 
included as covariates in the RISC model. An intervention on these risk factors can be 
assumed to work through the modification of these covariates, similar to method I, or 
directly on event incidence rates as in method II and III. With this in mind, our results 
further stress the importance of thorough consideration of the assumptions underlying 
a simulation model and performing extensive model validation.
In conclusion, this study points out that the choice of  modeling  method of the 
effectiveness of statin treatment in simulation studies can influence the optimal decision 
and the uncertainty associated with it. 
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teChnICAl AppendIx
In this Appendix, we provide additional information on the RISC model and analyses.
RISC Model 
The RISC model is a Monte Carlo state-transition model (schematically presented in 
Figure 6) with six states: (1) the CVD death state, (2) the non-CVD death state, (3) the 
Coronary Heart Disease (CHD) state, (4) the Stroke state, (5) the CHD and Stroke state 
and (6) the Well state (being alive without coronary heart disease or stroke). The model 
simulates incident CVD events in individuals based on risk factor dependent transition 
probabilities, using Cox regression equations. Individual risk factor profiles were 
modeled and tracked over time. The model was built in TreeAge (version 2009, TreeAge 
Software, Inc., Williamstown, USA).
Probabilities for the transitions between the six health states were based on six 
multivariable Cox regression equations. The development of these equations was 
described in a previous article on the RISC model (1). The first equation estimated the 
cumulative hazard from the Well state to the CHD state and from the Stroke state to 
the CHD & Stroke state. The second equation estimated the cumulative hazard from 
the Well state to the Stroke state and from the CHD state to the CHD & Stroke state. 
In developing these models, censoring was performed for an incident stroke and 
CHD respectively. In both equations, previous CHD and/or stroke were included as a 
covariable. The third and fourth equations estimated the 6-months cardiovascular 
mortality rate (case-fatality) after a CHD and stroke event respectively. Six-month case-
fatalities were used as proxies for the immediate fatality rates of these events. The 
probability of dying from a fourth CHD event and third stroke event were assumed to 
be 100%. The fifth and sixth Cox regression equations estimated the cumulative hazards 
of the remaining CVD mortality, which is caused by other causes than CHD or stroke 
(see Table 6 for equations). For extrapolation to a lifelong follow-up, follow-up time was 
divided into 5-year intervals and a cycle length of one year was chosen. The first 5 years, 
baseline values of covariables were used together with the one-year cumulative hazards 
from the Cox models for each cycle. For the remaining follow-up, the same baseline 
one-year cumulative hazards were used, but values of the covariables were updated 
every 5 years by using multiple linear regression for continuous variables and logistic 
regression for dichotomized variables. From the outcomes of the logistic regression 
equations regarding dichotomized variables, binomial distributions were created. Every 
5 year period during follow-up, presence (1 or 0) of the dichotomized variables was 
derived from these distributions. Cumulative hazards of fatal and non-fatal events were 
separately weighted for their total cumulative hazards to ascertain that all probabilities 
for respectively cardiovascular and non-cardiovascular mortality vs. survival and stroke 
and CHD events vs. disease-free survival summed to one. For each transition, cumulative 
hazards were converted to probabilities by exponentiation. Occurrences of events and 
duration in each health state were stored using Monte Carlo tracker variables to allow 
for the calculation of incidences of the different events. These tracker variables are 
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variables used to count the occurrences of a state transition representing an event in 
TreeAge.
Myopathy and Hepatitis
An individual could experience an episode of myopathy each cycle, tracked by 
t_myopathy. If an episode of myopathy occurred, we assumed a 1.6% probability of 
hospital admittance, for an average stay of 7.5 days, and a reduction of 0.5 in quality of 
life. In case of hospital admittance, a 10% mortality rate was assumed and an average 
remaining life expectancy of 15 years for individuals who would have survived (2). After 
admittance, a 30 day recovery period with a reduction of 0.2 in quality of life was 
modelled. In case of hospitalisation we assumed a one time cost of $13,000. Standard 
lab follow up was expected to cost $30. An individual could experience an episode 
of hepatitis each cycle, tracked by t_hepatitis. If an episode of hepatitis occurred, we 
assumed a 0.45 % probability of hospital admittance, for an average stay of 7.1 days, and 
a reduction of 0.5 in quality of life (2). After admittance, a 30 day recovery period with a 
reduction of 0.2 in quality of life was modelled. In case of hospitalisation we assumed 
a one time cost of $17,000. Standard lab follow up was expected to cost 40$. Based on 
the probabilities of hospital admittance, we calculated the expected costs in case of 
myopathy and hepatitis to be 180 euro and 90 euro respectively (costs were converted 
to 2010 euro’s).
Table 6. Model Input Parameters
Cox Proportional 
Hazards Equations
Equations* 
CHD: Hazard function = baseline cumulative hazard x EXP(β1*male + β2*age + β3*age*age + 
β4*diabetes*glucose + β5*TC + β6*HDL + β7*PP + β8*PP*male + β9*angina + β10*ABI + 
β11*ABI*ABI + β12*smoking + β13*famhistMI + β14*CVD + β15*creat-β16)
Stroke: Hazard function = baseline cumulative hazard x EXP(β1*male + β2*age + β3*hypertension 
+ β4*hypertension*age + β5*SBP + β6*smoking + β7*famhistMI + β8*TIA + β9*CVD + 
β10*CVD*male + β11*AF + β12*ABI-β13)
6-months CHD event 
mortality: 
Hazard function = baseline cumulative hazard x EXP(β1*age + β2*diabetes*glucose + 
β3*hypertension + β4*hypertension*age + β5*creat-β6)
6-months Stroke event 
mortality:
Hazard function = baseline cumulative hazard x EXP(β1*age + β2*smoking + 
β3*famhistCVD + β4*ABI + β5*TC + β6*creat + β7*HDL + β8*ABI*ABI + β9*age*HDL-β10)
CVD mortality: Hazard function = baseline cumulative hazard x EXP(β1*age + β2*male + β3*diabetes 
+ β4*HDL + β5*hypertension + β6*hypertension*age + β7*smoking + β8*CVD + 
β9*ABI + β10*ABI*AΒI + β11*AF + β12*AF*male + β13*age*AF + β14*male*CVD + 
β15*CVD*TC*TC-β16)
Non-CVD mortality: Hazard function = baseline cumulative hazard x EXP(β1*male + β2*age + 
β3*diabetes*glucose + β4*TC + β5*smoking + β6*smoking*age + β7*BMI + β8*BMI*age 
+ β9*WHR + β10*WHR*age + β11*WHR*CVD + β12*famhistCVD + β13*famhistCVD*age + 
β14*ABI + β15*ABI*age + β16*CVD-β17)
*Beta coefficients were drawn from a table comprising estimated beta coefficients from Cox regression equations developed in 100 
bootstrapped datasets.
Abreviations: ABI = ankle-brachial index, AF = atrium fibrillation, BMI = body mass index, CHD = coronary heart disease, C.I.’s = 
confidence intervals, creat = creatinine, CVD = cardiovascular disease, HDL = famhistMI, family history of myocardial infarction, high-
density lipoprotein, famhistCVD = family history of cardiovascular disease, PP = pulse pressure, SBP = systolic blood pressure, TC = total 
cholesterol, TIA = transient ischaemic attack, WHR = waist-to-hip ratio
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Figure 6. Schematic presentation of RISC model.
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AbstRACt 
Background: Physicians need to inform asymptomatic individuals about personalized outcomes 
of statin therapy for primary prevention of cardiovascular disease (CVD). However, current 
prediction models focus on short-term outcomes and ignore the competing risk of death due to 
other causes. We aimed to predict the potential lifetime benefits with statin therapy taking into 
account competing risks.
Methods and Findings: A microsimulation model based on 5-year follow-up data from the 
Rotterdam Study, a populationbased cohort of individuals aged 55 years and older, was used 
to estimate lifetime outcomes with and without statin therapy. The model was validated in-
sample using 10-year follow-up data. We used baseline variables and model output to construct: 
1) a web-based calculator for gains in total and CVD-free life expectancy and 2) colour charts 
for comparing these gains to the SCORE (Systematic COronary Risk Evaluation) charts. In 2,428 
subjects (mean age 67.7, 35.5% men), statin therapy increased total life expectancy by 0.3 years 
(SD 0.2) and CVD-free life expectancy by 0.7 years (SD 0.4). Age, sex, smoking, blood pressure, 
hypertension, lipids, diabetes, glucose, body mass index, waist-to-hip ratio, and creatinine were 
included in the calculator. Gains in total and CVD-free life expectancy increased with blood 
pressure, unfavourable lipid levels and body mass index after multivariable adjustment. Gains 
decreased considerably with advancing age, while SCORE 10-year CVD mortality risk increased 
with age. Twenty-five percent of subjects with a low SCORE risk achieved equal or larger gains in 
CVD-free life expectancy than the median gain in subjects with a high SCORE risk.
Conclusions: We developed tools to predict personalized increases in total and CVD-free life 
expectancy with statin therapy. The predicted gains we found are small. If the underlying model 
is validated in an independent cohort, the tools may be useful in discussing with patients their 
individual outcomes with statin therapy.
Abbreviations: CHD = coronary heart disease, CVD = cardiovascular disease, ESC = European Society of 
Cardiology, OECD = Organisation for Economic Co-operation and Development; RISC = Rotterdam Ischemic 
Heart Disease & Stroke Computer Simulation, SCORE = Systematic COronary Risk Evaluation 
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IntRoduCtIon
Current guidelines recommend that asymptomatic individuals at high cardiovascular disease (CVD) 
risk should be identified for statin therapy. For this purpose, risk assessment is performed using 
prediction models estimating short-term, i.e. 5 to 10-year CVD risk (1, 2). The higher the predicted 
CVD risk, the stronger is the recommendation to initiate statin therapy. This reasoning is based 
on solid evidence demonstrating a CVD risk reducing effect (3, 4) with an expected larger absolute 
benefit as CVD risk increases (5). For shared decision making, physicians need to communicate 
to the patient personalized information about the outcomes of statin therapy (6). Whether the 
magnitude of the expected benefit would outweigh the disadvantages of statin therapy (e.g. side 
effects, the disutility of taking a pill every day), can be discussed with the individual in order to 
reach agreement on initiation of the drug therapy.
Using the currently available short-term CVD prediction models for estimating treatment benefits 
has limitations. First, statin therapy is generally continued over the remainder of the course of a 
lifetime, and information for decision-making should reflect the expected long-term benefit (7). 
Second, shortterm risk reductions are generally small and difficult to interpret by lay people (8). 
Third, competing risk of death due to other causes than CVD is generally not taken into account. 
Especially in frail individuals, who are also at high risk of dying due to other causes, ignoring the 
competing risk of non-CVD death leads to overestimation of CVD risk and thus overestimation 
of the treatment benefit (9). Decision models have the ability of extrapolating short-term follow-
up data to a lifetime horizon while taking into account competing risks of death. Results can 
be expressed on a time scale, as gains or losses in (CVD-free) life expectancy. Life expectancy 
measures have the advantage that the aggregated treatment benefits over the full life span can be 
represented by a single value. This could provide information complementary to the conventional 
communication of risk reduction, which is limited to the use of fixed time points (10). Presenting 
data in various different ways can be helpful to assess the certainty about therapy choices and 
could improve the quality of decision-making (11).
Our aim was to predict personalized lifetime benefits with statin therapy for prevention of CVD in 
asymptomatic individuals without a history of CVD.
Methods
The decision model
We used a previously developed microsimulation state-transition model, the Rotterdam Ischemic 
Heart Disease & Stroke Computer Simulation Model (RISC model), which was built in TreeAge 
(version Data Professional release 10, TreeAge Software, Inc., Williamstown, USA) (12). The RISC 
model was developed using 7-year follow-up data from 3,501 participants of the Rotterdam 
Study, a population-based cohort study of individuals aged 55 years and older followed from 
1990 and onwards. Only participants were used with complete data on the baseline risk factors 
in the development of the RISC model (13). Instead of using the 7-year hazard rates, more stable 
5-year hazard rates were used for extrapolation to a lifetime horizon in order to evaluate the 
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lifetime effects of CVD preventive strategies. In the model, life courses of subjects are simulated 
using six health states: well, post non-fatal coronary heart Disease (CHD), post non-fatal stroke, 
post non-fatal CHD and nonfatal stroke, cardiovascular death, and non-cardiovascular death 
(see Figure 1). CHD was defined as: acute myocardial infarction (International Classification of 
Diseases, 10th version (ICD-10) code I21), PTCA and CABG. Stroke was limited to non-hemorrhagic 
and unspecified strokes (ICD-10 codes I63, I64) in order to be able to model the adverse bleeding 
risk of preventive interventions such as aspirin therapy separately. Cardiovascular death was 
defined as mortality due to hypertensive diseases (ICD-10 codes I10-15), ischemic heart disease 
(ICD-10 codes I20-I25), sudden cardiac death (ICD-10 codes I46, I49), congestive heart failure 
(ICD-10 code I50), cerebrovascular disease (ICD-10 codes 160 – 167), other arterial disease (ICD-
10 codes I70-I79), or sudden death (ICD-10 code R96). Noncardiovascular death was defined as 
mortality due to all other causes (all other ICD-10 codes). Within 5 years of follow-up, 176 CHD 
events, 127 stroke events, 165 CVD deaths, and 264 non-CVD deaths occurred in the development 
population of 3,501 subjects. Transitions between health states were individualized using 
multivariable Cox regression models, while adjusting for competing risk. Consequently, the 
“one-cycle cumulative incidence” for each event was calculated by the ratio of the cumulative 
hazard of the event of interest censored for all other events to the cumulative hazard of any event, 
multiplied by the probability of any event. If constant hazards are assumed within each cycle, 
the overall cumulative incidences will be estimated correctly (14). The Cox regression models were 
fitted in 100 bootstrapped datasets to take into account the parameter uncertainty of hazard 
ratios. Each simulated individual entered the model starting in the Well state, with his or her 
baseline risk profile. Secular trends in risk factor levels were modeled across the age span using 
crosssectional analyses of baseline data. The individual’s risk profile at baseline and (if alive) the 
updated risk profile at the beginning of each simulated subsequent fifth year was used as input 
for the Cox regression equations. In addition, the Cox regression equations included age-risk 
factor interactions. Two life course scenarios were modeled: “with statin therapy” vs “without 
statin therapy”. A cycle length of 1 year without discounting to provide an “actual” life expectancy 
was applied (for more information about the RISC model, see Text S1).
Model validity
The RISC model was constructed with extrapolation of 5-year predictions based on 7-year follow-
up data of 3,501 subjects. However, at the moment of this analysis, we had access to data with 
a mean follow-up duration of 11.8 years including 367 CHD events, 343 stroke events, 494 CVD 
deaths and 846 non-CVD deaths. Therefore, we were able to evaluate the validity of extrapolation 
to the longer term by comparing simulated and observed cumulative incidences at 5 and 10 
years follow-up. We modelled the life courses of the 3,501 Rotterdam Study participants. To 
assess parameter uncertainty, we calculated 95% confidence intervals (95%CIs) by consecutively 
sampling beta coefficient estimates from the Cox regression analyses performed in the 100 
bootstrapped datasets. Observed cumulative incidences and 95% CIs were calculated with taking 
into account the competing death risks and loss-to-follow-up by using the R cuminc function 
available from the mstate package. To assess model discrimination, we calculated the Harrell’s 
C-statistic (15) for 10-year CHD events, stroke events, CVD mortality and non-CVD mortality. We 
adjusted the C-statistic for competing risk by setting the censoring time to “infinity” (i.e. the 
maximum follow-up time of 10-years +1) for those who died of causes other than the event of 
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interest (9). In addition, we compared the 10-year CVD mortality risk from the RISC model with 
the European Society of Cardiology (ESC) SCORE (Systematic COronary Risk Evaluation) charts. 
Because uncertainty exists about which SCORE charts to use for Dutch individuals (16), we compared 
10-year CVD mortality risk to the three available versions: high-risk region, low-risk region and 
Dutch recalibrated SCORE charts. SCORE 10-year CVD mortality risks were calculated using the 
equations provided by Conroy et al (17) and Van Dis et al (16). For calculation of the RISC model’s 10-
year CVD mortality risk, we included death by CVD other than stroke and CHD. The RISC model’s 
average 10-year CVD mortality risk estimations and the predictions by each SCORE equation were 
plotted by tenths of predicted 10-year CVD mortality by the RISC model. This was only done for a 
subset of 1,047 asymptomatic subjects younger than 65 years, meeting the population criteria for 
which the SCORE equations are applicable (17). The 95% CIs of estimates by the RISC model were 
calculated by sampling from the 100 beta coefficient bootstrap replicates as previously described; 
95%CIs of SCORE predictions were estimated using non-parametric bootstrapping of the data in 
each tenth.
Other death
CVD death
StrokeWell CHD CHD & Stroke
Figure 1. Schematic representation of the RISC model.
Statin therapy efficacy
The effect of statin therapy was modeled on the occurrence of first CHD and stroke events in 2,428 
subjects who did not use statin therapy at baseline and were free of CVD (defined as: myocardial 
infarction, transient ischaemic attack, stroke diagnosed by a physician and/or a self-reported 
history of CABG, PTCA, or carotid surgery); angina pectoris; intermittent claudication; and atrial 
fibrillation. We conservatively assumed that there was no statin effect on direct transitions from 
the Well state to the Cardiovascular Death state, but that this was solely effectuated through its 
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effect on CHD and stroke events. We did not model additional therapy effects after occurrence of 
CVD and did not consider the negligible fatal adverse effects of statin therapy (18). The odds ratios 
(ORs) for first CHD and stroke events were derived from a recent meta-analysis (see Table S1) (3). This 
meta-analysis provides effect estimates for statins with doses that are generally recommended for 
primary prevention. We assumed that adherence to statin therapy was adequately captured in the 
statin effect, as observed in trials with an intention-to-treat analysis. Because benefits are known 
to be significant within the first year of treatment (19), we assumed that the full extent of the statin 
effect was achieved within one year. In addition, we kept odds ratios (ORs) constant over all ages 
and risk factor levels (3, 20).
Personalized Prediction of Lifetime Benefits
We ran the RISC model for the 2,428 subjects under the scenarios with and without statin therapy. 
To take into account parameter uncertainty of the Cox-regression beta coefficients underlying 
the state transition probabilities, 100 linked sets of coefficients were derived using bootstrapping. 
ORs with statin therapy for first CHD and stroke events were randomly sampled using log-normal 
distributions based on the reported 95% confidence limits. To limit the stochastic error in event 
occurrences, we used 200 random walks per parameter set. Thus, the RISC model output consisted 
of the average lifetime outcomes from 20,000 runs per subject (100 parameter sets x 200 random 
walks) under the two scenarios (“with statin therapy” vs “without statin therapy”). The uncertainty 
in the predictions was addressed by running the RISC model while aggregating at the parameter 
level. To show this parameter uncertainty, we presented average outcomes with 95%CIs. 
Heterogeneity was addressed by running the RISC model while aggregating at the individual 
level (Rotterdam Study subjects); the standard deviations presented represent the variation in 
outcomes across individuals.
Because it is infeasible to run the complicated RISC model for use in clinical practice, we developed 
easily programmable equations that predict the RISC model’s output using the baseline risk 
profile of the individual. We used the data generated by the RISC model while aggregating at the 
individual level as described above. Depending on the outcome chosen, linear and generalized 
linear models with repeated measure statements were used for constructing these equations. Our 
primary outcomes were total life expectancy and CHD/stroke-free life expectancy. In addition, 
we predicted the lifetime risk of developing a first CHD or stroke event (either fatal or non-fatal), 
lifetime CHD/stroke mortality risk, and lifetime total CVD mortality risk. We selected the following 
candidate predictors: age; sex; current smoking; systolic and diastolic blood pressure; hypertension 
(defined as either reporting use of antihypertensive medication and/or a systolic blood pressure 
≥160 mmHg or a diastolic blood pressure ≥95 mmHg at baseline); total cholesterol; high-density 
lipoprotein (HDL) cholesterol; diabetes mellitus (defined as either reporting use of antidiabetic 
medication and/or a random or postload serum glucose level ≥11.0 mmol/L at baseline); serum 
glucose; body mass index; waist-to-hip ratio; and serum creatinine. We chose these variables, 
because they are reliably and easy to obtain during an office-based health check. Interactions 
with statin therapy, age and sex were tested. Continuous variables were entered as linear and 
quadratic terms. Final models were selected based on the Akaike’s Information Criterion (AIC), 
which calculates the log-likelihood penalized for the number of parameters used. All analyses 
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were performed using R version 2.12.2 (R Foundation for Statistical Computing, www.R-project.
org). For details on statistical analyses see the Text S1. 
The predictions by the RISC model have not been independently validated and are thus not ready 
for clinical use. However, to facilitate validation, we developed a web-based calculator using the 
Cleveland Clinic risk calculator constructor (http://rcc.simpal.com/) provided by the Cleveland 
Clinic Foundation (Cleveland, OH, USA), a non-profit corporation. The calculator is available at 
http://www.erasmusmc.nl/clinical-epidemiology/patientcare/. As the calculator is constructed 
using software hosted by the Cleveland Clinic Foundation, users are asked to agree to the 
software license of this organization upon first use. To illustrate the output of the web-based 
calculator, we contrasted the expected lifetime benefits (expressed in total life expectancy and 
CHD/stroke-free life expectancy) with statin therapy to 10-year total CVD mortality risks for four 
different risk profiles.
In order to compare gains in total and CHD/stroke-free life expectancy with office-based 
assessment of 10-year total CVD mortality risk as recommended in the ESC 2007 guidelines, we 
constructed colour charts similar to SCORE risk charts. To show the distribution of the simulated 
gains in total and CHD/stroke-free life expectancy according to SCORE risk estimations we drew 
scatter plots for the asymptomatic population younger than 65 years.
Ethics Statement and Data Access
The Rotterdam Study has been approved by the institutional review board (Medical Ethics 
Committee) of the Erasmus Medical Center and by the review board of The Netherlands Ministry 
of Health, Welfare, and Sports. The approval has been renewed every 5 years. The steering 
committee of the Rotterdam Study does not allow free sharing of data. Currently, Rotterdam 
Study data are only shared within collaborative research projects. Therefore, the data needed for 
constructing the web-based calculator unfortunately cannot be made available for altering to 
different scenarios.
Results
Model Validity
At year 5, the observed (95% CI) vs simulated (95% CI) incidences of CHD, stroke, CVD 
and non-CVD mortality were 5.0 (4.3 – 5.8)% vs 4.7 (4.2 – 5.4)%, 3.6 (3.0 – 4.3)% vs 3.2 
(2.7 – 3.8)%, 4.7 (4.0 – 5.4)% vs 4.8 (3.6 – 6.1)%, and 7.6 (6.7 – 8.5)% vs 8.1% (7.1 – 9.2)%, 
respectively. At year 10, these percentages were 8.5 (7.6-9.5)% vs 8.9 (7.9 – 10.0)%, 7.6 
(6.7 – 8.5)% vs 6.9 (5.9 – 8.1)%, 10.9 (9.9 – 12.0)% vs 10.9 (8.6 – 13.6)% and 17.7 (16.5 – 
19.0)% vs 17.9 (16.1 – 20.0)%. The C-statistic (95% CI) for CHD was 0.73 (0.70 – 0.76), for 
stroke 0.67 (0.64 – 0.70), for CVD mortality 0.80 (0.78 – 0.82) and for non-CVD mortality 
0.74 (0.72 – 0.76).
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In the 1,047 subjects younger than 65 years, the low-risk region SCORE equation 
provided 10-year total CVD mortality estimations that were most similar to the RISC 
model output (see Figure S1). The other two SCORE equations overestimated 10-year 
total CVD mortality risk as compared to the RISC model, particularly in the upper two 
deciles of SCORE risk estimations (see Figures S2 and S3).
Population Results
The baseline characteristics of the study population are summarized in Table 1. In the 
2,428 subjects (mean age 67.7, SD 8.1, 35.5% men), the average total life expectancy 
without statin therapy was 18.3 years (SD 6.5). The average remaining life expectancy 
for females (males) at the age of 60 years was 25.5 (20.4) years, at 65 it was 21.4 (16.7) 
years and at 80 it was 10.5 (7.0) years. These figures were less favourable in the original 
Rotterdam Study cohort including symptomatic individuals (N = 3501): 25.3 (19.8) 
years, 21.1 (16.1) years and 10.2 (6.6) years respectively. Average CHD/strokefree life 
expectancy in the asymptomatic study population was 16.0 years (SD 5.8). For females 
(males) this was 21.8 (16.4) years at the age of 60, 18.4 (13.5) years at 65 and 9.6 (5.6) 
years at the age of 80.
Statin therapy resulted in an average gain in life expectancy of 0.3 (95%CI 0.2 – 0.3) 
years, and ranged from 0.0 to 2.0 years. The gain in CHD/stroke-free life expectancy 
with statin therapy was 0.7 (95%CI 0.5 – 1.0) years and ranged from 0.1 to 2.8 years. The 
absolute risk reduction in CVD incidence by statin therapy was larger than the decrease 
of CVD mortality: 6.6 (95% CI 4.5 – 8.5)% vs. 3.0 (95%CI 2.0 – 3.9)%. The competing other 
CVD and non-CVD lifetime mortality risks increased with 0.9 (95%CI 0.3 – 1.7)% and 2.1 
(95%CI 1.3 – 3.0)%, respectively. The effects of statin therapy on the various outcomes 
are summarized in Table 2. Both the heterogeneity (SDs and ranges) and the parameter 
uncertainty (95%CIs) of gains with statin therapy are shown.
Personalized Prediction of Lifetime Benefits
For the use of the web-based calculator (http://www.erasmusmc.nl/clinical-
epidemiology/patientcare/), information on 13 predictors is required: age, sex, smoking, 
sytolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), hypertension, total 
cholesterol (mmol/L), HDL cholesterol (mmol/L), diabetes mellitus, serum glucose 
(mmol/L), body mass index (kg/m2), waist-to-hip ratio, and serum creatinine (μmol/L). 
Ranges for possible values of continuous predictors were based on the 2.5th and 97.5th 
centiles of these variables in the 2,428 subjects (see Table 1). Higher systolic blood 
pressure, higher total cholesterol, lower HDL cholesterol, and larger body mass index 
considerably increased gains in total and CHD/stroke-free life expectancy with statin 
therapy, adjusted for the other co-variables. Increasing age however most importantly 
decreased these gains. Diabetes mellitus also slightly decreased these gains. Effects of the 
other predictors on changes in total and CHD/stroke-free life expectancy were generally 
small. Table 3 presents the 10-year total CVD mortality risks and lifetime outcomes with 
and without statin therapy for selected risk profiles. Subjects with a low 10-year CVD risk 
can achieve a similar or larger gain in (CHD/stroke-free) life years with statin therapy as 
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subjects with a high 10-year risk. For example, a 55-year-old non-smoking female at a 
10-year risk of 2% could achieve a similar gain in (CHD/stroke-free) life expectancy with 
statin therapy as a 65-year-old smoking male at a 10-year risk of 15% (see risk profiles 
1 and 2 from Table 3). A 55-year old non-smoking male with hypercholesterolemia and 
hypertension at a 3% 10-year risk can achieve a larger gain in (CHD/strokefree) life years 
with statin therapy than a 75-year old smoking male with hypertension and diabetes at 
a 21% 10-year risk (see profiles 3 and 4 from Table 3).
Table 1. Characteristics of 2,428 subjects aged 55 years and older, free of cardiovascular disease and 
symptoms at baseline. 
Characteristics RISC model study population
Age (years)
2.5th – 97.5th range
67.7 (8.1)
55 – 85
Male sex – no. (%) 863 (35.5)
Current cigarette smoking – no. (%) 582 (24.0)
Blood pressure (mm Hg)
 Systolic 
2.5th – 97.5th range
139.2 (22.4)
100 – 186
 Diastolic 
2.5th – 97.5th range
74.7 (11.6)
53 – 98
Hypertension – no. (%) 768 (31.6)
Serum cholesterol (mmol/L)
2.5th – 97.5th range
6.7 (1.3)
4.5 – 9.2
Serum HDL-cholesterol (mmol/L)
2.5th – 97.5th range
1.4 (0.4)
0.8 – 2.2
Diabetes mellitus – no. (%) 215 (8.9)
Serum glucose (mmol/L)
2.5th – 97.5th range
6.8 (2.5)
4.3 – 13.6
Body mass index (kg/m2)
2.5th – 97.5th range
26.2 (4.3)
20.1 – 34.3
Waist-to-hip ratio
2.5th – 97.5th range
0.90 (0.09)
0.73 – 1.08
Serum creatinine (μmol/L)
2.5th – 97.5th range
80.6 (15.8)
58 – 110
Hypertension is defined as either reporting use of antihypertensive medication or having a systolic blood pressure ≥160 mmHg or a 
diastolic blood pressure ≥95 mmHg. Diabetes mellitus is defined as either reporting use of antidiabetic medication or having a serum 
glucose level ≥11.0 mmol/L. HDL = high-density lipoprotein. Data are number of individuals (%) or mean (SD).
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Figure 4. The gain in CHD/stroke-free life expectancy (LE) in months with statin therapy calculated 
with the RISC model. 
Note that these charts demonstrate that CHD/stroke-free life expectancy gained with statin therapy is highest for young individuals 
with otherwise high risk factor levels. 
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Figure 5. Distribution of gains in total life expectancy according to SCORE 10-year total cardiovascular 
disease (CVD) mortality risk (%). 
Note that many individuals with a low SCORE 10-year CVD mortality achieved similar and higher gains as those with high SCORE 
10-year CVD mortality. Ten year CVD mortality risks were calculated using the SCORE- European Low-Risk equation in 1047 subjects 
younger than 65 years without cardiovascular disease and/or symptoms at baseline. 
SCORE = Systematic COronary Risk Evaluation.
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Figure 6. Distribution of gains in CHD/stroke-free life expectancy according to SCORE 10-year total 
cardiovascular disease (CVD) mortality risk (%). 
Note that many individuals with a low SCORE 10-year CVD mortality achieved similar and higher gains as those with high SCORE 
10-year CVD mortality. Ten year CVD mortality risks were calculated using the SCORE- European Low-Risk equation in 1047 subjects 
younger than 65 years without cardiovascular disease and/or symptoms at baseline. 
SCORE = Systematic COronary Risk Evaluation.
We compared the low-risk region SCORE charts with the predicted gain in life 
expectancy by statin therapy (Figure 2). These charts demonstrate that the 10-year total 
CVD mortality risk is highest for elderly smoking individuals with otherwise high risk 
factor levels, suggesting that these individuals would benefit most from statin therapy. 
Figures 3 and 4 however, demonstrate that the lifetime benefits with statin therapy 
are highest for young non-smoking individuals with otherwise high systolic blood 
pressure and cholesterol levels. For example, a 55-year-old non-smoking female at a 
10-year CVD mortality risk of 1% could achieve a similar gain in total life expectancy 
with statin therapy as a 65-year-old smoking male at a risk of 26%. Figures 5 and 6 plot 
SCORE risk estimations vs. gains in total and CHD/stroke-free life expectancy. These 
plots demonstrate that many individuals with low SCORE values achieved similar or 
larger gains than those with high SCORE values. In Figure 5, 19% and in Figure 6, 25% 
of the subjects with a SCORE below 0.05 had benefits greater than or equal to the gains 
observed in 50% of the population with a SCORE of 0.05 or more.
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dIsCussIon
In this modeling study, we found that in 2,428 asymptomatic subjects, statin therapy 
resulted in robust, small gains in total life expectancy and somewhat larger gains in 
CHD/stroke-free life expectancy. The expected benefit of statin therapy was determined 
by a number of baseline variables. From these variables, we constructed a web-based 
calculator and colour charts. Once the underlying model has been independently 
validated, these tools can be used for communication of the expected lifetime benefits 
with statin therapy in persons aged 55 years and older. Inconsistencies occurred between 
the predicted benefits and what can be expected from the currently recommended 10-
year CVD risk assessment. These inconsistencies were predominantly caused by age, 
which acts on lifetime benefits in the opposite direction to its effect on 10-year CVD risk. 
Individuals at low 10-year CVD risk may achieve a similar or even larger gain in total and 
CHD/stroke-free life expectancy as those at high 10-year risk.
For CVD prevention in asymptomatic individuals, most decision tools are used for 
predicting the individual’s risk over a time period ranging from 5 to 10 years without 
calculating potential treatment benefits (1). If treatment benefits are presented, they are 
usually calculated as absolute risk reductions without taking into account competing 
risks (21, 22, 23, 24, 25). Two decision tools for making choices on statin therapy were based on 
Markov models predicting lifetime outcomes with and without statin therapy (26, 27). The 
underlying decision models used data from multiple sources for estimating CVD events 
and age- and sex-specific life tables for competing death probabilities, which are not 
necessarily compatible (28). In contrast, we used event probability estimations from one 
data source. Furthermore, we modeled the occurrence of stroke events separately from 
CHD events. Statin therapy has a different effect on strokes (3) and ignoring this effect 
would lead to incomplete estimation and communication of treatment benefits.
Despite these strengths, our results must be interpreted in the light of some limitations. 
First, the RISC model was used to extrapolate 5-year predictions to a lifetime horizon, 
which may be very sensitive to the method chosen (29). The RISC model extends 
cumulative incidence functions by updating age and risk factor levels using 5-year 
time intervals. Secular trends in risk factor levels were modeled across the age span 
using cross-sectional data and thus potential chronological and cohort effects were not 
taken into account. We evaluated the validity of these extrapolations with subsequently 
available Rotterdam Study data not used in developing the RISC model and found that 
the deviations were generally limited. Developing predictions on longer follow-up data, 
e.g. 30 years, would allow for a more comprehensive evaluation of long-term validity (30). 
However, this approach is also questioned given the chronological changes in CVD 
event rates and associated risk factors (31, 32), which are less likely to affect validity if 
more recent and thus shorter follow-up data is used (33). We did not evaluate the model’s 
performance on predicting outcomes at the individual level (discrimination) and group 
level (calibration) using external data. This would be necessary to investigate to what 
extent the personalized predictions are transportable to other settings and geographical 
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sites, but is beyond the scope of this study. Second, the relative risk reducing effect 
of statin therapy was kept constant over age and various risk factor levels. Although, 
a number of observational studies (34) found that the protective effect of cholesterol 
lowering on CVD events decreases in individuals aged 70 to 89, this was not confirmed 
by experimental research (20, 21). Meta-analyses of statin trials demonstrate that effects 
on cardiovascular events are fairly independent of various risk factor levels (3, 35). These 
trials however predominantly included subjects with elevated risk factor levels. In the 
Rotterdam Study, individuals with normal risk factor levels were also included and it 
is therefore not known whether the relative risk reduction will be different for these 
individuals. Thus, we can not exclude a small overestimation of the statin therapy effect 
in those with normal risk levels. Third, although we did account for baseline statin use, 
we did not take into account initiation of statin therapy during followup.Omitting this 
information would lead to an underestimation of the effect of statin therapy. However, 
in the 90s, mass screening for dyslipidemia was not advocated and statins were only 
prescribed to patients with a history of CVD or with persistent severe dyslipidemia after 
dietary intervention (36). Follow-up examinations of the Rotterdam Study population in 
1997 revealed that the statin use was quite limited (37). Thus, the underestimation of the 
statin effect by treatment drop-ins will be small. Fourth, the RISC model’s outcomes did 
not perfectly match with all the outcomes as evaluated within statin trials. Therefore, we 
were not able to model a statin effect on total stroke events and solely modeled an effect 
on first ischemic and unspecified stroke. However, these stroke subtypes contribute to 
92% of all first stroke events in the Rotterdam Study (38). In addition, we did not model 
a direct statin effect on CVD mortality by causes other than MI and stroke. Although a 
reduction in a major component of CVD mortality, sudden cardiac death, is observed 
in symptomatic patients treated with statins, the effect for subjects without manifest 
CVD seems negligible (39). Nevertheless, we cannot exclude a small underestimation 
of benefits due to these choices. Finally, the RISC model’s output on cardiovascular 
mortality was most compatible with a population resembling inhabitants of a low CVD 
risk region. This finding confirms results from another cohort study (16), suggesting that 
cardiovascular mortality in Dutch individuals is most similar to predictions by the low-
risk region SCORE equation. In addition, the generalizability of our results also depends 
on the competing mortality rate due to other diseases. Our estimations of remaining life 
expectancy for females and males at the age of 60, 65 and 80 years, however reasonably 
match with those of low CVD risk countries projected by the Organisation for Economic 
Co-operation and Development (40). Thus, the web-based calculator and colour charts 
should be used with caution in individuals from higher CVD risk regions.
The competing mortality risks from other CVD and non-CVD death causes, which 
were not affected by statin therapy, sometimes resulted in counterintuitive lifetime 
outcomes. For example, age is the most important factor for increasing both the yearly 
probabilities for occurrence of CHD and stroke events, and the fatality of these events. 
Thus, age is expected to increase the health benefit by statin therapy. However, in the 
Rotterdam Study age is even stronger associated with an increase in yearly mortality by 
other death causes (9). Subsequently, changes with statin therapy in lifetime outcomes 
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were smaller with increasing age, because prevented CHD and stroke events were also 
increasingly substituted by fatal other events. Although the average gain in total life 
expectancy with statin therapy may seem small, it is larger than calculated for some 
other preventive interventions targeted at the general population (29). One should 
recognize that gains were much larger in particular subjects, and were averaged out 
by subjects who never experienced CVD. It should also be acknowledged that with the 
benefits of statin therapy, the costs, side effects and disutility of daily pill use are likely 
to be acceptable across various age groups and risk levels, especially in a “low statin 
cost era” (41, 42). In addition, we observed that gains in CHD/stroke-free life expectancy 
were generally larger than those in total life expectancy. Two phenomena can explain 
this observation. First, a large proportion of the CHD and stroke events were not fatal. 
Gains in CHD/stroke-free life expectancy are mainly driven by statin effects on non-fatal 
CHD and stroke event rates, while gains in total life expectancy are driven by effects on 
CHD and stroke death rates. Second, individuals in whom fatal CHD and stroke events 
are avoided are also likely to be at elevated risk for death by other causes. Our finding 
of a smaller effect of statin therapy on life expectancy is in agreement with the results 
from statin trials, in which generally only modest effects are demonstrated for crude 
total mortality risks, while effects on crude CHD and stroke incidence risks are more 
pronounced (3).
Currently, statin therapy choices are based on short-term CVD risk assessment without 
statin therapy and an expected risk reduction with statin therapy over the same time 
period. We converted survival benefits with statin therapy into total life expectancy 
and CHD/stroke-free life expectancy. We believe that the prediction of statin therapy 
effects on (disease-free) life expectancy can be complementary to the 10-year CVD risk 
assessment in two ways. First, instead of regarding a fixed time point i.e. 10 years, the 
benefit of statin therapy considering the entire survival curve can be communicated by 
primary care physicians. Second, the benefit of statin therapy is calculated taking into 
account competing mortality risks. The potential value of personalizing the gain in total 
and CHD/stroke-free life expectancy with statin therapy is best illustrated by Figures 5 
and 6. A substantial number of individuals with 10-year total CVD mortality risk lower 
than 5%, for whom statin therapy is generally not recommended according to current 
ESC guidelines, may benefit to the same extent as individuals with a high risk. A similar 
pattern will apply to predictions based on other CVD risk models, such as risk scores 
based on the Framingham Study (43, 44), because these use the same risk factors with 
effects pointing in equal directions.
While making decisions on statin therapy, the benefit in life expectancy that diminishes 
with advancing age may be considered by physicians, especially in the elderly. If 
independently validated, physicians may use the web-based calculator and colour charts 
to frame survival outcomes in different ways and to discuss them with the patient in 
light of the expected duration of statin use. The longer the life expectancy, and therefore 
the expected duration of statin use, the higher the costs and possibility of adverse 
effects. Besides the costs averted by CVD prevention, these important outcomes would 
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influence the decision, but were not taken into account in our analysis. In addition, it 
should be acknowledged that the calculated differences in the personalized lifetime 
outcomes may vary across different clinical settings and are subject to the parameter 
uncertainty in the underlying decision model. These caveats would need to be discussed 
with patients when they are informed on the benefits of statin therapy.
In conclusion, we demonstrated that life expectancy benefits with statin therapy can be 
predicted using an individual’s risk factor profile. The predicted gains in life expectancy 
we found are generally small. If the underlying model is validated in an independent 
cohort, the developed tools may be useful in discussing with patients their individual 
outcomes with statin therapy. Ideally, communication of personalized outcomes will 
ultimately result in better clinical outcomes. Improved understanding of potential 
gains, will however not necessarily go hand-in-hand with an improvement of clinical 
outcomes, because patients could make more conservative choices about statin 
therapy when more information on benefits is provided (45). In addition to an external 
validation of our predictions, personalized estimates for costs and side effects of statin 
therapy should be included in future research. Finally, the impact of communicating life 
expectancy benefits on satisfaction, behavioural and clinical outcome measures should 
be studied.
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AbstRACt
Background: To evaluate the performance of Framingham predictions of cardiovascular 
disease (CVD) risk corrected for the competing risk of non-CVD death, in an independent 
European cohort of older individuals and subsequently extend the predictions by 
disentangling CVD into coronary heart disease (CHD) and stroke separately.
Methods: We used the Rotterdam Study data, a prospective cohort study of individuals 
aged 55 years and older (N = 6,004), to validate the Framingham predictions of CVD, 
defined as first occurrence of myocardial infarction, coronary death or stroke during 15 
years of follow-up, corrected for the competing risk of non-CVD death. We subsequently 
estimated the risks of CHD and stroke separately, and used the sum as a predictor for the 
total CVD-risk. Calibration plots and c-statistics were used to evaluate the performance 
of the models.
Results: Performance of the Framingham predictions was good in the low- to 
intermediate risk (≤30%, 15-yr CVD-risk) (17.5% observed vs 16.6% expected) but 
poorer in the higher risk (>30%) categories (36.3% observed vs 44.1% expected). The 
c-statistic increased from 0.66 to 0.69 after refitting. Separately estimating CHD and 
stroke revealed considerable heterogeneity with regard to the contribution of CHD and 
stroke to total CVD-risk.
Conclusions: Framingham CVD-risk predictions perform well in the low- to intermediate 
risk categories in the Rotterdam Study. Disentangling CVD into CHD and stroke 
separately provides additional information about the individual contribution of CHD 
and stroke to total individual CVD-risk.
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IntRoduCtIon
The use of risk scores as tools to predict cardiovascular disease (CVD) has been widely 
advocated in primary prevention (1-5). Guidelines on the prevention of CVD incorporate 
risk scores in order to make treatment recommendations (6, 7). However, older individuals 
are at high risk of death due to other causes than CVD. Currently recommended 
Framingham risk scores tend to overestimate CVD risk in an older population, as non-
CVD mortality competes with CVD events (8), and the competing risk is not taken into 
account in these models. 
Although traditional Framingham risk scores have been successfully externally validated 
in some other populations, recalibration was often necessary to obtain valid estimates (9). 
The 30-year CVD risk function developed by Pencina et al (3), based on the Framingham 
Offspring cohort was developed to address the need for both long-term CVD prediction 
and taking into account the competing risk of non-CVD death. The function estimates 
total CVD as the combination of coronary heart disease (CHD) and stroke. In contrast 
with more traditional risk scores, this Framingham risk function has not been externally 
validated. 
Both CHD and stroke contribute to the risk of total CVD, but can be regarded as 
different clinical events, for which different risk factors have been identified (5, 10). As the 
prevention of both events sometimes are associated with different recommendations 
(11), disentangling the risk of total CVD into both components could provide clinicians 
with useful additional information for treatment management. 
Therefore, using 15-year follow-up data from the participants of the Rotterdam Study 
Cohort -a population based cohort study of elderly individuals (12), we aimed to 1) 
evaluate the performance of Framingham predictions of cardiovascular disease (CVD) 
risk corrected for the competing risk of non-CVD death, in an independent European 
cohort and 2) update the predictions by disentangling CVD into coronary heart disease 
(CHD) and stroke separately.
Methods
Study Population
Of the 7,983 respondents originally included in the Rotterdam Study, 6,871 individuals 
both visited the research center and signed an informed consent. Of those, 6,004 
individuals had no history of CHD and stroke. Individuals have been followed in an 
ongoing effort from 1990 onwards and consisted of regular examinations with interviews 
and direct digital linkage to medical files from the general practitioners working in the 
research area, death registries and other available medical sources, ensuring accurate 
follow-up of fatal and non-fatal CVD events and cause-specific mortality (12). The medical 
records of nursing home were also evaluated. At baseline, participants were interviewed 
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at home by trained research assistants using a computerized questionnaire. Baseline 
data included information on the current health status, history of cardiovascular disease, 
current medication use, and cardiovascular risk factors. Subsequently, the participants 
were invited to the research center in order to obtain measurements on cardiovascular 
risk factors, including body mass index, blood pressure, total cholesterol, high-density 
lipoprotein (HDL) cholesterol, and non-fasting glucose level. All subjects gave written 
informed consent, and the study was approved by the medical ethics committee of 
Erasmus MC.
Assessment of risk factors
Details of the assessment of CVD risk factors and medical history in the Rotterdam Study 
are described into more detail elsewhere (13). In short, participants were categorized 
with regard to current smoking status (nonsmoker defined as never smoked or 
abstinence for at least 2 years). Systolic blood pressure was calculated as the mean of 
two measurements (14). Serum total and HDL cholesterol levels were determined by 
an automated enzymatic procedure. Diabetes mellitus was defined as current use of 
anti-diabetic medication and/or a random or post-load serum glucose ≥200 mg/dL 
(11.1 mmol/L). 
Clinical end points
Events were classified using ICD-10 codes. We focused on ‘hard’ CVD as the outcome 
of interest, defined as the composite of hard CHD (consisting of myocardial infarction 
and coronary death and stroke, both fatal and non-fatal -in correspondence with 
the outcome used in the Framingham CVD risk function. In order to adjust for the 
competing risk of non-CVD death -as was done in the Framingham model, we defined 
non-CVD mortality as any death due to causes other than from CVD events. All events 
were independently adjudicated by two research physicians. Consensus was met in a 
separate session and if necessary medical specialists were consulted. We used follow-up 
information available until January 1, 2007 leading to a maximum follow-up duration of 
17 years for an individual. 
 
Statistical analysis
Complete risk profiles were available in 5,436 of the 6,004 individuals used in the analysis. 
We imputed missing values of systolic blood pressure, total and HDL cholesterol, 
diabetes status, antihypertensive medication use and current smoking status of the 
Rotterdam Study participants with imputation models that included all risk factors –
age, sex, systolic blood pressure, use of anti-hypertensives, smoking, diabetes, total 
and HDL cholesterol, and the log cumulative hazard for hard CVD (15). All continuous 
variables were log-transformed by taking the natural logarithm in correspondence with 
the Framingham model, and truncated at their 1st and 99th percentile. Fifteen-year risks 
of hard CVD and competing non-CVD death for the 6,004 Rotterdam Study Participants 
were calculated using the baseline survival at 15 years of both events as reported by 
Pencina (3), and the linear predictors of CVD and non-CVD death calculated using the 
published hazard rate ratios (model 1). 
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A standard Cox model may provide biased estimates of absolute long-term risk because 
it treats those who die of a non-CVD cause as eligible for the development of a CVD 
event. We therefore used the model proposed by Andersen et al (16, 17), as incorporated 
by Pencina in the Framingham model. This model calculates the cumulative incidence 
of CVD per individual, by summation of the cause-specific hazard multiplied by the 
survival of the CVD event and the competing non-CVD death event at each failure time. 
We compared the average predicted 15-year risk of CVD, with the average observed 
outcome in the Rotterdam Study participants (18). We then recalibrated the Framingham 
CVD model by updating the 15-year baseline survival of CVD -and non-CVD death as 
well, with the survival as observed in the Rotterdam Study (model 2). To check whether 
the overall effect of the risk factors based on the Framingham data is valid for the 
Rotterdam Population, we recalibrated model 2, by allowing for a different effect for the 
slope of the linear predictors of CVD and non-CVD death (model 3). Subsequently, we 
refitted the Framingham CVD model for CVD and non-CVD death, and compared the 
coefficients of the risk factors found by fitting the model in the Rotterdam Population 
data, with the original ones published by Pencina (model 4). Finally, we refined the 
original model by estimating the hazards of hard CHD and stroke separately. This was 
done as the weights assigned to different risk factors and the shape of the lifetime 
hazard function may be different for CHD and stroke (2). Accounting for this difference 
could potentially further improve CVD risk classification. We therefore fitted three cause-
specific Cox-models, one for hard CHD, one for stroke and on for the competing event 
defined as death from any cause other than MI, coronary disease or stroke (model 5). We 
subsequently calculated the cumulative incidences for hard CHD and stroke, and added 
the cumulative incidences of hard CHD and stroke to obtain the estimate for (total) CVD. 
Discrimination for each model was assessed by the concordance index (c-statistic) 
adjusted for the competing risks by setting the failure time of an individual who 
experienced the competing event to infinity. In practice, this was done by adding 1 to the 
maximum follow up time i.e. 15 years (8). Subsequently, calibration of CVD was assessed 
by calibration plots, comparing predicted risks of CVD with observed incidences, per 
decile of predicted CVD risk, for each of the five models. We used deciles of predicted 
CVD risk to make the categories consistent across the plots. The observed incidences 
were adjusted for competing risks, using the R ‘CumInc’ function, which is included in 
the R ‘mstate’ library (17). 
An Excel risk score calculator was constructed to provide clinicians with a tool to estimate 
the cumulative incidences of CHD, stroke and CVD conditional on an individuals’ risk 
profile. All analyses were performed using SPSS version 19 (SPSS for Windows) and R 
version 2.14 (R Foundation for Statistical Computing, Vienna, Austria).
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Results
Baseline characteristics of the 6,004 Rotterdam Study participants used in this analysis 
are presented in Table 1. During 15 years of follow up, 539 (first) hard CHD, 630 (first) 
stroke and 1,719 competing non-CVD deaths occurred in these individuals.
Table 1. Baseline characteristics for the 6,004 Rotterdam Study Participants included in the analysis. 
Risk Factor
Men, n (%) 2251 (37.5)
Systolic BP mmHg, median (IQR)
missing data, n (%)
138 (123 – 153)
52 (1.0%)
Antihypertensive drugs, n (%)
missing data, n (%)
654 (10.9 %)
4 (0.0%)
Current smoking, n (%)
missing data, n (%)
1,345 (22.4 %)
162 (2.7%)
Total cholesterol mg/dL, median (IRQ)
missing data, n (%)
255.8 (224.8 – 286.8)
77 (1.3%)
HDL-cholesterol mg/dL, median (IRQ)
missing data, n (%)
50.4 (42.6 – 62.0)
103 (1.7%)
Diabetes mellitus, n (%)
missing data, n (%)
618 (10.3 %)
406 (6.7%)
IQR: interquartile range
Calibration
Calibration of the Framingham CVD model was found to be good in the low- to 
intermediate risk (<=30%, 15-yr risk) categories (17.5% observed vs 16.6% expected) but 
relatively poor in the higher risk (>30%, 15-yr risk) categories (36.3% observed vs 44.1% 
expected) (Figure 1). Updating the baseline hazards and slope of the linear predictors 
of CVD and non-CVD death improved calibration in the higher risk categories slightly 
(36.2% observed, vs 42.3% expected) but overestimation remained. After refitting the 
CVD risk function in the Rotterdam data, calibration improved substantially (low to 
intermediate categories: 16.6% observed vs 16.6% expected ; higher risk categories: 
39.3% observed vs 38.9% expected). Separately estimating CHD and stroke improved 
calibration even somewhat further (low to intermediate categories: 16.7% observed vs 
16.6% expected ; higher risk categories: 38.8% observed vs 38.8% expected) (Figure 2). 
Calibration of the competing non-CVD death event, evaluated by plotting the observed 
risk of non-CVD death vs predicted per decile of CVD risk, revealed that the risk of non-
CVD is underestimated for the original Framingham CVD function for all categories of 
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individuals, and increased with CVD risk. After refitting, calibration of non-CVD mortality 
improved as well (Figure 3).
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Figure 1. Calibration plot, showing predicted and observed 15-year risk of CVD for each decile of 
predicted 15-year CVD risk -based on the original Framingham CVD function (3) (model 1, left) and the 
recalibrated score by adjusting baseline hazards of CVD and non-CVD death (model 2, right)
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Figure 2. Calibration plot, showing predicted and observed 15-year risk of CVD for each decile of 
predicted 15-year CVD risk -based on the refitted function (model 4, left) and refitting the CVD and 
non-CVD death function, by separately analyzing CHD and stroke (model 5, right)
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Figure 3. Calibration plot, showing predicted and observed 15-year risk of competing non-CVD death 
for each decile of predicted 15-year CVD risk -based on the original Framingham CVD function (3) 
(model 1, left) and after refitting the CVD and non-CVD death function in the Rotterdam Study data 
(model 4, right)
Discrimination
C-statistics for the Framingham CVD risk function applied to the Rotterdam Study 
population for the prediction of 15-year CVD risk was 0.66 and 0.68 after refitting the 
Framingham CVD risk function in the Rotterdam Study population. Estimating the 
hazard of CVD separately for CHD and stroke and using the sum as an estimate for total 
CVD, did not further increase the c-statistic for 15-year CVD risk rounded at two decimal 
points. 
Beta coefficients
Refitting the Framingham CVD risk function in the Rotterdam data led to differences 
in beta coefficients compared to the original ones published by Pencina (Table 2a). For 
CVD, the log of age was found to have a stronger effect on CVD whereas sex, the log of 
systolic blood pressure, log of total and HDL cholesterol, current smoking status and 
diabetes were significantly less strong. For the competing risk of non-CVD death, the 
log of age was also found to have a significantly stronger effect, whereas the log of 
systolic blood pressure, current smoking and diabetes mellitus had a less strong effect 
(Table 2b). Separately estimating the hazards CHD and stroke, resulted in different beta 
coefficients for both events compared to estimating the hazard of CVD as a combined 
endpoint (Table 2c).
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Table 2. Coefficients for the Framingham CVD risk function, for 15-year CVD and non-CVD competing 
death in the Rotterdam Study data, evaluating a refitted function for CVD as combined endpoint (A, 
model 4), competing non-CVD death (B, model 4), and for CHD and stroke separately (C, model 5). 
Original: coefficients reported by Pencina (3). 
A
CVD Refitted Original 
coefficient p-value in  
refitted model
coefficient p-value refitted  
vs original
Male sex 0.44 <0.0001 0.55 0.08
Natural logarithm of age 5.28 <0.0001 2.28 <0.001
Natural logarithm of systolic blood pressure 1.68 <0.0001 2.00 0.11
Natural logarithm of serum Total cholesterol 0.24 0.46 1.48 <0.001
Natural logarithm of serum HDL cholesterol -0.49 <0.0001 -0.88 0.002
Current smoking 0.33 <0.0001 0.70 <0.001
Use of antihypertensives 0.23 0.004 0.39 0.05
Diabetes mellitus 0.46 <0.0001 0.91 <0.001
B
Non-CVD death Refitted Original
coefficient p-value coefficient p-value refitted  
vs original
Male sex 0.37 <0.001 0.48 0.07
Natural logarithm of age 8.49 <0.001 3.531 <0.001
Natural logarithm of systolic blood pressure 0.28 0.11 1.43 <0.001
Natural logarithm of serum Total cholesterol -0.92 <0.001 0.01 <0.001
Natural logarithm of serum HDL cholesterol -0.12 0.24 0.09 0.042
Current smoking 0.58 <0.001 0.97 <0.001
Use of antihypertensives 0.05 0.56 0.12 0.34
Diabetes mellitus 0.19 0.01 0.45 <0.001
C
CHD Stroke
coefficient p-value coefficient p-value
Male sex 0.64 <0.0001 0.12 0.2
Natural logarithm of age 5.89 <0.0001 6.09 <0.0001
Natural logarithm of systolic blood pressure 1.0006 <0.0001 2.06 <0.0001
Natural logarithm of serum Total cholesterol 0.97 <0.0001 -0.76 0.001
Natural logarithm of serum HDL cholesterol -0.91 <0.0001 -0.07 0.65
Current smoking 0.27 0.0028 0.35 <0.0001
Use of antihypertensives 0.39 <0.0001 0.22 0.06
Diabetes mellitus 0.51 <0.0001 0.39 <0.0001
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15-year risk of CHD, stroke and CVD
To illustrate the effect of different individual risk profiles on CVD risk and on the mixture 
of CHD and stroke, the cumulative incidences of CHD, stroke and CVD were plotted for 
a 15-year period for 4 individuals (Figure 4 A-D). For individual A and B, stroke was the 
major component of CVD. The opposite was true for individuals C and D.
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Figure 4. Individual predictions for 4 individuals. (A) 70-year old woman, smoker, systolic blood 
pressure of 103, total (HDL) cholesterol 4.1 mmol/L 1.5, treated for Hypertension (B) 70 year old man, 
systolic blood pressure of 132, Total (HDL) cholesterol 5.0 mmol/L 1.80, Diabetic (C) 56-year old man, 
Systolic blood pressure of 124, Total (HDL) cholesterol 6.4 mmol/L 0.9, and (D) 65-year old woman, 
Systolic blood pressure of 129, Total (HDL) cholesterol 6.7 mmol/L 0.9, Treated for Hypertension
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dIsCussIon
Our analyses show that the Framingham CVD risk predictions perform reasonably well 
in predicting in the relatively older Rotterdam population for individuals at low to 
intermediate risk. For the higher risk categories, recalibration by refitting the function in 
the Rotterdam Study population was required to obtain valid estimates. Disentangling 
CVD into CHD and stroke separately revealed considerable heterogeneity with regard to 
the contribution of CHD and stroke to the total risk of CVD.
To our knowledge, this is the first attempt to validate this Framingham CVD risk 
function corrected for competing death in another population. Previous studies on the 
validity of Framingham risk functions in the Rotterdam Study focused on 10-year CHD 
and stroke separately (14, 19) and found predictive performance to be reasonable in the 
lower risk categories for both events -but recalibration was necessary for the apparent 
overestimation in the higher risk categories. In the current analysis we extended the 
previous work by incorporating a longer period of follow-up and made adjustments 
for competing risks. In accordance with the earlier findings for 10-year CHD and stroke, 
we found that recalibration was especially important in the higher CVD risk categories. 
Our study bears some limitations. First, the weights of the risk factors in the original 
Framingham CVD risk function were estimated over a 30-year period, whereas we 
validated the risk function for a 15-year period. If the hazard ratios of the risk factors 
included in the Framingham function would change over time, this could contribute 
to part of the miscalibration we observed of the original function. For the original 
Framingham function, Pencina did not find evidence for the hazard rate ratios to be 
time-dependent, which makes different hazard rate ratios for different time-horizons 
less likely (3). From a clinical point of view, a 15-year risk is probably of greater interest 
in older individuals due to the shorter life expectancy and the potential effect of co-
morbidities and competing causes of death. Second, when separately analyzing CHD 
and stroke, we used the same set of risk factors. A further improvement in predictive 
performance could be expected if we would allow for a different set of risk factors for 
both events and competing event respectively. Third, we did not evaluate the inclusion 
of novel risk factors, which might further contribute to improvement in risk classification.
As the Framingham population was younger on average than the Rotterdam Study 
participants, we expected the baseline hazard of CVD to be higher in the Rotterdam 
Data. However, we observed that the Framingham function overestimated CVD risk, 
especially in the higher risk strata. Part of this overestimation could be explained by 
the fact that the Framingham function at the same time underestimated the risk of 
the competing non-CVD death which is of particular importance in older individuals. 
Underestimation of the competing event results in a higher predicted risk of the CVD 
event (8). After adjusting the baseline hazards for both the CVD event and the competing 
risk of non-CVD death, the overestimation of CVD risk diminished. 
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The hazard rate ratios of the risk factors were sometimes different in magnitudes and 
significance of the effects from the ones reported by Pencina et al (3). Our observation 
that total cholesterol (in the presence of other factors) did not appear a significant 
predictor for CVD in the Rotterdam data was supported by earlier analyses from Bos et 
al in the Rotterdam Study (20, 21). They found that serum cholesterol has a protective effect 
on stroke, whereas HDL-cholesterol has no significant effect. This is similar to what we 
found when we analyzed the hazard of stroke separately from CHD. This could explain 
the non-significant effect for serum total cholesterol on total CVD in our analysis, as 
the coefficient for total CVD is a weighted average of the coefficients for stroke and 
CHD separately. The difference in coefficients for age can be partly explained by the 
log-transformation (log), together with the older age of the Rotterdam Study cohort 
compared to Framingham. The increase from log 70 years to log 71 years -a one unit 
increase on the age scale, is smaller than the log increase from 40 to 41. This implies 
that the coefficient for age in the Rotterdam data should compensate for these smaller 
increments in the log-transformed risk factor.
We demonstrated that estimating the hazards for CHD and stroke separately allows for 
the simultaneous prediction of the risks of these events and found that the weights 
assigned to the risk factors included in the Framingham risk function are different for 
both. By separately estimating the hazards of these events, discrimination increased 
only very little, whereas calibration improved substantially compared to predicting CVD 
as a combined endpoint. The major contributor to CVD, being either CHD or stroke, 
differed between individual risk profiles, as illustrated by the four examples. This can 
have important clinical implications for the allocation of preventive interventions. For 
example, aspirin is currently recommended in men with a high risk of CHD, while in 
women the recommendation is only made for those with a high risk of stroke (11). 
As we treated CHD, stroke and non-CVD as competing events, our risk function provides 
information on the separate events and also allows for adding the separate risks of 
CHD and stroke to obtain an estimate of total CVD risk. This provides clinicians with 
additional information beyond a risk function which estimates CVD as a single endpoint 
or separate models for CHD and stroke which do not account for competing risks. 
Secondly, treatment benefits of preventive interventions such as cholesterol-lowering 
drugs can be more precisely estimated by applying the different risk reductions for 
CHD and stroke separately instead of applying the overall reduction on CVD. Further 
improvement in the prediction of CVD could be obtained by subcategorizing CHD and 
stroke in fatal and non-fatal events, ischemic and non-ischemic events in the case of 
stroke, and myocardial infarction and heart failure in the case of CHD.
In conclusion, Framingham CVD-risk predictions perform well in the low- to intermediate 
risk categories in the Rotterdam Study. Recalibration is necessary as the Framingham 
function overestimates CVD risk in the higher risk strata of the Rotterdam Study 
population. Disentangling CVD into CHD and stroke separately provides additional 
information about the individual contribution of CHD and stroke to total individual CVD-
risk and provides clinicians with additional information about the relative contribution 
of CHD and stroke.
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AbstRACt
Importance: Distinguishing intracerebral hemorrhage (ICH) and ischemic stroke (IS) 
risks may improve clinical decision-making. 
Objective: To develop and validate 10-year cumulative incidence functions of ICH and 
IS. 
Design, Setting, and Participants: We used data on 27,493 participants from three 
population-based cohort studies: the Atherosclerosis Risk in Communities (ARIC) Study, 
median age 54, 45% male, median follow-up 20.7 years; the Rotterdam Study, median 
age 68, 38% male, median follow-up 14.3 years; and the Cardiovascular Health Study 
(CHS), median age 71, 41% male, median follow-up 12.8 years. Among these participants 
325 ICH events, 2,559 IS events, and 9,909 non-stroke deaths occurred. We developed 
10-year cumulative incidence functions for ICH and IS using stratified Cox regression 
and competing risks analysis. Basic models including only established, non-laboratory 
risk factors were extended with diastolic blood pressure, the total cholesterol/HDL-
cholesterol ratio, body-mass index, waist-to-hip ratio, and glomerular filtration rate. The 
cumulative incidence functions’ performances were assessed in each cohort separately 
by the Harrell’s C-statistic, cross-validation, and calibration plots.
Main Outcome and Measures: Intracerebral hemorrhage and ischemic stroke events 
during 10-year follow-up.
Results: The total cholesterol/HDL-cholesterol ratio was associated inversely with ICH, 
but positively with IS (p for difference across stroke subtypes <0.001). For the basic ICH 
model, C-statistics (95% CI) of 0.805 (0.739 – 0.871), 0.625 (0.555 – 0.695) and 0.676 
(0.603 – 0.750) in the ARIC, Rotterdam, and CHS cohort increased to 0.811 (0.743 – 0.879), 
0.626 (0.556 – 0.696) and 0.696 (0.624 – 0.767) by model extension. For IS, C-statistics 
of 0.789 (0.768 – 0.811), 0.696 (0.677 – 0.716) and 0.658 (0.637 – 0.679) increased to 
0.798 (0.777 – 0.819), 0.697 (0.677 – 0.717) and 0.663 (0.642 – 0.684) by model extension. 
Improvements in C-statistics were in general reproduced by cross-validation. Models 
were well calibrated in all cohorts. Correlations between 10-year ICH and IS risk were 
moderate in each cohort (r = 0.57, 0.59, 0.37, respectively).
Conclusions and Relevance: We developed and cross-validated cumulative incidence 
functions for separate prediction of absolute10-year ICH and IS risk. These functions can 
be useful to further specify an individual’s stroke risk. 
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IntRoduCtIon
Stroke is the second leading cause of death and one of the major causes of disability 
in most Western countries (1). The incidence of stroke steadily increases from middle-
age onwards. Although most strokes are ischemic strokes (IS), approximately 10% are 
intracerebral hemorrhages (ICH) which has a higher case-fatality than IS: 41% vs 14% (2).
 
Multiple risk factors that influence stroke risk are well established and can be used 
to estimate an individual’s stroke incidence over a 10-year time period (3-6). These 
established 10-year stroke risk models generally apply to IS only or to any stroke. 
Distinguishing the cumulative incidences of stroke subtypes, i.e. ICH vs. IS, could be 
valuable for various reasons. First, risk factors may vary for the different stroke subtypes 
or may have different or even opposing effects (7). Consequently, the likely effects of 
modifying these risk factors may vary per stroke subtype. Second, although prevention 
with aspirin therapy has a net preventive effect on stroke, it decreases the occurrence of 
IS, whereas it increases the risk of ICH (8). Therefore, decision-making for aspirin therapy 
can be improved on the individual level by predicting ICH and IS risk separately. Third, 
the consequences (e.g. the case-fatality) of both subtypes differ and a more refined risk 
communication to the individual and the public can be facilitated.
Also, currently used stroke risk scores were developed using standard Cox regression 
modeling. Standard survival analysis will generally overestimate the cumulative 
incidence, because it fails to treat those who die of non-stroke causes as ineligible 
for development of stroke events. Methods to adjust for competing risks are now 
increasingly being used for cardiovascular risk prediction (9). 
In this study, we aimed to develop and validate separate prediction models for 
estimation of the 10-year cumulative incidences of ICH and IS. We therefore performed 
a combined analysis of individual data from three population-based cohort studies: 
Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study 
(CHS), and the Rotterdam Study. 
Methods
Study design and population
We constructed a dataset with data from: 1) the ARIC Study; 2) the CHS; and 3) the 
Rotterdam Study. The ARIC study cohort (10) comprises 15,792 individuals aged 45 to 
64 years old at baseline, who were recruited from 4 different regions in the U.S. from 
1987 to 1989. In the CHS (11), individuals over the age of 65 living in 4 U.S. communities 
were recruited from the Health Care Financing Administration (HCFA or Medicare) 
eligibility lists in two phases. First, 5,201 participants were recruited from 1989 to 1990. 
In a second wave, 687 African-Americans were recruited from 1992 to 1993 leading to 
a cohort of 5,888 participants. The Rotterdam Study (12) consists of 7,983 inhabitants 
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of Ommoord, a district in the city of Rotterdam, the Netherlands, aged 55 years and 
older. Baseline examinations were conducted from 1990 to 1993. For details on baseline 
measurements of the three studies see Appendix 3. All studies received approval from 
medical ethical committees. 
The subjects eligible for the current analysis were those without prior stroke (N = 15,297 
in the ARIC cohort, N = 5,639 in CHS, N = 7,546 in the Rotterdam Study), did not use 
anticoagulation (N = 15,222 ARIC study, N = 5,572 CHS, N = 7,177 Rotterdam Study), 
and did not have atrial fibrillation (N = 15,217 ARIC cohort, N = 5,446 CHS, N = 6,910 
Rotterdam Study) at baseline. The latter two exclusion criterions were used because 
specific guidelines and prediction models already exist for these patients (13). In addition, 
we excluded participants who were not African-American or white/European, leaving 
N = 27,493 subjects (N = 15,170 ARIC study, N = 5,413 CHS, N = 6,910 Rotterdam Study) 
for the analysis. Based on results from the Framingham Study (3, 14) and previous work 
conducted in the ARIC, CHS and Rotterdam cohorts (4, 5, 15, 16), we considered age, gender, 
African-American ethnicity, current smoking, systolic blood pressure, antihypertensive 
medication use, diabetes mellitus, and history of coronary heart disease as established 
predictors in a basic non-laboratory model for each stroke type. Subsequently, we 
evaluated whether predictions could be improved by extending the models with 
the following risk factors: diastolic blood pressure; total cholesterol; high-density 
lipoprotein cholesterol; body mass index; waist-to-hip ratio; and estimated glomerular 
filtration rate (eGFR). 
Outcome definitions
Details of outcome ascertainment are described elsewhere (17-19) and in Appendix 3 
Table 1. In brief, ARIC outcomes were ascertained through yearly telephone interviews, 
follow-up examinations, community hospital surveillance, and reported deaths. CHS 
outcomes were ascertained through 6 monthly telephone interviews, surveillance 
of HCFA Medicare Utilization files and reported deaths. In the Rotterdam Study, 
participants were continuously monitored for events through automated linkage of the 
study database with files from general practitioners and the municipality. The medical 
records of nursing homes were also evaluated. We excluded ascertained subarachnoid 
and traumatic hemorrhages. Furthermore, we assumed that most unspecified stroke 
events would be ischemic of nature. Therefore, we estimated the cumulative incidence 
of IS using a combined endpoint of classified ischemic and unspecified stroke events 
as a proxy for the true IS incidence in order to avoid underestimation. Any stroke was 
defined as the sum of ICH and IS. The censoring date was December 31st 2009 for the 
ARIC study, January 1st 2009 for the Rotterdam Study, and June 30th, 2008 for the CHS 
dataset.
501599-L-bw-van Kempen
Separate Prediction of Intracerebral Hemorrhage and Ischemic Stroke | 151
Table 1. Baseline characteristics 
ARIC 
(N = 15,170)
Rotterdam
(N = 6,910)
CHS
(N = 5,413)
Age, years – median (IQR) 54 (49, 59) 68 (62, 76) 71 (68, 76)
Male gender, n (%) 6,828 (45) 2,633 (38) 2,240 (41)
African American ethnicity, n (%) 4,072 (27) 0 838 (15)
Systolic BP, mmHg – median (IQR) 119 (108, 131)
14 (0)
137 (123, 153)
728 (11)
134 (121,149)
9 (0)
Diastolic BP, mmHg – median (IQR)
missing data, n (%)
70 (66, 80)
16 (0)
73 (66, 81)
729 (11)
70 (63, 78)
16 (0)
Antihypertensive medication use, n (%)
missing data, n (%)
3,787 (25)
85 (1)
2,085 (30)
6 (0)
2,487 (46)
7 (0)
Current smoking, n (%)
missing data, n (%)
3,981 (26)
15 (0)
1,520 (23)
205 (3)
654 (12)
6 (0)
Diabetes mellitus, n (%)
missing data, n (%)
1,780 (12)
141 (1)
637 (11)
975 (14)
843 (16)
55 (1)
Prior coronary heart disease, no%
missing data, n (%)
1,707 (12)
330 (2)
949 (16)
1074 (15)
1,071 (20)
47 (1)
Total cholesterol, mmol/l – median (IQR)
missing data, n (%)
5.5 (4.8, 6.2)
239 (2)
6.6 (5.8, 7.4)
700 (10)
5.5 (4.8, 6.1)
46 (1)
HDL-C, mmol/l – median (IQR)
missing data, n (%)
1.3 (1.0, 1.6)
237 (2)
1.3 (1.1, 1.6)
726 (11)
1.3 (1.1, 1.6)
54 (1)
BMI, kg/m2 – median (IQR)
missing data, n (%)
26.9 (24.0, 30.4)
25 (0)
26.0 (23.8, 28.4)
772 (11)
26.1 (23.5, 29.2)
17 (0)
Waist-to-hip ratio – median (IQR)
missing data, n (%)
0.94 (0.88, 0.98)
28 (0)
0.90 (0.84, 0.97)
1081 (16)
0.94 (0.87, 0.98)
34 (1)
eGFR, ml/min/ 1.73 m2 – median (IQR)
missing data, n (%)
89.0 (79.7, 102.3)
146 (1)
77.3 (67.3, 87.7)
2254 (33)
76.7 (64.2, 89.9)
59 (1)
Statin therapy use, n (%)
missing data, n (%)
85 (1)
115 (1)
141 (2)
6 (0)
121 (2)
7 (0)
Abbreviations: ARIC = Atherosclerosis Risk in Communities Study; BMI = body-mass index; BP = blood pressure; CHS = Cardiovascular 
Health Study; GFR = glomerular filtration rate; HDL = high-density lipoprotein; IQR = interquartile range
Statistical analysis
Two separate prediction models for the 10-year cumulative incidence of ICH and IS were 
developed using competing cause-specific hazards methodology (see Appendix 3 for 
more details). In addition, we developed an ‘any stroke’ model, which can be subdivided 
into an ICH and IS component. Cause-specific Cox regression models stratified by study 
cohort were developed with time since study entry as time scale. All continuous predictors 
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were truncated at their 1st and 99th percentile to limit the influence of extreme values (20). 
In the basic models, effect modification by gender was evaluated for age, systolic blood 
pressure, diabetes mellitus and history of coronary heart disease. An interaction term 
for systolic blood pressure and antihypertensive medication use was included (3, 14). In 
the extended models, we evaluated replacement of total and HDL cholesterol variables 
by the total cholesterol/HDL ratio and systolic by diastolic blood pressure (21). We verified 
the assumption of linearity for continuous predictors included in the extended models 
using restricted cubic spline functions with four knots adjusted for study and all other 
predictors. Non-linearity was solved by square or log transformations. Finally, we tested 
heterogeneity of effects across studies by study-predictor interaction terms. 
Discriminative ability was assessed by Harrell’s concordance statistic (C-statistic) 
adjusted for competing risks by setting the follow-up time to the maximum follow-up 
time if competing death occurred (22). Model calibration was assessed by calibration plots 
and Chi square statistics, comparing predicted with observed cumulative incidences 
using the R ‘CumInc’ function of the R ‘mstate’ library. Equally sized groups per study 
were made according to age tertiles for ICH and quintiles for IS. Cross-validation of the 
predictions was performed in each study dataset separately. For this purpose, models 
were fit in two cohorts and evaluated in the other. Reclassification by extending the 
basic models was assessed by the continuous net reclassification improvement (23). 
Ninety-five % CIs were estimated by bootstrapping datasets with recalculation of the 
observed cumulative incidences within each bootstrap sample. Scatter plots showing 
the relationship between the ICH and IS components within any stroke risk were made 
for each dataset using extended models. 
Missing covariables were imputed for each study separately using single imputation 
with the R ‘aregImpute’ function of the R ‘Hmisc’ library. Imputation models included 
all potential predictors and the log cumulative hazard for each outcome. Hypothesis 
tests were two-sided and decisions on selection of predictor main effects were made 
upon an improvement of the Akaike Information Criterion (AIC). Interactions and non-
linear effects were included using a P value <0·05. The effect of excluding predictors 
with highly significant heterogeneous hazard ratios (P <0·01 for ICH, P<0·001 for IS and 
competing death) on cross-validated model performance was evaluated in a sensitivity 
analysis. We used R version 2.14.2 for all statistical analyses.
Results
Study population
The baseline characteristics of the included ARIC (median age 54, 45% male), Rotterdam 
Study (median age 68, 38% male), and CHS (median age 71, 41% male) participants 
are given in Table 1. Systolic blood pressure levels were lower in the ARIC study than 
in the Rotterdam and CHS cohorts. Rotterdam Study participants had an average 
total cholesterol level that was higher than observed in the two U.S. cohorts. The CHS 
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included more subjects treated by antihypertensive drugs and subjects with a history of 
coronary heart disease, but fewer current smokers. In total, 325 participants experienced 
an ICH, 2,559 experienced an IS event, and 9,909 died from a competing death cause. 
The 10-year cumulative incidence for ICH was approximately one-ninth of the 10-year 
cumulative incidence of IS in all studies (Table 2). 
Table 2. Incident event data
ARIC 
(N = 15,217)
Rotterdam
(N = 6,910)
CHS
(N = 5,446)
Overall incident events, n 
Intracerebral hemorrhage
Ischemic stroke
Competing non-stroke death
103 
920 
3,727 
99 
820 
3,035 
123 
819 
3,147
10-year incident events, n (cumulative incidence, %) 
Intracerebral hemorrhage
Ischemic stroke
Competing non-stroke death
42 (0.3)
360 (2.4)
1,179 (7.8)
57 (0.8)
523 (7.6)
1,814 (26.3)
62 (1.1)
530 (9.8)
1,433 (26.5)
Median follow-up duration, years (IRQ) 20.7 (17.5, 21.7) 14.3 (7.2, 16.2) 12.8 (7.4, 18.3)
Person-years of follow-up 279,741.9 81,997.6 66,325.4
Abbreviations: ARIC = Atherosclerosis Risk in Communities Study, CHS = Cardiovascular Health Study
* Sum of hemorrhagic and IS events may exceed the total of any stroke events, since a hemorrhagic event may be preceded by an 
ischemic event and vice versa.
Hazard ratios
Gender, diabetes, prior coronary heart disease, waist-to-hip ratio and eGFR were not 
found to be statistically significant and were excluded from ICH models, whereas 
these were included in IS models. Table 3 shows the multivariable-adjusted HRs and 
95% CIs for incident ICH and IS events. Both for ICH and IS, replacement of total and 
HDL cholesterol by total cholesterol/HDL-C ratio and the simultaneous inclusion of 
systolic and diastolic blood pressure (despite correlations of 0.69, 0.59, and 0.51 in 
ARIC, Rotterdam, and CHS cohorts) improved AIC. The extended ICH model is reported 
without BMI, although BMI had a statistically significant inverse relation with the ICH 
hazard: 0.97 (95%CI 0.94 – 0.99) per unit increase. However, the BMI association varied 
significantly across the three studies and exclusion improved the cross-validated model 
performance as compared to the basic model. 
Although for both stroke subtypes, risk increased if diastolic blood pressure was high, 
low and mid-range values were less positively associated with ICH than with IS. Mid-
range total cholesterol/HDL-C ratio values as compared to low and high values were 
inversely associated with ICH, whereas total cholesterol/HDL-C ratio were monotonically 
positively associated with IS risk. The association of the total cholesterol/HDL-C ratio 
statistically differed across stroke subtypes (P <0.001). The HRs for ICH additionally 
censored for IS and vice versa are given in eTables 8 and 9 in the Supplement; these did 
not largely differ from those shown in Table 3. 
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Table 4. Prognostic performance 
Basic  
ICH model
Extended  
ICH model
Basic  
IS model
Extended  
IS model
Model development in ARIC, 
Rotterdam and CHS 
Evaluated in ARIC 
C statistic (95%CI) 0.805 (0.739, 0.871) 0.811 (0.743, 0.879) 0.789 (0.768, 0.811) 0.798 (0.777, 0.819)
total NRI (95%CI) – 0.28 (-0.06, 0.62) – 0.29 (0.18, 0.39)
event NRI (95%CI) – 0.10 (-0.17, 0.47) – 0.28 (0.17, 0.38)
non-event NRI (95%CI) – 0.18 (0.17, 0.20) – 0.01 (0.00, 0.03) 
Chi-Square calibration  6.15 7.06 10.24 12.55
Evaluated in Rotterdam
C statistic (95%CI) 0.625 (0.555, 0.695) 0.626 (0.556, 0.696) 0.696 (0.677, 0.716) 0.697 (0.677, 0.717)
total NRI (95%CI) – 0.19 (-0.03, 0.45) – 0.15 (0.06, 0.23)
event NRI (95%CI) – -0.16 (-0.37, 0.18) – 0.11 (0.02, 0.21)
non-event NRI (95%CI) – 0.35 (0.31, 0.37 ) – 0.03 (0.01, 0.07)
Chi-Square calibration  5.86  6.90 10.20 10.03
Evaluated in CHS 
C statistic (95%CI) 0.676 (0.603, 0.750) 0.696 (0.624, 0.767) 0.658 (0.637, 0.679) 0.663 (0.642, 0.684)
total NRI (95%CI) – 0.04 (-0.26, 0.31) – 0.05 (-0.026, 0.13)
event NRI (95%CI) – 0.03 (-0.23, 0.30) – -0.20 (-0.31, -0.12)
non-event NRI (95%CI) – 0.00 (-0.02, 0.03) – 0.25 (0.23, 0.28)
Chi-Square calibration  3.62  2.46 9.92 14.46
Cross-validation
C statistic (95%CI) in ARIC 0.729 (0.652, 0.806) 0.734 (0.653, 0.814) 0.760 (0.737, 0.783) 0.768 (0.745, 0.790)
C statistic (95%CI) in Rotterdam 0.622 (0.552, 0.693) 0.626 (0.556, 0.696) 0.694 (0.674, 0.713) 0.692 (0.672, 0.712)
C statistic (95%CI) in CHS 0.667 (0.595, 0.740) 0.684 (0.614, 0.753) 0.651 (0.630, 0.672) 0.654 (0.633, 0.676)
Abbreviations: ARIC = Atherosclerosis Risk in Communities Study, CHS = Cardiovascular Health Study, ICH = intracerebral hemorrhage; 
IS, ischemic stroke, NRI = net reclassification improvement
Event NRI is calculated as the difference in the probability being reclassified upwards and the probability being reclassified downwards 
conditional on experiencing the event within 10 years: P(up│event) – P(down│event)
Non-event NRI is calculated as the difference in the probability being reclassified downwards and the probability being reclassified 
upwards conditional on not experiencing the event within 10 years: P(down│event) – P(up│event)
Total NRI is calculated as the sum of event NRI and non-event NRI.
Model performance
Extending the basic models generally led to small improvements in the C-statistic, 
ranging from 0.001 to 0.020 for ICH, and 0.001 to 0.009 for IS. The continuous total NRIs 
were positive, with more pronounced changes in the ARIC cohort. Improvements in 
C-statistics were reproduced by cross-validation except for IS predictions in Rotterdam 
Study data (Table 4). Model calibration in each cohort was good and did not differ to a 
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relevant extent between basic and extended models both for ICH and IS prediction; also 
see the Chi square statistics in Table 4. C-statistics (95% CI) for any stroke predictions 
were similar to IS predictions, and did not improve with model extension: 0.788 
(0.767 – 0.809), 0.690 (0.671 – 0.709), 0.659 (0.638 – 0.679). Results on calibration by 
the any stroke prediction models were similar to those on IS prediction. Predicted ICH 
risk tended to increase with IS risk for each study, but the correlation between both 
predicted risks was moderate in ARIC, Rotterdam, and CHS cohorts (r = 0.57, 0.59, 0.37, 
Figure 1). 
dIsCussIon
In this study, we developed and cross-validated cumulative incidence functions for 
estimating 10-year risks of ICH and IS using three population-based cohorts consisting 
of middle-aged and elderly individuals. In addition to estimating the incidences of 
the two stroke subtypes separately, any stroke incidence was estimated by taking into 
account the mutually competing risk of both stroke subtypes and death by other causes. 
Extending basic non-laboratory ICH and IS models with more risk factors only led to 
limited improvement of discriminative ability, with more pronounced improvement in 
the ARIC cohort. By using our prediction models, individuals can be identified with low 
10-year IS risk, but high ICH risk, and vice versa.
Studies on hemorrhagic stroke prediction are scarce. By performing a systematic 
literature search (see eAppendix), we found only two studies, both conducted in 
Chinese populations. In one study (25), a prediction model for hemorrhagic stroke was 
developed and validated in a cohort of 4,400 steelworkers free of stroke at baseline 
with an average age of 45 years. The number of hemorrhagic strokes was low: 33 
events in the development set and 15 in the validation set. Multivariable-adjusted 
HRs of age (1.89 per 10 years) and systolic blood pressure (1.22 per 10 mmHg) were 
similar to ours. For diastolic blood pressure (1.49 per 10 mmHg) and total cholesterol 
(1.00 per mmol/L), non-linearity was not explored, and therefore these associations 
are not comparable with ours. In addition, the model was not validated in the general 
population or in older adults. In the other study (26), major bleeding risk scoring schemes 
designed for atrial fibrillation patients treated with anticoagulation were validated in 
3,602 individuals without atrial fibrillation at baseline, who experienced 54 ICH events 
during approximately 18 years of follow-up. C-statistics of the various risk scores ranged 
from 0.59 to 0.72. Individuals with previous stroke were however not excluded and ICH 
event ascertainment was registry-based. Other prognostic studies focused on either 
assessment of any stroke risk (3, 4, 14, 16, 27-33) or IS risk (5, 6, 20, 34, 35) usually within a time horizon 
of 5 to 10 years. 
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Figure 1. Contribution of intracerebral hemorrhage and ischemic stroke to 10-year any stroke 
incidence
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In contrast to these previous studies, we developed models for the separate 10-year risk 
assessment of ICH and IS while taking into account competing risks. By combining data 
from three large population-based cohorts, we were able to acquire a sufficient number 
of ICH events for multivariable prediction modeling. Furthermore, we also included 
elderly individuals with an age above 75, which increases the generalizability of our 
prediction models. Especially in those at older age, competing risks become relevant, 
mainly because the competing death rate rapidly increases. We demonstrated that also 
in the older age categories predictions were well calibrated. A final strength of our study 
is that the measurement of risk factors was reasonably similar across the three studies. 
Despite these strengths, our results must be interpreted in the light of some limitations. 
First, we did not consider novel risk markers such as biomarkers, genetic risk factors, and 
imaging tests that are also known to be associated with stroke risk. For example, studies 
have demonstrated an independent association of C-reactive protein with IS but not ICH 
risk (36), and carotid intima-media thickness measurement (cIMT), and apolipoprotein E 
genotype with both ICH and IS risk (37-39). However, cIMT and apolipoprotein E genotype 
are generally difficult to assess during an office-based risk assessment, which would 
limit the translation to clinical practice, and C-reactive protein was not available as 
baseline variable in the ARIC study. A second study limitation is that neuroimaging 
was not performed in all participants with stroke symptoms. The Rotterdam Study in 
particular included participants living in nursing homes, who could not be referred to 
a neurologist or admitted to a hospital. As a consequence, a proportion of strokes were 
not further specified. We included these as IS events, which could have led to some small 
bias in prediction, a small overestimation of the average IS risk and underestimation of 
ICH risk. Third, the baseline age ranges of the ARIC, Rotterdam and CHS cohorts did not 
entirely overlap. As a consequence the age association was not fully determined by the 
three datasets combined. Therefore, our predictions should additionally be validated in 
other independent populations with varying age ranges.
Specifying whether a first stroke is either ICH or IS, is potentially clinically valuable. 
Specifically, a more refined estimate of the expected benefits and harms can be made 
about preventive interventions with different effects on ICH and IS risk. For example, 
according to U.S. Preventive Services Task Force guidelines, middle-aged and elderly 
women are encouraged to use aspirin when the potential benefit of reduction in 
ischemic strokes outweighs the bleeding risks (40). Our cumulative incidence functions 
may be used to refine communication of the expected benefit (by number of IS events 
avoided) and harm (by number of induced ICH events in addition to gastrointestinal 
bleedings) to support shared decision making. However, differences in consequences 
of ICH and IS events, e.g. the varying case-fatality rates, should be considered as well. In 
addition, to estimate expected absolute risk differences and numbers needed to treat, 
stratified analyses of randomized clinical trials that disentangle the effects of various 
preventive interventions on stroke subtype and competing death rates are required.
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ConClusIons
We developed and cross-validated cumulative incidence functions for separate 
prediction of absolute10-year ICH and IS risk. These functions can be useful to further 
specify an individual’s stroke risk. 
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AppendIx 
Baseline measurements and predictor definitions 
In the three studies, participants were asked to fast for 12 hours before undergoing a 
clinical examination. Height, weight, waist circumference, and hip circumference were 
measured at the study center. Current smoking status was assessed by home-interview in 
the Rotterdam Study and telephone interview in ARIC and CHS. In the Rotterdam Study, 
previous coronary heart disease history was defined as self-reported prior myocardial 
infarction, PTCA or CABG verified by medical records. In ARIC and CHS, history of coronary 
heart disease was based on questions about physician-diagnosed myocardial infarction, 
coronary bypass, and coronary angioplasty, or based on ECG evidence of myocardial 
infarction. In the Rotterdam Study, atrial fibrilliation was defined by ECG at baseline 
and information from general practitioners. In ARIC and CHS, atrial fibrilliation was 
determined by ECG. In all 3 studies, systolic and diastolic blood pressure was calculated 
as the average of two consecutive measurements, with in ARIC and CHS the average of 
the 2nd and 3rd of three measurements. In ARIC and CHS, current use of antihypertensive 
medication use was self-reported, in the Rotterdam Study it was additionally based on 
information from the general practitioner. All 3 studies enzymatically measured 12-
hour fasting total and high density lipoprotein (HDL) cholesterol. In all studies, diabetes 
mellitus was defined as fasting plasma glucose ≥126 mg/dL (≥7 mmol/L) or non-
fasting plasma glucose ≥200 mg/dL (≥11.1 mmol/L) or self-reported use of diabetes 
medications or diagnosed diabetes. Serum creatinine was assessed by Jaffé methods 
and standardized to Modification of Diet in Renal Disease (MDRD) values. Because 
serum creatinine assessment methods were not calibrated to be traceable to isotope 
dilution mass spectrometry (IMDS), we used the original abbreviated MDRD equation 
for glomerular filtration rate eGFR: 186.3*(serum creatinine)−1.154*(age)−0.203*(0.742 if 
female)*(1.212 if African American) see abstract: Levey et al, J Am Soc Nephrol 11:A0828, 
2000.
Outcome definitions and ascertainment
In ARIC, stroke was defined as a rapid onset neurological deficit lasting >24 hours or until 
death, without an apparent cause such as trauma, tumor, infection or anticoagulation 
therapy. In CHS and the Rotterdam Study the same definition was used, but 
anticoagulation therapy used at the time of the event did not preclude events as being 
classified as a stroke. However, we did not exclude these events, because a previous study 
showed that exclusion did not alter results. If ascertained, subarachnoid hemorrhage 
was excluded as an outcome. We adopted the classification of stroke subtypes as made 
by each study (see Table 1). If a stroke did not match any of these criteria, it was classified 
as an unspecified stroke event. We assumed that most unspecified stroke events would 
be ischemic of nature. 
In the ARIC study, stroke criteria were implemented as a computer algorithm and 
reviewed by a physician blinded to the automated results. A second physician resolved 
disagreements between the computer and initial physician. In the CHS, potential 
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stroke events were referred to a Cerebrovascular Adjudication Committee, consisting 
of a neurologist from each site, a neuroradiologist, and a neurologist or internist 
representing the coordinating center. In the Rotterdam Study, an experienced stroke 
neurologist (P.J.K.) verified all diagnoses. 
Analyses
We calculated cumulative incidence functions for each individual using the predictor 
effects derived from the Cox regression analyses and cause-specific baseline hazard 
functions estimated in the pooled dataset. For each stroke subtype, the cumulative 
incidence was obtained by summation of the individualized cause-specific hazard 
multiplied by the individualized survival of the stroke subtype and the competing event 
(i.e. death by other causes) at each failure time using the following equation: 
∑Istroke(10) =        hstroke(ti )S(ti – 1)
ti<10
We therefore estimated predictor effects of cardiovascular risk factors on time to first 
1) fatal or non-fatal intracerebral hemorrhage, and 2) ischemic stroke, by using Cox 
regression with censoring for end-of-study, loss-to-follow-up or death by other causes 
for each subtype. Hazard ratios were estimated using the complete available follow-up. 
The end-of-study censoring date was December 31st 2009 for the ARIC study, June 30th, 
2008 for the CHS and January 1st 2009 for the Rotterdam Study dataset. While modeling 
ischemic stroke, subjects were allowed to experience intracerebral hemorrhage(s) 
earlier on and vice versa. Therefore, the cumulative incidences of the stroke subtypes 
derived from this analysis will exceed the cumulative incidence of any stroke if added. 
Time to death by other causes was modeled with censoring for the stroke subtype of 
interest and including the same predictors as used in each final stroke subtype model.
For prediction of any stroke (either intracerebral hemorrhage or ischemic stroke), we 
modeled the cumulative incidences of intracerebral hemorrhage and ischemic stroke 
events in absence of having one of the other stroke events. Cumulative incidences of 
both stroke subtypes derived from this analysis can be added to obtain the cumulative 
incidence of any stroke. Subjects who experienced ischemic stroke were in addition 
censored for estimating the intracerebral hemorrhage hazard and vice versa. The 
competing events for intracerebral hemorrhage were defined as ischemic stroke and 
death by other causes than intracerebral hemorrhage; and for ischemic stroke as 
intracerebral hemorrhage and death by other causes than ischemic stroke. For the 
competing death Cox models, we included all candidate predictors considered for the 
basic stroke models. For the extended competing death models, additional predictors 
were selected if also included in the extended stroke model. Predictor effects for the 
any stroke model were selected from those included in the intracerebral hemorrhage, 
ischemic and non-ischemic stroke mortality cause-specific models. 
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Systematic review
We searched MEDLINE by PubMed for studies on stroke prediction to May 14, 2013 with 
search terms for “stroke”, “prediction”, “risk scores”, “validation”, and “cohort studies”. We 
limited our search to articles in the English language. We identified 1469 citations and 
scanned titles and abstracts on relevancy. We included eligible articles for review of full 
text if the study purpose was to develop or validate prediction models for individualizing 
the absolute risk of non-fatal and/or fatal stroke events in asymptomatic subjects who 
were not selected on risk factor status. 
Full Pubmed search syntax
stroke* [tiab] AND (prediction [tiab] OR risk scor* [tiab] OR risk function* [tiab] OR 
validation[tiab] OR validate[tiab]) AND (communit* [Text Word] OR cohort studies[MeSH 
Terms] OR cohort*[Text Word] OR population-based [Text Word]) AND English[lang]
Results May 14, 2013: 
1469 titles
Inclusion after reading titles/abstracts:
22 studies1-22
Inclusion for data extraction:
18 studies1-15, 20-22
4 studies16-19 were excluded, because no prediction model for calculation of individual 
risks was presented.
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Table e-2. Test results heterogeneity in predictor effects intracerebral hemorrhage
Predictor P value cohort interaction  
in the basic model
P value cohort interaction  
in the extended model
Age per 10 y increase 0.96 0.86
Male sex – –
African American 0.01 0.03
Current smoking 0.75 0.81
Diabetes – –
Antihypertensive medication use 0.03 0.02
Systolic BP per 10 mm Hg increase 
if medication use 0.04 0.04
if no medication use 0.08 0.05
Prior coronary heart disease – –
Diastolic BP per 10 mm Hg increase – 0.29
Diastolic BP per 10 mm Hg increase squared – –
Total cholesterol/HDL cholesterol ratio – 0.15
Total cholesterol/HDL cholesterol ratio squared – –
BMI per 5 units increase – <0.01
Abbreviations: BP = blood pressure, BMI = body-mass index, HDL = high-density lipoprotein
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Table e-3. Test results heterogeneity in predictor effects ischemic stroke
Predictor P value cohort interaction  
in the basic model
P value cohort interaction  
in the extended model
Age per 10 y increase
in men 0.39 0.39
in women 0.62 0.54
Male sex 0.46 0.43
African American <0.001 <0.001
Current smoking 0.001 <0.001
Diabetes <0.001 <0.001
Antihypertensive medication use 0.08 0.09
Systolic blood pressure per 10 mm Hg increase
if medication use 0.03 0.04
if no medication use 0.22 0.22
Prior coronary heart disease 
in men 0.01 0.01
in women 0.24 0.27
Diastolic BP per 10 mm Hg increase – 0.05
Diastolic BP per 10 mm Hg increase squared – –
Total cholesterol/HDL cholesterol ratio – <0.001
GFR per 10 ml/min/ 1.73 m2 increase – 0.22
GFR per 10 ml/min/ 1.73 m2 increase squared – –
Waist-to-hip ratio per 0.1 increase – 0.02
Abbreviations: BP = blood pressure, GFR = glomerular filtration rate, HDL = high-density lipoprotein
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Table e-4. Test results heterogeneity in predictor effects competing death censored for any stroke
Predictor P value cohort interaction  
in the basic model
P value cohort interaction  
in the extended model
Age per 10 y increase
in men 0.80 0.64
in women 0.44 0.08
Male sex 0.90 0.49
African American <0.001 <0.001
Current smoking <0.001 <0.001
Diabetes <0.001 <0.001
Antihypertensive medication use 0.01 0.01
Systolic BP per 10 mm Hg increase
if medication use 0.002 0.002
if no medication use 0.08 0.07
Prior coronary heart disease 
in men <0.001 <0.001
in women 0.004 0.02
Diastolic BP per 10 y increase – 0.003
Diastolic BP per 10 y increase squared – –
Total cholesterol: HDL ratio – <0.001
Total cholesterol: HDL ratio squared – –
GFR per 10 ml/min/ 1.73 m2 increase – 0.004
GFR per 10 ml/min/ 1.73 m2 increase squared – –
Waist-to-hip ratio per 0.1 increase – <0.001
Abbreviations: BP = blood pressure, BMI = body-mass index, GFR = glomerular filtration rate, HDL = high-density lipoprotein
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Table e-7. Predictors and hazard ratios with 95%CIs for competing death censored for any stroke
Predictor Basic model HR (95%CI) Extended model HR (95%CI)
Age per 10 y increase
in men 2.93 (2.82 – 3.05) 2.79 (2.67 – 2.91)
in women 3.09 (2.98 – 3.20) 2.97 (2.85 – 3.08)
Male sex 2.19 (1.68 – 2.85) 2.23 (1.71 – 2.91)
African American 1.17 (1.11 – 1.24) 1.13 (1.06 – 1.20)
Current smoking 2.13 (2.04 – 2.23) 2.09 (2.00 – 2.19)
Diabetes 1.64 (1.55 – 1.73) 1.56 (1.48 – 1.64)
Antihypertensive medication use 1.97 (1.52 – 2.55) 1.85 (1.43 – 2.39)
Systolic blood pressure per 10 mm Hg increase
if medication use 1.04 (1.02 – 1.05) 1.04 (1.02 – 1.06)
if no medication use 1.08 (1.06 – 1.09) 1.08 (1.06 – 1.09)
Prior coronary heart disease 
in men 1.68 (1.57 – 1.80) 1.65 (1.54 – 1.76)
in women 1.47 (1.37 – 1.58) 1.44 (1.35 – 1.55)
Diastolic BP per 10 y increase – 0.55 (0.47 – 0.65)
Diastolic BP per 10 y increase squared 1.04 (1.03 – 1.05)
Total cholesterol/HDL ratio – 0.81 (0.76 – 0.87)
Total cholesterol/HDL ratio squared 1.02 (1.01 – 1.03)
GFR per 10 ml/min/ 1.73 m2 increase – 0.68 (0.64 – 0.72)
GFR per 10 ml/min/ 1.73 m2 increase squared – 1.02 (1.02 – 1.02)
Waist-to-hip ratio per 0.1 increase – 1.13 (1.10 – 1.16)
Abbreviations: BP = blood pressure, GFR = glomerular filtration rate, HDL = high-density lipoprotein
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Table e-8. Predictors and hazard ratios with 95%CIs for intracerebral hemorrhage censored for 
ischemic stroke and competing death
Predictor Basic model HR (95%CI) Extended model HR (95%CI)
Age per 10 y increase 1.99 (1.65 – 2.40) 2.08 (1.72 – 2.52)
Male sex
African American 1.83 (1.35 – 2.49) 1.58 (1.14 – 2.17)
Current smoking 1.50 (1.13 – 2.00) 1.49 (1.12 – 1.99)
Diabetes 
Antihypertensive medication use 5.76 (1.20 – 27.74) 5.84 (1.27 – 26.79)
Systolic BP per 10 mm Hg increase 
if medication use 1.08 (0.98 – 1.19) 1.03 (0.93 – 1.13)
if no medication use 1.24 (1.16 – 1.33) 1.18 (1.08 – 1.27)
Prior coronary heart disease 
Diastolic blood pressure per 10 y increase – 0.21 (0.09 – 0.48)
Diastolic blood pressure per 10 y increase squared – 1.12 (1.06 – 1.18)
Total cholesterol/HDL ratio – 0.58 (0.40 – 0.85)
Total cholesterol/HDL ratio squared – 1.04 (1.00 – 1.08)
Abbreviations: BP = blood pressure, CHS = Cardiovascular Health Study, HDL = high-density lipoprotein 
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Table e-9. Predictors and hazard ratios with 95%CIs for ischemic stroke censored for intracerebral 
hemorrhage and competing death
Predictor Basic model HR (95%CI) Extended model HR (95%CI)
Age per 10 y increase
in men 1.89 (1.75 – 2.05) 1.88 (1.73 – 2.05)
in women 2.13 (1.99 – 2.28) 2.09 (1.95 – 2.25)
Male sex 2.62 (1.55 – 4.42) 2.21 (1.30 – 3.75)
African American 1.33 (1.19 – 1.48) 1.34 (1.19 – 1.50)
Current smoking 1.64 (1.49 – 1.80) 1.63 (1.48 – 1.79)
Diabetes 1.78 (1.61 – 1.96) 1.68 (1.52 – 1.86)
Antihypertensive medication use 3.80 (2.30 – 6.26) 3.29 (2.00 – 5.42)
Systolic BP per 10 mm Hg increase
if medication use 1.11 (1.08 – 1.14) 1.09 (1.06 – 1.13)
if no medication use 1.20 (1.17 – 1.23) 1.17 (1.14 – 1.21)
Prior coronary heart disease 
In men 1.64 (1.42 – 1.89) 1.60 (1.39 – 1.85)
In women 1.22 (1.06 – 1.40) 1.19 (1.04 – 1.36)
Diastolic blood pressure per 10 y increase – 0.72 (0.52 – 0.99)
Diastolic blood pressure per 10 y increase 
squared
– 1.03 (1.00 – 1.05)
Total cholesterol: HDL ratio – 1.05 (1.03 – 1.08)
GFR per 10 ml/min/ 1.73 m2 increase – 0.78 (0.70 – 0.87)
GFR per 10 ml/min/ 1.73 m2 increase squared – 1.01 (1.01 – 1.02)
Waist-to-hip ratio per 0.1 increase – 1.11 (1.05 – 1.18)
Abbreviations: BP = blood pressure, BMI = body-mass index, GFR = glomerular filtration rate, HDL = high-density lipoprotein
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Table e-11. Performance of any stroke prediction for the ARIC, CHS and Rotterdam studies
Basic model Extended model
Model development in pooled ARIC, CHS and 
Rotterdam dataset
Validation with ARIC 
C statistic (95%CI) 0.788 (0.767, 0.809) 0.785 (0.765, 0.806)
total NRI (95%CI) – 0.05 (0.02, 0.09)
event NRI (95%CI) – 0.03 (0.00, 0.05)
non-event NRI (95%CI) – 0.02 (0.00, 0.03)
Chi-Square calibration 9.69 11.17
Validation with Rotterdam
C statistic (95%CI) 0.690 (0.671, 0.709) 0.690 (0.671, 0.710)
total NRI (95%CI) – 0.17 (0.10, 0.26)
event NRI (95%CI) – 0.06 (-0.02, 0.15)
non-event NRI (95%CI) – 0.11 (0.09, 0.14)
Chi-Square calibration 10.08 10.24
Validation with CHS 
C statistic (95%CI) 0.659 (0.638, 0.679) 0.658 (0.638, 0.679)
total NRI (95%CI) – -0.06 (-0.14, 0.05)
event NRI (95%CI) – -0.29 (-0.37, -0.21)
non-event NRI (95%CI) – 0.23 (0.20, 0.25)
Chi-Square calibration 15.92 15.68
Abbreviations: ARIC = Atherosclerosis Risk in Communities Study, CHS = Cardiovascular Health Study, NRI = net reclassification 
improvement
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Figure e-5. Calibration plots of cumulative incidence functions for intracerebral hemorrhage in the 
three cohorts – Basic model 
Predicted vs observed 10-year cumulative incidence (95%CI) of intracerebral hemorrhage within age tertiles. Predictions based on 
cumulative incidence functions are indicated by circles, predictions based on standard survival models are indicated by crosses. 
Because 95%CIs are equal, these are only depicted for cumulative incidence functions.
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Figure e-6. Calibration plots of cumulative incidence functions for intracerebral hemorrhage in the 
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Predicted vs. observed 10-year cumulative incidence (95%CI) of intracerebral hemorrhage within age tertiles. Predictions based on 
cumulative incidence functions are indicated by circles, predictions based on standard survival models are indicated by crosses. 
Because 95% CIs are equal, these are only depicted for cumulative incidence functions.
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Figure e-7. Calibration plots of cumulative incidence functions for ischemic stroke in the three 
cohorts – Basic model
Predicted vs observed 10-year cumulative incidence (95%CI) of ischemic stroke within age quintiles. Predictions based on cumulative 
incidence functions are indicated by circles, predictions based on standard survival models are indicated by crosses. Because 95% CIs 
are equal, these are only depicted for cumulative incidence functions.
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Figure e-8. Calibration plots of cumulative incidence functions for ischemic stroke in the three 
cohorts – Extended model 
Predicted vs observed 10-year cumulative incidence (95%CI) of ischemic stroke within age quintiles. Predictions based on cumulative 
incidence functions are indicated by circles, predictions based on standard survival models are indicated by crosses. Because 95% CIs 
are equal, these are only depicted for cumulative incidence functions.
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AbstRACt
Background: According to population-based cohort studies CT coronary calcium 
score (CTCS), carotid intima-media thickness (cIMT), high-sensitivity C-reactive protein 
(CRP), and ankle-brachial index (ABI) are promising novel risk markers for improving 
cardiovascular risk assessment. Their impact in the U.S. general population is however 
uncertain. Our aim was to estimate the predictive value of four novel cardiovascular risk 
markers for the U.S. general population. 
Methods and findings: Risk profiles, CRP and ABI data of 3,736 asymptomatic subjects 
aged 40 or older from the National Health and Nutrition Examination Survey (NHANES) 
2003-2004 exam were used along with predicted CTCS and cIMT values. For each subject, 
we calculated 10-year cardiovascular risks with and without each risk marker. Event 
rates adjusted for competing risks were obtained by microsimulation. We assessed the 
impact of updated 10-year risk scores by reclassification and C-statistics. In the study 
population (mean age 56 ± 11 years, 48% male), 70% (80%) were at low (<10%), 19% 
(14%) at intermediate (≥10 – <20%), and 11% (6%) at high (≥20%) 10-year CVD (CHD) 
risk. Net reclassification improvement was highest after updating 10-year CVD risk with 
CTCS: 0.10 (95%CI 0.02 – 0.19). The C-statistic for 10-year CVD risk increased from 0.82 
by 0.02 (95%CI 0.01 – 0.03) with CTCS. Reclassification occurred most often in those 
at intermediate risk: with CTCS, 36% (38%) moved to low and 22% (30%) to high CVD 
(CHD) risk. Improvements with other novel risk markers were limited. 
Conclusions: Only CTCS appeared to have significant incremental predictive value in 
the U.S. general population, especially in those at intermediate risk. In future research, 
cost-effectiveness analyses should be considered for evaluating novel cardiovascular 
risk assessment strategies.
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IntRoduCtIon
Cardiovascular disease (CVD) remains the leading cause of death in the U.S. 
population (1). Current guidelines recommend aggressive risk modifying treatment 
regimens in apparently healthy individuals deemed to be at high cardiovascular risk (2). 
These individuals can be identified using risk scores based on traditional risk factors 
as defined by the Framingham Heart Study (3, 4). However, the accuracy of Framingham 
risk scores (FRS) for predicting CVD outcomes can be improved by adding novel risk 
markers, including imaging techniques and biomarkers. 
Recently, the U.S. Preventive Services Task Force and the American College of Cardiology 
Foundation/American Heart Association Task Force published recommendations on 
which novel risk markers to use for cardiovascular risk assessment (5, 6). Four novel risk 
markers that are expected to have added predictive value beyond the FRS are: the 
CT coronary artery calcium score (CTCS), high-sensitivity C-reactive protein (CRP), the 
ankle-brachial index (ABI) and measurement of carotid intima-media thickness (cIMT). 
Most importantly, studies should have demonstrated that risk assessment including 
these novel markers should correctly reclassify individuals into clinically relevant 
risk categories. These risk categories are defined by 10-year risk: e.g. <10% (low risk), 
10 – 19% (intermediate risk) and ≥20% (high risk). 
Due to heterogeneous results (7-9) and selection of study populations it remains difficult 
to generalize from published cohort studies that adding these novel markers to the FRS 
would indeed lead to improved classification in the U.S. population as a whole (10). In 
order to synthesize the existing evidence quantitatively, computer simulation modeling 
with data input from meta-analyses combined with study data representative of the 
entire population overcomes a number of these limitations (11). 
In this study, we aimed to update traditional 10-year FRSs by the published independent 
associations of CTCS, cIMT, CRP, and ABI with cardiovascular events. Our final purpose 
was to assess to what extent the predictive value of traditional risk assessment would 
be improved by these four novel markers in asymptomatic participants of the National 
Health and Nutrition Examination Survey (NHANES), a cross-sectional study designed to 
be a representative sample of the U.S. general population. 
Methods 
Systematic Review of the Novel Risk Markers’ Predictive Effects 
We adopted two recent individual-level meta-analyses for the association of a one unit 
SD (1.11) log mg/L increase of CRP, and the association of a 0.1 mm increase in mean 
cIMT with coronary heart disease (CHD) and stroke event rates (12, 13). Both were adjusted 
for traditional risk factors. For CTCS and ABI, we updated the 2009 systematic review by 
the USPSTF (14) through April 19, 2013 (for detailed search syntaxes and study inclusion 
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criteria see the Text S1). Two reviewers independently included potentially eligible 
articles based on title and abstract. Only studies that recruited subjects from the general 
population, and which excluded or adjusted for prior CHD and stroke were included. 
Articles were included if both reviewers agreed that the study design was a cohort, 
nested case-control, or case-cohort study. Also, systematic reviews that included these 
study types were considered. Relative risk estimates had to be calculated for CHD and/
or stroke, with CHD defined as myocardial infarction or coronary death. We excluded 
studies that analyzed the novel risk marker with adjustment for less than 5 of the 8 
Framingham risk factors: age, sex, smoking, systolic blood pressure, antihypertensive 
drug therapy, total cholesterol, high density (HDL) cholesterol and diabetes mellitus. 
One reviewer extracted the reported relative risks and 95% CI limits of an increase in 1 
unit log (CTCS + 1) for CTCS, and of an ABI ≤0.90 vs >0.90. If relative risks were reported 
using other units, these were converted in order to match the aforementioned units 
(see the Text S1 for details). Data extraction was checked by a second reviewer. We used 
the R ‘meta.summaries’ function of the ‘rmeta’ package to compute summary estimates 
and 95% CIs by random-effects modeling. Heterogeneity was assessed statistically with 
the Woolf’s test where values <0.05 indicate significant heterogeneity.
Study Population
We selected data on 3,736 individuals aged 40 or older without a history of myocardial 
infarction or stroke at baseline from the 2003 – 2004 NHANES exam, taking into account the 
sampling weights. We used the following datasets: NHANES 2003 – 2004 Demographics 
Data, NHANES 2003 – 2004 Examination Data, NHANES 2003 – 2004 Laboratory Data, 
and NHANES 2003 – 2004 Questionnaire Data, see http://wwwn.cdc.gov/nchs/nhanes/
search/nhanes03_04.aspx. We included the following variables: age at the exam visit, 
sex, current smoking, systolic blood pressure, total cholesterol, HDL cholesterol, fasting 
plasma glucose level, anti-diabetic treatment, antihypertensive treatment, ankle-
brachial index, and high-sensitivity C-reactive protein. Because values for CTCS and 
cIMT were not measured in the NHANES study, we merged the NHANES dataset with 
a subset of the Rotterdam Study Cohort. The Rotterdam Study is a population-based 
cohort study of individuals aged 55 years and older living in Rotterdam, the Netherlands 
(15). Baseline examinations were performed between 1990 and 1993 (Rotterdam Study-I). 
Traditional FRS risk factors, CTCS, cIMT, hs-CRP, ABI, and information on cardioprotective 
drugs were simultaneously measured during the third examination round (1997 to 
1999) in a subset (N = 1,915) of the Rotterdam Study-I cohort. Details on how these 
novel risk markers and the other variables were measured are published elsewhere (16, 17). 
We imputed the missing CTCS and cIMT values of NHANES subjects within the merged 
dataset. For the imputation, we used a flexible additive imputation model including all 
other variables. After the imputation, only NHANES individuals were selected for the 
analysis (see Table 1 for baseline characteristics, andText S1 for details on the dataset 
preparation). 
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Table 1. Baseline characteristics of 3,736 NHANES and 1,915 Rotterdam Study individuals
Variable NHANES Median [IQR] RS Median [IQR]
Age 53 [46 – 63] 70 [66 – 75]
Sex (%male) 48% 45%
Current Smoking 23% 16%
Systolic blood pressure (mm Hg) 125 [115 – 139] 140.0 [124 – 155]
HRX 27% 28%
Total cholesterol (mg/dl) 209 [183 – 235] 225 [203 – 250]
HDL cholesterol (mg/dl) 51 [42 – 63] 51 [43 – 62]
Glucose (mg/dl) 97 [90 – 106] 99 [94 – 110]
Anti diabetic medication 8% 6.2%
CTCS*
0 37% 10%
1-100 36% 41%
101-400 14% 23%
400-1000 8% 15%
≥1000 5% 11%
Natural logarithm of (CTCS+1) 2.6 [0 – 4.8] 4.81 [2.6 – 6.3]
cIMT (mm)* 0.78 [0.69 – 0.93] 0.86 [0.76 – 0.95]
CRP (mg/L) 2.1 [0.9 – 4.6] 2.4 [1.2 – 4.4]
ABI ≤0.9 5.0% 15.6%
Abbreviations: CTCS = CT coronary artery calcium score, HDL = high-density lipoprotein, HRX = antihypertensive drug treatment, 
NHANES = National Health and Nutrition Examination Survey; RS, Rotterdam Study.
SI conversion factors: To convert CRP to nanomoles per liter, multiply by 9.524; HDL and total cholesterol to millimoles per liter, multiply 
by 0.0259.
*Imputed by multivariable algorithms
Updating Framingham Risk Scores
For both the 10-year cardiovascular risk assessment and simulation of event rates, we 
used the 30-year FRS as basis for our models (18). It uses the 8 aforementioned traditional 
risk factors to calculate 30-year cumulative incidences for both CVD and non-CVD deaths, 
while taking into account competing risks. CVD is defined as myocardial infarction, 
coronary death and stroke, non-CVD death is defined as mortality due to all causes 
other than CVD. In order to calculate CHD and stroke risks separately, we applied a sex-
specific ratio of the reported CHD to stroke events to the baseline CVD survival function. 
For men, the CHD: stroke event ratio was 348/104 and for women it was 133/86. We 
assumed that the reported regression coefficients of the traditional risk factors were 
similar for CHD and stroke. To resemble currently recommended risk assessment, we 
calculated 10-year CVD and CHD risks without adjustment for competing risk. We used 
the baseline CHD and CVD survival probability at year 10 and subsequently updated 
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the traditional FRS with one novel risk marker at a time. We recalibrated the baseline 
survival probability by assuming no change in the average survival probability. For both 
10-year CVD and CHD, the different models (FRS only, FRS + CTCS, FRS + IMT, FRS + CRP, 
and FRS + ABI) were used to classify the 3,673 NHANES subjects into to the following risk 
categories: <10%, ≥10-<20%, ≥20%. In addition, we also classified into <6%, ≥6-<20%, 
≥20%: categories (19).
Cardiovascular outcomes
To simulate cardiovascular event rates, we constructed a state-transition model using 
TreeAge software (2009 version, TreeAge Software, Inc., Williamstown, MA, USA), 
consisting of three health states: ‘Well’, ‘Post-CVD’ and ‘Dead’ (see Table S1 for input 
parameters). A one-year cycle length was used. One-year transition-probabilities were 
based on the 30-year FRS updated with all four novel risk markers together, assuming 
independency of predictive effects. We recalibrated the baseline survival function 
through 30 years of follow-up, while ascertaining that the average 30-year cumulative 
incidences for CVD and non-CVD death calculated by the state-transition model were 
equal to the average risks calculated by the original 30-year FRS for the NHANES study 
sample (see the eMethods for details).
Predictive Value of the Four Updated Risk Scores
Reclassification tables were created by cross-tabulating NHANES individuals using the 
three risk categories of the traditional and each updated FRS. Occurrences of events within 
these individuals were modeled through a state-transition model using Monte Carlo 
microsimulation. We calculated risks in subjects reclassified upwards and downwards 
for both cases and non-cases and calculated the net reclassification improvement (NRI) 
applicable to survival and competing risk data (20). For the intermediate risk category, we 
calculated a bias-corrected NRI (21). In addition, long-term 30-year risks were reported in 
the reclassification tables to evaluate whether those who are reclassified have a long-
term risk that is in agreement with the reclassification. To further assess the models’ 
discriminative performance, we calculated the Harrell’s C-statistic (22) using simulated 
10-year time-to-event data. To take into account the uncertainty of the hazard ratios of 
the novel risk markers, 95% CIs were calculated by randomly sampling from lognormal 
distributions defined by the summary estimates and standard errors taken from the 
meta-analyses.
Ethics Statement 
For the 2003 – 2004 NHANES, Institutional Review Board (IRB) approval and documented 
consent was obtained from all participants (Protocol #98-12). The Rotterdam Study has 
been approved by the institutional review board (Medical Ethics Committee) of the 
Erasmus Medical Center and by the review board of The Netherlands Ministry of Health, 
Welfare, and Sports. The approval has been renewed every 5 years. 
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Results
Systematic Review of the Novel Risk Markers’ Predictive Effects 
From the USPSTF report (14), eight studies on CTCS and ten studies on ABI were included 
in our review. For ABI, we did not use the reported estimates on CHD and stroke, 
because these were based on a comparison between an ABI ≤0.9 and 1.11 – 1.40 instead 
of ≤0.9 vs >0.9 (23). Combined with the citations found through our additional search, in 
total 1,107 citations were included in our systematic review. Seventeen articles were 
used for the data extraction; for reasons of exclusions see Figure 1. In 11 of the articles 
the effect of the novel risk marker was adjusted for seven or more Framingham risk 
factors (for the study details see Table S2). 
Excluded (N = 896)
Duplicates: 29
Not eligible: 867
Title/abstract review (N = 948)
MEDLINE:
CTCS: 776
ABI: 150
Previous USPSTF report:
CTCS: 8
ABI: 10
After reading reference lists:
CTCS: 4
Included articles (N = 17) †
Hard CHD:
CTCS: 7
ABI: 5
Stroke:
CTCS: 2
ABI: 6
Full text review (N = 52)
ABI: 18
CTCS: 34
Excluded (N = 35)*
Not general population: 14
No hard CHD and stroke as outcome: 10
No relative eects (HR/OR/RR) reported: 8
Not adjusted for ≥5 traditional RFs: 2
Overlap with other study: 9
Figure 1. Literature search and selection
Numbers of articles of each step of the review process are indicated. 
*Group total exceed the reported number for the excluded articles because several reasons for exclusion were allowed. †Group total 
exceed the number for the included articles, because one article may include estimates for both CHD and stroke.
Abbreviations: ABI, ankle-brachial index; CHD, coronary heart disease; CTCS, computed tomography calcium scoring; HR, hazard ratio; 
OR = odds ratio, RR = risk ratio, USPSTF = United States Preventive Services Task Force
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For the association between CTCS and CHD, we performed a meta-analysis on a total of 
30,945 individuals and 548 events. Only two studies were found on the association of 
CTCS with stroke, comprising 7,118 subjects and 117 stroke events. For the ABI meta-
analyses, 21,122 subjects with 1,206 CHD events and 36,941 subjects with 987 stroke 
events were used. One study on the association between ABI and CHD also counted 
angina as a CHD event (24). As the authors explicitly stated that the analysis limited to 
hard CHD events (i.e., excluding angina) showed similar results, we included this study 
in the analysis. Summary estimates from the meta-analyses are given in Table 2. We 
found no statistical evidence for heterogeneity between studies. The forest plots are 
included in the Figures S1-S4.
Table 2. Hazard Ratios and confidence intervals from the meta-analyses
Novel risk marker HR [95%CI] for CHD HR [95%CI] for Stroke Source
Log(CTCS+1) 1.35 [1.28 – 1.43] 0.97 [0.84 – 1.12] This manuscript
0.1 mm IMT 1.08 [1.05 – 1.10] 1.12 [1.10 – 1.15] Den Ruijter et al (13)
Log(CRP) / SD* (mg/L) 1.22 [1.17 – 1.27] 1.16 [1.10 – 1.27] Emerging Risk Factors Collaboration (12)
ABI ≤0.9 1.47 [1.18 – 1.84] 1.26 [1.05 – 1.50] This manuscript
* Pooled SD = 1.11 mg/L
Predictive Value of the Four Updated Risk Scores
Most NHANES subjects were at low (<10%) 10-year CVD and CHD risk: respectively 2,641 
(71%) and 2,999 (80%). The number of NHANES subjects with intermediate (≥10-<20%) 
risk was limited: 697 (19%) for CVD and 525 (14%) for CHD as the outcome. These 
numbers approximately doubled with using the alternative threshold values ≥6-<20% 
to 1385 (37%) for CVD and 1075 (29%) for CHD.
Amongst the updated models, the FRS + CTCS had the highest NRI (Table 4). For the 
FRS updated with the other novel risk markers, the reclassification was limited and the 
NRI was close to zero for both CVD and CHD as end point (see Table 4 and Tables S4 and 
S5). Net reclassification improvement results were similar when using the <6, ≥6-<20%, 
≥20% risk categorization. The number of high risk (≥20%) individuals reclassified to 
lower risk was limited -even for CTCS. Those who were reclassified upwards had a much 
higher 30-year CVD and CHD risk than the risk for those remaining in their risk category 
or who were reclassified downwards (Table 3 and Table S4a).
Subjects who were traditionally classified as intermediate (≥10-<20%) 10-year CVD 
risk, were most frequently reclassified by CTCS. In this intermediate risk category, 0.39 
(95%CI 0.23 – 0.55) of those with a CVD event within 10 years were reclassified upwards, 
whereas only 0.17 (95%CI 0.09 – 0.27) were reclassified downwards. For the subjects 
who did not experience an event, 0.37 (95%CI 0.35 – 0.39) were reclassified downwards 
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and 0.18 (95%CI 0.11 – 0.25) upwards. The resulting bias-corrected NRI from updating 
FRS by CTCS in the intermediate risk category was 0.15 (95%CI 0.05 – 0.27). Defining 
≥6-<20% as the intermediate risk category, the bias-corrected NRI was 0.13 (95%CI 0.06 
– 0.21). The C-statistic of the FRS increased most by adding CTCS (Table 4 and Table S5). 
It increased from 0.82 (95%CI 0.79 – 0.85) to 0.84 (95%CI 0.81 – 0.86) for predicting CVD 
and from 0.84 (95%CI 0.82 – 0.86) to 0.87 (95%CI 0.84 – 0.89) for predicting CHD. 
Table 3. Ten-year cardiovascular disease (CVD) risk reclassification by CTCS 
FRS + CTCS Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2520.53 116.06 4.41 2641
% Events [ 95% CI ]
10 yr CVD 2.5 [1.9 – 3.2] 11.2 [6.1 – 16.6] 19.7 [0 – 85.8] 2.9 [2.3 – 3.5]
30 yr CVD 14.8 [13.0 – 16.2] 49.2 [39.8 – 57.3] 68.6 [0 – 100] 16.4 [15.0 – 18.0]
≥10- <20%
N 240.28 309.36 147.36 697
% Events [ 95% CI ]
10 yr CVD 6.7 [3.5 – 9.6] 12.9 [9.0 – 16.4] 24.8 [17.7 – 31.4] 13.3 [10.8 – 16.0]
30 yr CVD 32.5 [27.0 – 38.9] 50.5 [45.5 – 55.9] 69.3 [60.9 – 77.6] 48.3 [43.6 – 51.9]
≥20%
N 6.62 80.72 310.66 398
% Events [ 95%CI ]
10 yr CVD 9.7 [0 – 42.9] 13.9 [7.8 – 21.3] 40.3 [33.0 – 47.9] 34.4 [28.8 – 40.6]
30 yr CVD 33.7 [0 – 75.0] 48.4 [39.9 – 58.2] 74.1 [68.3 – 78.9] 68.2 [63.2 – 72]
Overall
N 2767.43 506.14 462.43 3736
% Events [ 95% CI ]
10 yr CVD 2.8 [2.3 – 3.5] 12.7 [9.6 – 15.4] 35.2 [30.0 – 40.0] 8.2 [7.3 – 40.0]
30 yr CVD 16.4 [14.8 – 17.8] 49.8 [45.0 – 54.3] 72.5 [67.6 – 76.7] 27.9 [26.3 – 76.7]
Classification on the basis of 10-year CVD risk assessment using <10%, ≥10-<20%, and ≥20% as risk thresholds.
Abbreviations: CTCS = CT coronary artery calcium score.
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dIsCussIon
In this study, we modeled the predictive value of adding four novel cardiovascular risk 
markers to traditional Framingham risk scores (FRSs) in individuals representative of 
the U.S. general population. Whereas previous studies have focused on the predictive 
value of risk markers in specific longitudinal cohorts, we aimed to study the potential 
value of using risk markers in the US population as a whole. We used the two most 
commonly used endpoints 10-year CVD and CHD risk, together with two recommended 
risk categorization methods: <10%, 10-19%, ≥20% and <6%, 6 – 19%, ≥20% for low, 
intermediate, and high risk respectively. Among the four updated risk scores, the FRS 
updated with CTCS showed the most impact on reclassification for both CVD and CHD 
as endpoint, regardless of the risk thresholds used. Most reclassification occurred in 
those traditionally at intermediate risk; in other risk categories reclassification was less 
evident. FRS updated by cIMT, CRP and ABI had limited value with regard to appropriate 
reclassification and improvement of the C-statistic.
Previous cohort studies have demonstrated the added predictive value of CT coronary 
artery calcium score (CTCS), carotid intima-media thickness (cIMT), high-sensitivity 
C-reactive protein (CRP), and the ankle-brachial index (ABI) beyond FRS. The latter three 
risk markers were recently evaluated in large individual-level meta-analyses combining 
data from several cohort studies (12, 13, 23, 25). Although the meta-analyses showed that 
these markers are associated with CVD independently from Framingham risk factors, 
the impact on improving risk prediction and classification was generally limited. The 
meta-analysis evaluating cIMT for 10-year CVD prediction showed similar C-statistics for 
the FRS: 0.757, and FRS with addition of common cIMT: 0.759. Only a small NRI: 0.008 was 
observed in the total population, which increased to 0.036 in individuals at intermediate 
risk (13). This meta-analysis did not include recently published Framingham Study data 
that showed similar results: a small change in the C-statistic: 0.748 to 0.751 and 0.0 NRI. 
The meta-analysis on CRP showed a change in the C-statistic of 0.0039, and the NRI was 
0.0152 for CVD prediction. The Framingham Offspring data included within the analysis 
showed that the C-statistic of 0.7779 increased by 0.0040. In the other included cohort 
studies, changes in the C-statistic varied from -0.0027 to 0.0157 (25). In the meta-analysis 
on ABI, CHD risks were calculated after cross-tabulating a FRS for predicting 10-yr CHD 
risk categories by four different ABI categories. Meaningful reclassification by ABI was 
limited to women only: 7% of women at low risk and 10% of the women at intermediate 
risk were reclassified as high risk based on an ABI ≤0.90 (23). Changes in the C-statistic 
and NRI with ABI ≤0.90 have not been established. A recent study in the Atherosclerosis 
Risk in Communities Study (ARIC Study) showed only modest improvement in the 
C-statistic: 0.756 to 0.758 and a NRI of 0.008 (26). For CTCS, individual-level meta-analyses 
have not yet been conducted, although a systematic review of cohort studies shows 
that the impact on the C-statistic and NRI is generally larger: changes in the C-statistic 
varied from 0.04 to 0.13 and NRIs varied from 0.14 to 0.25 (9). The four risk markers were 
evaluated in a direct comparison by only two cohort studies: the Multi-Ethnic Study 
of Atherosclerosis (MESA) and the Rotterdam Study (17, 27). Both studies concluded that 
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among the four markers, CTCS has the most added value in those at intermediate risk. In 
MESA, addition of CTCS, cIMT, CRP or ABI to a FRS plus race/ethnicity led to NRIs of 0.659, 
0.102, 0.079, and 0.036 respectively. In the Rotterdam Study, these were 0.393, 0.046, 
0.092, and 0.073. These NRIs were, however, not bias-corrected (21).
Generalizing results on reclassification from cohort studies to the general population is 
not straightforward. The impact of a novel risk marker on improving risk classification is 
determined by the strength of the association with the outcome, but also depends on 
the joined distribution of the marker and traditional risk factors in the population (10). 
Because the distribution of risk factors in cohort studies is not comparable to the general 
population, we reproduced cardiovascular risk predictions by Framingham risk factors 
and novel risk markers within a recent NHANES sample while hypothesizing that these 
are generalizable. Although we were able to apply the summarized independent 
associations of novel risk markers with CVD to the NHANES sample, our study bears 
some important limitations. First, the NHANES did not include measurements of CTCS 
and cIMT. We therefore had to impute these measurements. We used correlations 
between Framingham risk factors and the other two novel risk markers as observed 
in the Rotterdam Study for the imputation process. Thus, the CTCS and cIMT values 
were distributed in the NHANES subjects conditionally on the assumption that the 
correlations in the Rotterdam Study are applicable to the NHANES population. Second, 
the NHANES data do not include CVD event rates and we therefore had to assume 
that the FRS (18) would be valid for the NHANES population in predicting event rates. 
However, it has been shown that Framingham-based predictions perform fairly well in 
most U.S. subpopulations (28). Third, for the simulation of CVD event rates, we assumed 
that the associations of the four novel risk markers with CVD were independent of each 
other. Few studies published the change in hazard ratios of these novel risk markers 
after subsequently adding them to the FRS. Generally, the amount of confounding is 
limited (29). Fourth, because our purpose was to evaluate the additional value of novel 
risk markers in the light of competing risk by non-CVD death, we chose a FRS that took 
into account the competing risk of non-CVD death for our simulation model. This FRS 
however uses total CVD as outcome and does not allow associations of traditional risk 
factors to be different for CHD and stroke events (3). We therefore hypothesized that 
these effects would be similar. Although this seems to be a reasonable assumption for 
the most important cardiovascular risk factors -age and sex, this may be less true for 
other risk factors such as lipid levels (30). However, CHD comprises the major part of total 
CVD. This implies that the associations of the traditional risk factors with CVD are closer 
to that of CHD than of stroke, and the results for reclassification of CHD will be relatively 
unaffected by this assumption. Finally, putting CHD and stroke and under the same term 
might be problematic when the goal is to individualize predictions while considering 
the difference in pathophysiology. For example, cIMT might well improve predictions 
of future stroke but not CHD. A separate assessment of stroke risk is generally however 
not advocated by most guideline groups, and we therefore did not evaluate a potential 
improvement of stroke prediction (31).
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Instead of a priori focusing on individuals at intermediate risk (14, 27), we also included 
low and high-risk individuals. In theory, reclassifying high-risk individuals without 
events downwards could be beneficial as well. However, we demonstrated that CTCS 
has the largest value in refining decision-making in the intermediate risk category. 
Reclassification of subjects originally at low or high risk was much more limited. The size 
of the U.S. general population considered to be at intermediate risk largely depends 
on the chosen outcome and risk thresholds. Thus, the potential impact of additional 
testing with novel risk markers to decrease the total number of events will vary with this 
definition. Its impact will also depend on the indirect association of the novel risk marker 
with competing non-CVD death, e.g. through a strong correlation with age. There is, 
however, no indication that those reclassified to high risk suffer from a larger risk of 
competing death as demonstrated by a concordant increase in long-term, 30-year risk. 
Ultimately, costs and effects of recommended preventive treatment on quality-adjusted 
life expectancy should be considered for evaluating the impact of novel cardiovascular 
risk assessment strategies (32). 
In conclusion, among four promising novel risk markers, only CTCS is expected to have 
significant incremental predictive value in the U.S. general population, and especially in 
those at intermediate risk. Future research should be performed to evaluate the clinical 
impact and cost-effectiveness of various novel cardiovascular risk assessment strategies.
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Meta-analyses
To standardize the reported units and categories into the desired units for CTCS: 
natural logarithm of (CTCS + 1) and the categorization of ABI: ≤0.9 vs >0.9, we assumed 
a log-linear relation between the hazard of coronary heart disease (CHD) and stroke 
with the natural logarithm of (CTCS + 1) and continuous ABI up to a value of 1.4. If 
categories were reported, we performed linear regression on the log hazard ratios with 
the reported median values of each category as co-variables to derive relative risks on 
a continuous scale. If medians were not reported for each category we estimated them 
using the group mean and standard deviation assuming a normal distribution. Medians 
on the untransformed CTCS scale were taken assuming that the natural logarithm of 
the median would approximate the median of the natural logarithm of (CTCS + 1). Two 
studies (1, 2) reported the HR of log2(CTCS+1) instead of the natural logarithm, these were 
converted to the natural logarithm scale using a factor 1.4427.
Imputation of CTCS and cIMT Values
The Rotterdam Study is a population-based cohort study of individuals aged 55 
years and older living in Rotterdam, the Netherlands (3). Demographics, traditional 
risk factors, CTCS, cIMT, hs-CRP, ABI, and information on cardioprotective drugs were 
measured during re-examination visits in a subset (N = 1,915) of this cohort (for baseline 
characteristics see Table 1 in manuscript). Details on how these novel risk markers and 
the other variables were measured are published elsewhere (4, 5). 
First we imputed missing values of the traditional risk factors in the NHANES individuals 
(N = 16,602), taking into account the according sample weights published by NHANES. 
Then we merged the imputed NHANES set with 1,915 individuals of the Rotterdam Study, 
including the novel risk markers. This extended set was bootstrapped with covariates 
age, sex, traditional risk factors, CVD history, cardioprotective drug information, and 
novel risk markers as input for the imputation algorithm. For imputation we have used 
the R ‘aregImpute’ function from the ‘Hmisc’ package. After the imputation procedure, 
we excluded NHANES subjects with prior CVD, NHANES subjects younger than 40 years 
of age and the Rotterdam study participants, leaving a study population of 3,736.
Recalibration of Updated Framingham Risk Scores (FRS)
We developed a state-transition model with three health states: Alive and CVD-free 
(Well), Post-CVD, and Dead (see Figure S5). One-year transition probabilities of Well  
CVD and Well  Dead were based on the 30-year FRS, which calculates the cumulative 
incidence of CVD and competing non-CVD death. 30-year cumulative CVD incidence 
ICVD is calculated by summing the product of CVD hazard hCVD at failure time ti and the 
survival of competing events S(ti-1) for all failure times up to 30 year follow-up:
∑ICVD(30) =        hCVD(ti )S(ti – 1)
ti<30
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We divided the baseline CVD-survival function into 2 survival functions: 1) coronary 
heart disease (CHD) and 2) stroke using the reported number of coronary heart disease 
and stroke events for men and women. The linear predictor of the 30-year FRS was 
extended with adjusted HRs of 4 novel risk markers based on systematic reviews of 
literature. Individual risk profiles including data on traditional and 4 novel risk factors 
were taken from 3,736 asymptomatic subjects of the National Health and Nutrition 
Examination Survey (NHANES) 2003 – 2004 examination round. To mimic survival 
selection of NHANES subjects at each time interval, we simulated cloned copies of 
NHANES subjects using Monte Carlo microsimulation within the state-transition model.
We followed a 4-step iterative calibration process:
(1) The microsimulation model was run for cycle t, starting at the first year t = 1, using 
the extended linear predictor values of NHANES subjects (uncalibrated simulated 
outcomes for cycle t) 
(2) The baseline CVD survival function was then recalibrated by a fixed term assuming 
that the average of the simulated outcomes during cycle t would equal the average 
calculated cumulative incidence based on the original FRS prediction (without the 
novel risk factors included) for cycle t.
(3) The microsimulation model was then updated using the recalibrated CVD function 
for the next cycle t +1.
(4) NHANES individuals who remained alive and CVD-free after the cycle t were 
selected for the recalibration step for the next period (transition from t = t to 
t = t+1). 
For validation, we compared the cumulative CVD incidences of the microsimulation 
state-transition model at each year t with the cumulative CVD incidence calculated by 
the original FRS (Figure S6).
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Systematic Review Search Strategy
Inclusion criteria:
Population: General (non-hospital) adult population free of hard coronary heart 
disease/ cardiovascular disease at baseline, not selected based by 
cardiovascular risk factors (e.g. renal disease, diabetes mellitus)
Intervention: Novel risk factor/biomarker + traditional “Framingham” risk factors: 
age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, 
treatment for hypertension, smoking status, and diabetes mellitus
Comparison: Odds/risk/rate/hazard with and without biomarker adjusted for 
traditional “Framingham” risk factors
Outcomes: 1) Hard coronary heart disease events: non-fatal myocardial infarction 
and fatal coronary heart disease 
2) Non-fatal/fatal stroke
Published: 1 September 2008 (ABI) / 1 July 2008 (CAC) – 19 April 2013
Study type: Cohort study or nested case-control study or case-cohort study or 
systematic review or meta-analysis of these study types
Language: English
 
Pubmed Search Syntaxes
Coronary Artery Calcium
(1) cohort studies [MeSH Terms] OR cohort*[Text Word] OR controlled clinical trial 
[Publication Type] 
(2) case-control studies [MeSH Terms] OR (case*[Text Word]) AND control*[Text Word])
(3) systematic [sb]
(4) #1 OR #2 OR # 3 
(5) cardiovascular diseases [MeSH Terms] 
(6) coronary disease [MeSH Terms]
(7) cardiovascular disease* [Title/Abstract]
(8) coronary artery disease* [Title/Abstract]
(9) coronary heart disease*[Title/Abstract]
(10) #5 OR #6 OR #7 OR #8 OR #9
(11) risk assessment [MeSH Terms]
(12) risk factors [MeSH Terms]
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(13) prognosis [MeSH Terms]
(14) risk factor* [Title/Abstract]
(15) predict* [Title/Abstract]
(16) Framingham [Title/Abstract] OR traditional [Title/Abstract] OR established [Title/
Abstract] OR independent [Title/Abstract] OR conventional [Title/Abstract] 
(17) (#11 OR #12 OR #13 OR # 14 OR #15) AND #16
(18) tomography, X-ray computed [MeSH Terms]
(19) electron beam computed tomograph* [Text Word] 
(20) electron beam* [Text Word]
(21) ebct [Text Word] 
(22) calcium scor* [Text Word]
(23) coronary calcium [Text Word]
(24) coronary artery calcium [Text Word]
(25) cacs [Text Word]
(26) #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
(27) #4 AND #10 AND #17 AND #26
(28) #27 AND English[lang] AND (“2008/07/01”[PDAT] : “2015/01/01”[PDAT])
Ankle Brachial Index
(1) cohort studies [MeSH Terms] OR cohort*[Text Word] OR controlled clinical trial 
[Publication Type] 
(2) case-control studies [MeSH Terms] OR (case*[Text Word]) AND control*[Text Word])
(3) systematic [sb]
(4) #1 OR #2 OR # 3 
(5) cardiovascular diseases [MeSH Terms] 
(6) coronary disease [MeSH Terms]
(7) cardiovascular disease* [Title/Abstract]
(8) coronary artery disease* [Title/Abstract]
(9) coronary heart disease*[Title/Abstract]
(10) #5 OR #6 OR #7 OR #8 OR #9
(11) risk assessment [MeSH Terms]
(12) risk factors [MeSH Terms]
(13) prognosis [MeSH Terms]
(14) risk factor* [Title/Abstract]
(15) predict* [Title/Abstract]
(16) Framingham [Title/Abstract] OR traditional [Title/Abstract] OR established [Title/
Abstract] OR independent [Title/Abstract] OR conventional [Title/Abstract] 
(17) (#11 OR #12 OR #13 OR # 14 OR #15) AND #16
(18) blood pressure [MeSH Terms] AND (ankle [Text Word] OR ankle [MeSH Terms])
(19) ankle brachial blood pressure [Text Word] 
(20) ankle brachial pressure [Text Word] 
(21) ankle brachial index [Text Word]
(22) abi [Text Word]
(23) 23 #18 OR #19 OR #20 OR #21 OR #22
(24) 24 #4 AND #10 AND #17 AND #23
(25) 25 #24 AND English[lang] AND (“2008/09/01”[PDAT] : “2015/01/01”[PDAT])
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Table S3. Ten-year cardiovascular disease (CVD) risk reclassification by cIMT, CRP, and ABI
a. cIMT
FRS + cIMT Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2604.21 36.79 0 2641
% Events [95%CI]
10 yr CVD 2.8 [2.2 – 3.4] 11.5 [2.4 – 21.4] NA 2.9 [2.3 – 3.5]
30 yr CVD 16 [14.5 – 17.6] 46.4 [ 30.1 – 59.5 ] NA 16.4 [15.0 – 18.0]
≥10-<20%
N 65.09 599.27 32.64 697
% Events [95%CI]
10 yr CVD 7.5 [1.7 – 12.9] 13.5 [11.1 – 16.2] 21.9 [ 10.3 – 37.7 ] 13.3 [ 10.8 – 16 ]
30 yr CVD 37.3 [28.2 – 50.1] 48.8 [44.0 – 53.8] 61.1 [ 44.6 – 77.2 ] 48.3 [ 43.6 – 51.9 ]
≥20%
N 0 30.77 367.23 398
% Events [95%CI]
10 yr CVD NA 17 [4.8 – 31.1] 35.9 [ 30 – 42.6 ] 34.4 [ 28.8 – 40.6 ]
30 yr CVD NA 53.3 [38.1 – 69.0] 69.5 [ 64.2 – 73.4 ] 68.2 [ 63.2 – 72 ]
Overall
N 2669.3 666.83 399.87 3736
% Events [95%CI]
10 yr CVD 2.9 [2.4 – 3.5] 13.5 [11.2 – 16.4] 34.8 [29.1 – 41.4] 8.2 [7.3 – 41.4]
30 yr CVD 16.5 [15.0 – 18.1] 48.8 [44.5 – 52.9] 68.8 [63.7 – 73.0] 27.9 [26.3 – 73.0]
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b. CRP
FRS + CRP Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2556.88 84.12 0 2641
% Events [95%CI]
10 yr CVD 2.7 [2.0 – 3.3 ] 9.6 [4.5 – 14.9] NaN [NA – NA] 2.9 [2.3 – 3.5]
30 yr CVD 15.5 [14.0 – 17.1] 42.9 [33.0 – 51.6] NaN [NA – NA] 16.4 [15.0 – 18.0]
≥10-<20%
N 101.76 546.83 48.41 697
% Events [95%CI]
10 yr CVD 8.2 [3.3 – 13.1] 13.4 [ 10.6 – 16.4] 23.6 [10.9 – 34.6] 13.3 [10.8 – 16.0]
30 yr CVD 36.7 [27.9 – 44.3] 48.7 [44.4 – 52.8] 68.6 [56.7 – 80.3] 48.3 [ 43.6 – 51.9]
≥20%
N 0 44.6 353.4 398
% Events [95%CI]
10 yr CVD NaN [NA – NA] 18.8 [ 8.9 – 33.0] 36.4 [ 30.7 – 42.2] 34.4 [ 28.8 – 40.6]
30 yr CVD NaN [NA – NA] 53.8 [ 43.2 – 65.2] 70 [ 64.6 – 73.9] 68.2 [ 63.2 – 72.0]
Overall
N 2658.64 675.55 401.81 3736
% Events [95%CI]
10 yr CVD 2.9 [2.3 – 3.4] 13.2 [10.7 – 16.0] 34.9 [ 29.1 – 40.6] 8.2 [ 7.3 – 40.6]
30 yr CVD 16.3 [14.7 – 17.9] 48.3 [43.8 – 52.1] 69.8 [ 64.5 – 74.0] 27.9 [ 26.3 – 74.0]
501599-L-bw-van Kempen
212 | Chapter 8
c. ABI
FRS + ABI Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2616.7 24.3 0 2641
% Events [95%CI]
10 yr CVD 2.8 [2.2 – 3.4] 10.6 [0 – 23.1] NA 2.9 [2.3 – 3.5]
30 yr CVD 16.1 [14.7 – 17.7] 47.6 [28.7 – 68.0] NA 16.4 [15.0 – 18.0]
≥10-<20%
N 42.46 638.3 16.24 697
% Events [95%CI]
10 yr CVD 8.8 [1.1 – 16.5] 13.3 [10.6 – 16.2] 23 [ 0 – 46.6 ] 13.3 [10.8 – 16.0]
30 yr CVD 39.5 [25.3 – 53.5] 48.4 [43.6 – 52.2] 63.9 [41.4 – 85.7] 48.3 [43.6 – 51.9]
≥20%
N 0 30.44 367.56 398
% Events [95%CI]
10 yr CVD NA 20.3 [6.6 – 33.9] 35.6 [29.8 – 41.7] 34.4 [28.8 – 40.6]
30 yr CVD NA 57.1 [42.6 – 73.0] 69.1 [64.3 – 72.9] 68.2 [ 63.2 – 72.0]
Overall
N 2659.16 693.04 383.8 3736
% Events [95%CI]
10 yr CVD 2.9 [2.4 – 3.5] 13.6 [11.2 – 16.9] 35.1 [29.3 – 41.4] 8.2 [7.3 – 41.4]
30 yr CVD 16.5 [15.0 – 18.1] 48.8 [44.2 – 52.8] 68.9 [64.0 – 73.2] 27.9 [26.3 – 73.2]
Classification on the basis of 10 yr CVD risk - i.e. combined endpoint of CHD and Stroke – assessment using <10%, ≥10-<20%, and 
≥20% as risk thresholds
Abbreviations: ABI = ankle-brachial index, cIMT = carotid intima-media thickness, CRP = high-sensitivity C-reactive protein, CVD = 
cardiovascular disease, FRS = Framingham risk score. 
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Table S4. Ten-year coronary heart disease (CHD) risk reclassification tables 
a. CTCS
FRS + CTCS Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2828 158 13 2999
% Events [ 95%CI ]
10 yr CHD 2 [1.4 – 2.3] 12.8 [7.6 – 18.2] 28.1 [0 – 58.7] 2.6 [2.1 – 3.3]
30 yr CHD 11.5 [10.5 – 12.4] 47.7 [38.8 – 55.6] 70.2 [33.3 – 100] 13.7 [12.3 – 15.0]
≥10-<20%
N 191 180 154 525
% Events [ 95%CI ]
10 yr CHD 5.6 [2.4 – 8.9] 13.8 [8.8 – 19.3] 27.7 [21 – 36.1] 15.0 [11.5 – 19.1]
30 yr CHD 24.2 [18.8 – 29.8] 47.1 [40.6 – 53.6] 64.5 [55.4 – 70.8] 43.9 [39.7 – 47.8]
≥20%
N 16 37 159 212
% Events [ 95%CI ]
10 yr CHD 7.7 [0 – 23.7] 12.4 [2.6 – 24.0] 42.4 [34.4 – 50.9] 34.5 [27.4 – 41.3]
30 yr CHD 25.2 [6.2 – 50.0] 36.9 [23.2 – 52.6] 66.3 [56.9 – 74.2] 58 [51.9 – 64.2]
Overall
N 3035 376 325 3736
% Events [ 95%CI ]
10 yr CHD 2.2 [1.6 – 2.7] 13.2 [9.4 – 16.7] 34.9 [29.0 – 40.7] 6.2 [5.2 – 40.7]
30 yr CHD 12.4 [11.3 – 13.3] 46.4 [41.1 – 50.8] 65.5 [58.4 – 71.4] 20.4 [19.1 – 71.4]
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b. cIMT
FRS + cIMT Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2968 30 0 2999
% Events [95%CI]
10 yr CHD 2.5 [2.0 – 3.2] 13.8 [4.9 – 24.1] NA 2.6 [2.1 – 3.3]
30 yr CHD 13.4 [12 – 14.7] 38.8 [22.8 – 52.3] NA 13.7 [12.3 – 15]
≥10-<20%
N 55 444 25 525
% Events [95%CI]
10 yr CHD 9.3 [3.6 – 15.2] 14.9 [11.5 – 19.4] 28.1 [13.9 – 48.3] 15.0 [11.5 – 19.1]
30 yr CHD 33.7 [20.9 – 44.7] 44.4 [40.1 – 48.5] 56.9 [39.3 – 72.6] 43.9 [39.7 – 47.8]
≥20%
N 0 11 201 212
% Events [95%CI]
10 yr CHD NA 19.4 [0 – 45.5] 35.3 [28.1 – 42.9] 34.5 [27.4 – 41.3]
30 yr CHD NA 51.7 [27.3 – 81.8] 58.4 [52.2 – 64.5] 58 [51.9 – 64.2]
Overall
N 3024 485 227 3736
% Events [95%CI]
10 yr CHD 2.7 [2.1 – 3.3] 14.9 [11.5 – 19.4] 34.5 [27.2 – 41.3] 6.2 [5.2 – 41.3]
30 yr CHD 13.8 [12.4 – 15.1] 44.2 [40.0 – 48.4] 58.2 [51.8 – 64.3] 20.4 [19.1 – 64.3]
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c. CRP
FRS + CRP Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2938 61 0 2999
% Events [95%CI]
10 yr CHD 2.5 [2.0 – 3.1 ] 11.8 [4.5 – 19.3] NA 2.6 [2.1 – 3.3]
30 yr CHD 13.1 [11.8 – 14.5] 39.5 [30.4 – 50.4] NA 13.7 [12.3 – 15.0]
≥10-<20%
N 77 428 20 525
% Events [95%CI]
10 yr CHD 8.4 [2.6 – 15.6] 15.2 [11.1 – 19.2] 36.1 [16.2 – 57.3] 15.0 [11.5 – 19.1]
30 yr CHD 31.6 [23.1 – 40.9] 45.1 [40.5 – 49.3] 64.6 [44.3 – 81.2] 43.9 [39.7 – 47.8]
≥20%
N 0 25 187 212
% Events [95%CI]
10 yr CHD NA 23.4 [8.0 – 42.9 ] 36.0 [27.9 – 42.5] 34.5 [27.4 – 41.3]
30 yr CHD NA 53.9 [36.0 – 70.1] 58.6 [ 52 – 65.1] 58.0 [51.9 – 64.2]
Overall
N 3015 514 207 3736
% Events [95%CI]
10 yr CHD 2.6 [2.0 – 3.3] 15.2 [11.3 – 18.9] 35.9 [28.5 – 42.0] 6.2 [5.2 – 42.0]
30 yr CHD 13.6 [12.3 –15.0] 44.9 [40.8 – 49.0] 59.2 [52.5 – 65.6] 20.4 [19.1 – 65.6]
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d. ABI
FRS + ABI Overall
FRS <10% ≥10-<20% ≥20%
<10%
N 2984 15 0 2999
% Events [95%CI]
10 yr CHD 2.6 [2.0 – 3.2] 14.4 [0 – 37.2] NA 2.6 [2.1 – 3.3]
30 yr CHD 13.5 [12.3 – 14.9] 43.1 [18.1 – 68.6] NA 13.7 [12.3 – 15.0]
≥10-<20%
N 46 452 27 525
% Events [95%CI]
10 yr CHD 8.4 [2.0 – 16.7] 14.7 [11.4 – 18.7 ] 29.7 [10.0 – 48.3] 15.0 [11.5 – 19.1]
30 yr CHD 31.5 [18.4 – 45.2] 44.3 [39.7 – 48.6] 56.4 [37.9 – 70.8] 43.9 [39.7 – 47.8]
≥20%
N 0 17 195 212
% Events [95%CI]
10 yr CHD NA 19.8 [5.4 – 38.2] 35.8 [28.7 – 42.8] 34.5 [27.4 – 41.3]
30 yr CHD NA 55.7 [33.3 – 77.8] 58.3 [52.3 – 64.2] 58.0 [51.9 – 64.2]
Overall
N 3030 484 222 3736
% Events [95%CI]
10 yr CHD 2.7 [2.1 – 3.4] 14.9 [11.5 – 18.7] 35.1 [28.1 – 41.9] 6.2 [5.2 – 41.9]
30 yr CHD 13.8 [12.5 – 15.2] 44.7 [39.9 – 49.0] 58.1 [51.6 – 63.7] 20.4 [19.1 – 63.7]
Classification on the basis of risk assessment using <10%, ≥10-<20%, and ≥20% as risk thresholds
Abbreviations: ABI = ankle-brachial index, cIMT = carotid intima-media thickness, CRP = high-sensitivity C-reactive protein, CTCS = CT 
coronary artery calcium score, CHD = coronary heart disease, FRS = Framingham risk score. 
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Figure S1. Forrest plot of hazard ratios of one unit increase in the natural logarithm of (CTCS+1) for 
CHD
Estimated heterogeneity variance: 0.0023 P = 0.146
Figure S2. Forrest plot of hazard ratios of one unit increase in the natural logarithm of (CTCS+1) for 
stroke
Estimated heterogeneity variance: 0.0069 P = 0.107
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Figure S3. Forrest plot of hazard ratios of an ABI ≤0.9 vs 0.9 for CHD 
Estimated heterogeneity variance: 0.032 P = 0.09
Figure S4. Forrest plot of hazard ratios of an ABI ≤0.9 vs >0.9 for stroke
Estimated heterogeneity variance: 0 P = 0.503
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Figure S5. Schematic representation of the microsimulation state-transition model
Figure S6. Comparison Original Framingham CVD estimations vs. Model’s predictions over a 30-yr 
time horizon
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AbstRACt 
Background: High sensitivity CRP (hsCRP), coronary artery calcification on CT (CT 
calcium), carotid artery intima media thickness on ultrasound (cIMT) and ankle-brachial 
index (ABI) improve prediction of cardiovascular disease (CVD) risk, but it’s unclear 
what’s the benefit of screening with these novel risk markers in the US population.
Methods and Results: A microsimulation model evaluating lifelong cost-effectiveness 
for individuals aged 40 – 85 at intermediate risk of CVD, using 2003 – 2004 NHANES-III 
(N = 3,736), Framingham Heart Study, US Vital Statistics, meta-analyses of independent 
predictive effects of the four novel risk markers and treatment effects was constructed. 
Using both an intention-to-treat (assumes adherence <100% and incorporates disutility 
from taking daily medications) and an as-treated (100% adherence and no disutility) 
analysis, quality adjusted life years (QALYs), lifetime costs (2014 US $), incremental 
cost-effectiveness ratio (ICER in $/QALY gained) of screening with hsCRP, CT coronary 
calcium, cIMT and ABI was established, compared with current practice, full adherence 
to current guidelines, and ubiquitous statin therapy. In the intention-to-treat analysis 
in men, screening with CT calcium was cost effective ($32,900/QALY) compared with 
current practice. In women, screening with hsCRP was cost effective ($32,467/QALY). In 
the as-treated analysis for both men and women, statin therapy was both more effective 
and less costly than all other strategies. 
Conclusions: When a substantial disutility from taking daily medication is assumed, 
screening men with CT coronary calcium is likely to be cost-effective whereas screening 
with hsCRP has value in women. The individual perceived disutility for taking daily 
medication should play a key role in the decision.
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IntRoduCtIon
Cardiovascular disease (CVD) remains one of the main causes of death in Western 
societies -including the United States (1). Guidelines on CVD prevention recommend 
lifestyle changes in low risk individuals (<7.5% 10-year risk of CVD including nonfatal 
MI, stroke or cardiac death) but advise supplemental drug therapy with statins for 
individuals at higher CVD risk (>7.5%) as well as anti-hypertensives as needed and 
sometimes aspirin (2-6). Risk stratification in current guidelines is largely based on 
traditional Framingham risk factors (7-9). These risk predictions can be improved by 
using novel risk markers such as coronary artery calcification on CT (CT calcium), high 
sensitivity CRP (hsCRP), carotid artery intima media thickness on ultrasound (cIMT) and 
the ankle-brachial index (ABI). All four markers have been identified by the U.S. Preventive 
Services Task Force and the American College of Cardiology Foundation/American Heart 
Association as potentially valuable for screening individuals for CVD (10, 6). A recent meta-
analysis has demonstrated that all four markers are independent predictors of CVD risk, 
and improve prediction beyond traditional Framingham risk factors (11). 
A substantial proportion of individuals from the U.S. population, classified as intermediate 
risk based on the Framingham risk factors -traditionally defined as a 10-year risk of 
coronary heart disease (CHD) of between 5 – 20% (12), are reclassified to the high risk 
category when the novel risk markers are taken into account (13) and may benefit from 
more aggressive treatment based on their reclassified risk. Reclassification to other risk 
categories suggests that the novel risk markers may be beneficial but reclassification 
by itself is insufficient evidence to justify implementation (14, 15). Studies, ideally clinical 
trials, demonstrating comparative effectiveness and cost-effectiveness are necessary. 
However, trial-based studies of (cost-) effectiveness often evaluate a limited number of 
strategies, typically cover a relatively short period of follow-up, and require large sample 
sizes. Decision modeling can overcome these limitations by synthesizing the best-
available evidence and extrapolating short-term study results, providing clinicians and 
policy-makers with information on expected long-term outcomes and accompanying 
uncertainties (16). Cost-effectiveness studies have been performed for a number of novel 
risk markers individually (17-19), but none have evaluated these markers in a comparative 
analysis.
In the absence of clinical trials assessing the benefit of screening individuals with novel 
risk markers, an evaluation using observational data is warranted (20). The objective of this 
study was to assess the comparative effectiveness and cost-effectiveness of screening 
asymptomatic individuals aged 40 and over from the U.S. population at intermediate 
risk of CVD, with either CT coronary calcium, hsCRP, ABI and cIMT.
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Methods
We developed a state-transition model using TreeAge for Health Care (TreeAge Pro 2009 
– TreeAge Software Williamstown MA) to analyze 7 strategies for an asymptomatic U.S. 
individual at intermediate risk for CVD. We considered an individual with a 10-year risk 
of CVD (combined endpoint of non-fatal MI, stroke and cardiac death) of 5% – 7.5% to 
be at intermediate risk for our base case analysis, and used both a risk of 2.5% – 7.5%, 
and a risk of 5% – 10% in sensitivity analyses. The model structure, model parameters, 
and data sources are briefly described here. Details of the modeling assumptions and 
parameter estimation are given in a supplementary online file. 
Model structure
The following strategies were considered (Figure 1):
(1) ‘Current practice’ (reference strategy) reflects no additional interventions and 
accounts for the proportion of individuals treated at baseline with statins, anti-
hypertensive medication or aspirin by their general practitioners, which is reflected 
in the incidence rates of CVD as modeled in this strategy 
(2)  ‘Current guidelines’ reflects full implementation of the 2013 ACC/AHA guidelines 
on the treatment of blood cholesterol and JNC-8 guidelines on high blood 
pressure (21) for primary prevention of CVD. This implies giving lifestyle advice 
to all, statin therapy when baseline low density lipoprotein (LDL) cholesterol 
exceeds 190 mg/dL (4.91 mmol/l) or an individual aged 40 to 75 is diagnosed 
with diabetes (5, 6), and anti-hypertensive medication when baseline systolic blood 
pressure exceeds 140 mmHg in an individual aged 40 – 60, and 150 mm Hg in 
an individual aged >60 years (21). In a sensitivity analysis we used 140 mmHg as 
threshold for individuals aged 60 years or over –in concordance with the JNC-7 
guidelines (22).
(3-6) ‘Screening’ with each of the four novel risk markers respectively. In these four 
strategies, either a CT scan was performed to determine the coronary artery 
calcium score [3], a serum hsCRP level was measured [4], the intima-media 
thickness was established by ultrasound (cIMT), [5] or the ankle-brachial index 
(ABI) was determined [6]. The 10-year CVD risk was recalculated on the basis of 
the Framingham risk factors, combined with each of the risk markers separately. 
In each of the screening strategies, a number of individuals were reclassified to 
a 10-yr CVD risk of 7.5% or higher (or 10% or higher in the sensitivity analysis). 
These individuals received therapeutic lifestyle advice, statin therapy -irrespective 
of their baseline cholesterol levels, and anti-hypertensive medication if systolic 
blood pressure was over 130 mmHg. In addition, men received low dose aspirin 
(80 – 100 mg daily) in accordance with the USPTSF guideline (2). Currently, aspirin 
is not recommended in women. Individuals who remained at a risk of 7.5% or 
lower (10% or lower in the sensitivity analysis) were treated as in strategy 2. For 
the ‘current guidelines’ and ‘screening’ strategies, we assumed that individuals who 
used any of the three drugs at baseline, would continue to use them.
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(7) ‘Statin therapy’: Everyone not currently on statin therapy would receive a moderate 
dose statin and would be otherwise treated as individuals in strategy 2. This 
strategy puts the four ‘screening’ strategies into a broader perspective, between 
the least aggressive strategy (‘current practice’) and a fairly aggressive strategy 
(‘statin therapy’), providing a range of possibilities for an individual at intermediate 
risk of CVD (20). 
Figure 1. Schematic representation of the 7 strategies modeled for individuals at intermediate risk 
for CVD: Current practice, Current Guidelines, Screening with CT calcium, hsCRP, cIMT and ABI, and 
Statin Therapy. 
LDL = low-density lipoprotein; SBP = systolic blood pressure.
Study Population and risk stratification
We analyzed 3,736 individuals aged 40 to 85 without a history of CHD or stroke at 
baseline from the 2003 – 2004 NHANES exam, taking into account the sampling 
weights for the U.S. population. The NHANES dataset was merged with a subset of the 
Rotterdam Study cohort (N =1,915) (23) in which all novel markers were measured to 
allow for estimation of CT coronary calcium and cIMT values as previously described (13). 
Only NHANES individuals were used for subsequent analyses. 
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The Framingham CVD model was used to model 30-year cumulative incidence of 
CVD (myocardial infarction, coronary death and stroke), while taking into account 
the competing risk of non-CVD death (8). To resemble currently recommended risk 
assessment, we also calculated 10-year CVD risks without adjustment for the competing 
risk of non-CVD death. Of the 3,736 NHANES individuals aged 40 – 85, we selected a 
total of 618 individuals who had a calculated 10-year risk of CVD of 5% – 7.5% for the 
base case analysis. 
Risk reclassification and treatment initiation for screening with each of 
the 4 novel risk markers.
We updated the Framingham based 10-year CVD risk score with each of the four 
risk markers (11) to yield 4 new risk stratification scores. For these updated scores, we 
recalibrated the baseline survival probability by assuming no change in the average 
survival probability compared to the old score. For each individual, we calculated 
updated 10-year CVD risks; one for each novel risk marker. In a number of cases, this 
new recalculated risk would surpass the 7.5% risk threshold (10% in sensitivity analysis), 
leading to medical therapy. 
 
Simulation model
For each of the 7 strategies, the simulation model tracked quality of life, costs, and 
time spent in one of the following three health states: 1) well; 2) post CVD event; 3) 
death (Figure 2). Each simulated individual started out in the “well” state. Individualized 
probabilities of a CHD event, stroke event, non-CVD death, case fatality rates of CHD 
and stroke events, extracranial major bleeding due to aspirin use, and lethal cancer due 
to radiation determined the transition to the other states during each annual cycle. The 
time horizon was the remaining lifetime of the simulated individuals. After a CVD event, 
individuals moved to the post-CVD-event state. After an extracranial major bleeding 
episode, we assumed that aspirin therapy would be discontinued. In the case of a 
nonfatal CVD event, individuals would be allocated medical treatment for secondary 
CVD prevention. 
Event rates 
A one-year cycle length was used. One-year transition-probabilities of CVD events and 
the probabilities for non-CVD events were both based on the 30-year Framingham CVD 
model (which adjusts for competing risk) updated and recalibrated with all four novel 
risk markers together, assuming independence of predictive effects of each individual 
novel risk marker. In order to calculate the incidences of CHD and stroke separately, 
we applied a sex-specific ratio for CHD to stroke events to the baseline CVD incidence 
function. Case-fatality rates of CHD and stroke events were based on one-year mortality 
rates of myocardial infarction and stroke events as observed in cohort studies (24). A 
hazard ratio of prior CVD for all-cause mortality was derived from the literature and 
used to adjust the post-CVD all-cause mortality (25). Extracranial bleeding rates and 
corresponding hazard rate ratios for aspirin use were taken from a recent meta-analysis 
on aspirin in the primary prevention of CVD (26). The additional risk of radiation induced 
fatal cancer due to CT scanning was added to the non-CVD event probability (27, 28).
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Figure 2: Markov model, with the ‘Well’, ‘Post CVD event’ and ‘Death’ state, and possible 
transitions between them. 
Statin TherapyABIcIMThsCRPCT CalciumCurrent GuidelinesCurrent Practice$18.0K$18.2K$18.4K$18.6K$18.8K$19.0K$19.2K$19.4K 
16.19016.13016.07016.010CostEffectivenessMen - 5%-7.5% - As-treated
Model Calibration
The model was calibrated on mortality data from the US National Vital Statistics, such 
that the annual simulated total mortality for the 3,736 NHANES individuals would match 
the age and sex adjusted observed mortality for year 1 to 30 (eFigure 2). 
Effectiveness of treatment
The benefits of statin and antihypertensive treatment on CHD and stroke incidence 
were obtained from meta-analyses and considered equal for men and women (29-31).
The relative risks for CHD and stroke were obtained from a meta-analysis of aspirin in 
primary prevention (26). Treatment adherence is an important determinant of treatment 
benefit (32). Although we used intention-to-treat-based relative risk reductions from 
clinical trials which take into account adherence, we assumed adherence in a population-
based setting to be 70% of that in the original trials (33). 
 
Costs 
Costs incorporated in the model included health-care costs and non-health-care 
costs and were assessed from the societal perspective for the U.S. (Table 2) adjusted 
to the year 2014 using consumer price indices. Health-care costs included costs of 
diagnostic procedures, personnel, materials, equipment, medications, costs for health 
care resource use in subsequent years after an event, and overhead. Costs for a non-
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contrast cardiac CT were based on healthcare reimbursement rates in 2014. Medication 
costs were based on 2014 retail prices from online pharmacy price lists across the US, 
assuming moderately potent generic statin use in individuals reclassified to >7.5% 
without diabetes, and potent statin use in diabetics (5), (rosuvastatin in the base case 
and atorvastatin (40 – 80mg) in a sensitivity analysis). Antihypertensive medication 
was a diuretic, combined with either an angiotensin II receptor blocker, ACE inhibitor 
or calcium channel blocker in 60% of individuals (21, 34). Medication costs were only 
accounted for in adherent individuals. For all strategies except ‘Current practice’, we 
included the costs of obtaining risk markers. Event-related costs included the costs of 
hospitalization, diagnostic workup, interventions, and rehabilitation during the first 
year after an event (35-41). 
Analysis
Important baseline characteristics, such as lipid levels, blood pressure, and statin, aspirin, 
or antihypertensive medication use, were determined for the U.S. individuals at an initial 
risk of 5 – 7.5% (N = 618), 5 – 10% (N = 980) and 2.5 – 7.5% (N = 1,502) and accounted 
for in the simulation model. For each of these three groups, the number of individuals 
who initiated statins, anti-hypertensives and aspirin in each strategy were determined. 
Quality-adjusted life years (QALYs), lifetime costs, incremental cost-effectiveness 
ratios (ICER) (i.e., additional costs divided by QALYs gained), were calculated. Future 
costs and effectiveness were discounted to take into account time preference, at the 
currently recommended U.S. discount rate of 3% for both costs and effectiveness (42). We 
considered $50,000/QALY gained as a commonly accepted threshold for the societal 
willingness-to-pay threshold for primary prevention (43, 44). We analyzed the results in two 
distinct ways. First, as an intention-to-treat analysis, in which we assumed the base case 
treatment adherence of 70% and a disutility of 6 months for taking daily medication for 
the remainder of an individual’s lifetime (45, 46). Second, we analyzed the results assuming 
each individual would actually take the medication, without incorporating a disutility 
for taking daily medication, similar to the as-treated analysis of an RCT and assuming 
that substantial disutility would lead to non-adherence. 
To model second-order parameter uncertainty, 1,000 independent samples were drawn 
from each of the input parameter distributions, generating outcome distributions for 
QALYs and costs for each strategy (outer loop simulation). In addition, 10,000 individuals 
were randomly drawn with replacement from the U.S. population at intermediate risk 
and were individually run through the model (inner loop simulation), modeling both 
heterogeneity and stochastic uncertainty. The results were aggregated at the parameter 
level and 95% credibility intervals (95%CI) were calculated to reflect parameter 
uncertainty. Furthermore, we calculated the probability that each of the strategies (1 to 
7) was cost-effective for varying willingness-to-pay thresholds. All analyses were done 
separately for men and women, and separately for the 3 definitions of intermediate risk 
(5% – 7.5%, 2.5% – 7.5%, and 5% – 10%). In sensitivity analyses, we checked whether 
the following alternative assumptions would affect the results: 1. using all generic 
medication –assuming similar effectiveness and generic statin prices, 2. use of systolic 
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blood pressure threshold of 140 mmHg in individuals older than 60 years -as used in the 
JNC-7 guidelines on hypertension, 3. assuming that the joint effect of 2 (or 3) types of 
medication would be lower or greater than the multiplication of their individual effects 
Results
Baseline characteristics, Treatment initiation
Review of the baseline characteristics (Table 1) of the US population at intermediate 
risk of CVD shows that women were older than men, and apart from smoking, HDL, and 
calcium score, had less favorable risk factor profiles. Compared with current practice, 
the number of men who would initiate anti-hypertensive medication and statins in a 
screening strategy was largest for the CT calcium strategy, closely followed by the hs-CRP 
strategy (Table 3). This pattern was seen for all three definitions of the intermediate risk 
category. In women, the hs-CRP strategy resulted in the largest number of individuals 
initiating anti-hypertensive medication and statins, closely followed by the CT-calcium 
strategy. 
Intention-to-treat analysis 
Using the base-case definition of intermediate risk of 5%-7.5%, statin therapy was the 
least effective (Figure 3). HsCRP, ABI, cIMT and current guidelines were all less effective 
and more costly than current practice and CT-calcium (Figure 3). CT calcium was the 
most effective at a cost of $32,900/QALY gained compared with current practice (eTable 
3). In women, CT calcium, ABI and cIMT were not considered cost-effective (Figure 4). 
Compared to current practice, hs-CRP was more effective at a cost of $32,467/QALY 
gained (eTable 4). 
In men at 2.5% – 7.5% risk, CT calcium was the most effective at a cost of $22,300/
QALY (Figure 5). In women at 2.5%-7.5% risk, hsCRP was the most effective but at a 
substantially higher cost of $185,091/QALY gained (Figure 6). In men at 5% – 10% risk, 
CT calcium was again the most effective at a cost of $32,700/QALY (Figure 7). In women 
at 5 – 10% risk, hsCRP was again the most effective at a cost of $15,050/QALY (Figure 8).
As-treated analysis 
In men, statin therapy dominated all other strategies irrespective of the definition of 
risk (Figure 3, Figures 5 and 7, eTable 3). In women, statin therapy was the most effective 
with a cost of $6,059/QALY gained compared with current practice with a range of 
$4,270-$10,556/QALY for varying risk definitions (Figure 4, Figures 6 and 8, eTable 4). 
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Figure 3. Cost (US dollars over the remaining lifetime) versus effectiveness (quality adjusted life years 
(QALYs)) of strategies 1 to 7 in men at intermediate risk of CVD (5% – 7.5%) a intention-to-treat and b 
as-treated analyses. Strategies closer to the bottom-right corner are more preferable (more effective 
and less costly). The solid line indicates strategies on the efficiency frontier: the choice depends on 
the societal willingness-to-pay for a QALY. The slope of the line represents the incremental cost-
effectiveness ratio. Scale of the x-axis (effectiveness) and y-axis (cost) chosen to optimize visual 
comparison of strategies.
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Figure 4. Cost (US dollars over the remaining lifetime) versus effectiveness (quality adjusted life years 
(QALYs)) of strategies 1 to 7 in women at intermediate risk of CVD (5%-7.5%) a intention-to-treat and 
b as-treated analyses. Strategies closer to the bottom-right corner are more preferable (more effective 
and less costly). The solid line indicates strategies on the efficiency frontier: the choice depends on 
the societal willingness-to-pay for a QALY. The slope of the line represents the incremental cost-
effectiveness ratio. Scale of the x-axis (effectiveness) and y-axis (cost) chosen to optimize visual 
comparison of strategies.
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Figure 5. Cost (US dollars over the remaining lifetime) versus effectiveness (quality adjusted life years 
(QALYs)) of strategies 1 to 7 in men at intermediate risk of CVD (2.5% – 7.5%) a intention-to-treat and 
b as-treated analyses. Strategies closer to the bottom-right corner are more preferable (more effective 
and less costly). The solid line indicates strategies on the efficiency frontier: the choice depends on 
the societal willingness-to-pay for a QALY. The slope of the line represents the incremental cost-
effectiveness ratio. Scale of the x-axis (effectiveness) and y-axis (cost) chosen to optimize visual 
comparison of strategies.
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Figure 6. Cost (US dollars over the remaining lifetime) versus effectiveness (quality adjusted life 
years (QALYs)) of strategies 1 to 7 in women at intermediate risk of CVD (2.5% – 7.5%) a intention-
to-treat and b as-treated analyses. Strategies closer to the bottom-right corner are more preferable 
(more effective and less costly). The solid line indicates strategies on the efficiency frontier: the choice 
depends on the societal willingness-to-pay for a QALY. The slope of the line represents the incremental 
cost-effectiveness ratio. Scale of the x-axis (effectiveness) and y-axis (cost) chosen to optimize visual 
comparison of strategies.
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Figure 7. Cost (US dollars over the remaining lifetime) versus effectiveness (quality adjusted life years 
(QALYs)) of strategies 1 to 7 in men at intermediate risk of CVD (5% – 10%) a intention-to-treat and b 
as-treated analyses. Strategies closer to the bottom-right corner are more preferable (more effective 
and less costly). The solid line indicates strategies on the efficiency frontier: the choice depends on 
the societal willingness-to-pay for a QALY. The slope of the line represents the incremental cost-
effectiveness ratio. Scale of the x-axis (effectiveness) and y-axis (cost) chosen to optimize visual 
comparison of strategies.
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Figure 8. Cost (US dollars over the remaining lifetime) versus effectiveness (quality adjusted life years 
(QALYs)) of strategies 1 to 7 in women at intermediate risk of CVD (5% – 10%) a intention-to-treat and 
b as-treated analyses. Strategies closer to the bottom-right corner are more preferable (more effective 
and less costly). The solid line indicates strategies on the efficiency frontier: the choice depends on 
the societal willingness-to-pay for a QALY. The slope of the line represents the incremental cost-
effectiveness ratio. Scale of the x-axis (effectiveness) and y-axis (cost) chosen to optimize visual 
comparison of strategies.
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Sensitivity analysis
The use of all generic medication, 140 mmHg threshold for initiating anti-hypertensive 
treatment in individuals over 60, or assuming synergy between multiple drugs, did not 
change the optimal strategy in men (CT calcium) or women (hsCRP) at a 5% – 7.5% risk 
in the intention-to-treat analysis (eTable 5). Assuming dyssynergy between the drugs 
resulted in less favorable results of screening ($162,486/QALY for CT calcium in men, 
$59,800/QALY for hsCRP in women).
Probabilistic sensitivity analysis
In men, the probability that CT calcium was cost-effective was marginally higher than 
the probability that current practice was cost-effective (35% vs 30%) (eFigure 3). In 
women, the probability that hsCRP was cost-effective was higher than the probability 
that current practice was cost-effective (45% vs 25%) (eFigure 4). 
dIsCussIon
We analyzed the comparative effectiveness and cost-effectiveness of screening 
United States individuals at intermediate risk with either CT calcium, hsCRP, ABI and 
cIMT, compared to current practice and guidelines or initiating statin therapy without 
screening. Whereas prior modeling studies evaluated a single novel biomarker (17, 47-49), this 
study compared multiple novel biomarkers. Furthermore, published studies considered 
initiation of a single drug (most often a statin) based on the information derived 
from the novel biomarker, whereas in this study we modeled the effect of all relevant 
cardioprotective medications for the primary prevention of CVD. Finally, previous studies 
compared screening vs. no screening as comparator, whereas this study evaluated three 
realistic comparison strategies.
In the intention-to-treat analysis, screening men with CT calcium was effective with 
acceptable ICER’s. All other novel biomarkers were more costly and less effective. This is 
explained in part by the observation that CT calcium results in the highest percentage of 
men being allocated any of the three cardioprotective drugs compared with screening 
with the other biomarkers. This, in turn, stems from both the strength of the association 
between the novel biomarker with CVD risk (12) and the distribution of the biomarker 
within the U.S. population at intermediate risk (13). Only in the statin therapy strategy 
were more men allocated statins, but at the cost of a substantial disutility from taking 
daily medication (45). Sensitivity analyses of the intention-to-treat scenario revealed 
the robustness of the favorability of CT calcium in men -only in the unlikely event of 
dyssynergy between cardioprotective drugs did the ICER exceed $100,000. However, 
analysis of parameter uncertainty suggests that the favorability of CT calcium appears 
to be a “close call” compared with current practice. Thus, policymakers should interpret 
the results for CT calcium with caution and future research in this area is justified. 
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In women, the intention-to-treat analysis revealed that screening with hsCRP was the 
optimal strategy, and was, associated with the highest percentage of women being 
allocated to cardioprotective drugs. Moreover, CT calcium is less favorable in women 
due to a higher risk of cancer due to radiation associated with a cardiac CT (27, 28). Results 
in women proved to be robust in sensitivity analyses as well, and analysis of parameter 
uncertainty revealed that favorability of hsCRP is fairly substantial, with current practice 
less of a competitor.
Disutility from daily medication plays a key role in the decision. Ubiquitously initiating 
statins results in a lower quality adjusted life expectancy in individuals without a clear 
indication for statins, whereas this penalty seems to be outweighed in individuals with 
an increased risk of CVD based on testing. In the as-treated analysis, which assumed no 
medication disutility initiating statins (without further screening) dominated all other 
strategies in men and was the most effective strategy in women with acceptable ICERs. 
A number of cost-effectiveness studies on CT calcium, hsCRP and ABI individually have 
previously been published (17, 47-49). For CT calcium, previous results are consistent with 
ours for the more favorable statin assumptions scenario (as-treated analysis) (19, 49) and 
generic availability of statins (17). For hsCRP, results were consistent when the potential 
harm of statin use was taken into account, corresponding to our intention-to-treat 
analysis (48. Initiation of anti-platelet medication based on ABI was found to be more 
effective than current practice {Vaidya, 2014 #586) which corresponds to our as-treated 
results, in which ABI was slightly more effective than current practice as well –but 
dominated by statin therapy in both men and women.
The results need to be interpreted in light of limitations related to the required modeling 
assumptions and imperfect available evidence. First, the ACC/AHA guidelines on risk 
assessment uses the Pooled Cohort Equations for calculating CVD risk, but has been 
criticized for overestimating actual risk (50). We used a Framingham Study based model 
by Pencina which was based on the same risk factors as the Pooled Cohort Equations 
and has been shown to perform fairly well in most U.S. subpopulations (51). Moreover, 
because our purpose was to evaluate the cost-effectiveness of the novel risk markers in 
light of competing risk by non-CVD death, we chose the Pencina model that took this 
competing risk into account. Second, the NHANES dataset did not include measurements 
of CT calcium and cIMT. We used correlations between Framingham risk factors and the 
other two novel risk markers as observed in the Rotterdam Study to add these values 
to the NHANES dataset -conditional on the assumption that the correlations in the 
Rotterdam Study are applicable to the NHANES population. As in other cost-effectiveness 
analyses, the differences in strategies with regard to the quality adjusted life expectancy 
were small (17, 52, 53). This finding is inherent to primary prevention and reflects the fact 
that many individuals need to be subjected to the preventive intervention in order to 
avoid events in a few. Fourth, we assumed that treatment adherence is independent 
of an individual’s disutility for taking daily medication. To account for this, we used 
the median (lower) instead of the mean value as reported by Fontana, using the fixed 
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value of 6 months instead of the full disutility distribution which included extremely 
high values of up to 10 years (45). Fifth, we focused on individuals at intermediate risk of 
CVD. As the recent ACC/AHA guidelines on risk assessment do not explicitly define an 
intermediate risk group, we used three different definitions, and our results indicated 
substantial agreement regardless of the definition chosen. One could argue that the 
novel biomarkers could have value in other subgroups as well, but generally, the largest 
impact is expected in an intermediate risk group (13).
Overall, this study sheds light on the comparative (cost-)effectiveness of four novel 
screening biomarkers for primary prevention of CVD (12). For U.S. individuals at 
intermediate risk, screening men with CT coronary calcium is likely to be cost-effective 
compared with the full range of relevant alternatives, but subject to parameter 
uncertainty, whereas screening with hsCRP has value in women. The perceived disutility 
of taking daily medication plays a key role in the optimal decision for an individual 
patient. Patients with a low tolerance for medication will benefit more from screening 
than individuals with high tolerance. Furthermore, recent studies have suggested 
that (54) the results of screening with CT calcium may influence treatment initiation 
and continuation downstream. The interplay between an individual’s disutility for 
taking daily medication, the result of screening with a novel biomarker and treatment 
adherence should be the subject of future research in order to elucidate the optimal 
decision for a patient.
501599-L-bw-van Kempen
244 | Chapter 9
RefeRenCes
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart Disease and Stroke 
Statistics--2013 Update: A Report From the American Heart Association. Circulation. 2013;127(1):e6-
e245.
2. Force USPST. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force 
recommendation statement. Ann Intern Med. 2009;150(6):396-404.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent 
clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. 
Circulation. 2004;110(2):227-39.
4. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention 
of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk 
Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American 
Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388-91.
5. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on 
the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report 
of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation. 2013.
6. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA 
Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
7. D’Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk 
profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.
8. Pencina MJ, D’Agostino RB, Sr., Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of 
cardiovascular disease: the framingham heart study. Circulation. 2009;119(24):3078-84.
9. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart 
disease using risk factor categories. Circulation. 1998;97(18):1837-47.
10. Force USPST. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive 
Services Task Force recommendation statement. Ann Intern Med. 2009;151(7):474-82.
11. Ferket BS, van Kempen BJH, Hunink MGM, Agarwal I, Kavousi M, Franco O, et al. Predictive Value of 
Updating Framingham Risk Scores with Novel Risk Markers in the U.S. General Population 2013.
12. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al. Comparison of novel risk 
markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 
2012;308(8):788-95.
13. Ferket BS, van Kempen BJ, Hunink MG, Agarwal I, Kavousi M, Franco OH, et al. Predictive value of 
updating Framingham risk scores with novel risk markers in the U.S. general population. PLoS One. 
2014;9(2):e88312.
14. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the 
role of reclassification measures. Ann Intern Med. 2009;150(11):795-802.
15. Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a 
new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-72; 
discussion 207-12.
16. Hunink M GP, Siegel J, et al. Decision making in health and medicine. Integrating evidence and values. 
Cambridge: Cambridge University Press; 2001.
17. van Kempen BJ, Spronk S, Koller MT, Elias-Smale SE, Fleischmann KE, Ikram MA, et al. Comparative 
effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in 
asymptomatic individuals. J Am Coll Cardiol. 2011;58(16):1690-701.
18. Galper BZ, Moran A, Coxson PG, Pletcher MJ, Heidenreich P, Lazar LD, et al. Using stress testing to guide 
primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness 
analysis. Circulation. 2012;125(2):260-70.
501599-L-bw-van Kempen
Cost-effectiveness of Four Novel Risk Markers for Screening CVD | 245
19. Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, et al. Using the coronary artery 
calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 
2014;7(2):276-84.
20. Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating 
health impact. Circulation. 2011;123(10):1116-24.
21. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-
based guideline for the management of high blood pressure in adults: report from the panel members 
appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the 
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: 
the JNC 7 report. JAMA. 2003;289(19):2560-72.
23. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, et al. The Rotterdam 
Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28(11):889-926.
24. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL. Sudden death after myocardial infarction. 
JAMA. 2008;300(17):2022-9.
25. Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial 
occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin 
Epidemiol. 2004;57(3):294-300.
26. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events 
in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 
2011;162(1):115-24 e2.
27. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure 
from 64-slice computed tomography coronary angiography. Jama. 2007;298(3):317-23.
28. Kim KP, Einstein AJ, Berrington de Gonzalez A. Coronary artery calcification screening: estimated 
radiation dose and cancer risk. Arch Intern Med. 2009;169(13):1188-94.
29. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects 
of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis 
of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
30. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary 
prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
31. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular 
disease: meta-analysis of 147 randomised trials in the context of expectations from prospective 
epidemiological studies. Bmj. 2009;338:b1665.
32. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. 
Circulation. 2009;119(23):3028-35.
33. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. Comparative 
effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 
2014;161(6):400-7.
34. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control 
among United States adults with hypertension: the National Health And Nutrition Examination Survey, 
2001 to 2010. Circulation. 2012;126(17):2105-14.
35. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump 
inhibitors for primary prevention. Arch Intern Med. 2011;171(3):218-25.
36. Kauf TL, Velazquez EJ, Crosslin DR, Weaver WD, Diaz R, Granger CB, et al. The cost of acute myocardial 
infarction in the new millennium: evidence from a multinational registry. Am Heart J. 2006;151(1):206-
12.
37. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the 
primary prevention of ischemic stroke. Stroke. 1998;29(9):1827-32.
38. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy 
in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern 
Med. 2008;168(15):1684-90; discussion 91.
501599-L-bw-van Kempen
246 | Chapter 9
39. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy 
for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001;141(5):727-34.
40. Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among 
patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res 
Opin. 2008;24(2):461-8.
41. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke 
statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
42. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping 
forward towards optimal decision rules. Health Econ. 2007;16(3):307-17.
43. Corso PS, Hammitt JK, Graham JD, Dicker RC, Goldie SJ. Assessing preferences for prevention versus 
treatment using willingness to pay. Med Decis Making. 2002;22(5 Suppl):S92-101.
44. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the 
$50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-7.
45. Fontana M, Asaria P, Moraldo M, Finegold J, Hassanally K, Manisty CH, et al. Patient-accessible tool for 
shared decision making in cardiovascular primary prevention: balancing longevity benefits against 
medication disutility. Circulation. 2014;129(24):2539-46.
46. Hutchins R, Viera AJ, Sheridan SL, Pignone MP. Quantifying the utility of taking pills for cardiovascular 
prevention. Circ Cardiovasc Qual Outcomes. 2015;8(2):155-63.
47. Vaidya A, Joore MA, Ten Cate-Hoek AJ, Ten Cate H, Severens JL. Screen or not to screen for peripheral 
arterial disease: guidance from a decision model. BMC Public Health. 2014;14:89.
48. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive 
protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation. 
2010;122(15):1478-87.
49. Sniderman AD, Thanassoulis G, Lawler PR, Williams K, Furberg CD. Comparison of coronary calcium 
screening versus broad statin therapy for patients at intermediate cardiovascular risk. Am J Cardiol. 
2012;110(4):530-3.
50. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 
2013;382(9907):1762-5.
51. D’Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P, Group CHDRP. Validation of the Framingham 
coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 
2001;286(2):180-7.
52. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, et al. Comparing impact and 
cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243-
54.
53. Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, et al. Personalized prediction 
of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. PLoS Med. 
2012;9(12):e1001361.
54. Nasir K, McClelland RL, Blumenthal RS, Goff DC, Jr., Hoffmann U, Psaty BM, et al. Coronary artery calcium 
in relation to initiation and continuation of cardiovascular preventive medications: The Multi-Ethnic 
Study of Atherosclerosis (MESA). Circ Cardiovasc Qual Outcomes. 2010;3(3):228-35.
55. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive 
protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant 
meta-analysis. Lancet. 2010;375(9709):132-40.
56. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al. Common carotid 
intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 
2012;308(8):796-803.
57. Marshall N. A Cost Effectiveness Analysis of Using the Ankle-Brachial Index to Screen for Peripheral 
Artery Disease. UCLA Electronic Thesis and Dissertations. - on July 19th, 20142012;https://escholarship.
org/uc/item/9g83j2zb#page-1.
58. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-60C.
501599-L-bw-van Kempen
Cost-effectiveness of Four Novel Risk Markers for Screening CVD | 247
59. Blood Pressure Lowering Treatment Trialists C, Sundstrom J, Arima H, Woodward M, Jackson R, Karmali 
K, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual 
patient data. Lancet. 2014;384(9943):591-8.
60. Red Book 2010: Pharmacy’s Fundamental Reference: PDR Network, LLC; 2010.
61. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary 
prevention of cardiovascular disease events in subgroups based on age, gender, and varying 
cardiovascular risk. Circulation. 2008;117(22):2875-83.
62. Nyman JA, Barleen NA, Dowd BE, Russell DW, Coons SJ, Sullivan PW. Quality-of-life weights for the US 
population: self-reported health status and priority health conditions, by demographic characteristics. 
Med Care. 2007;45(7):618-28.
63. Centers for Medicare & Medicaid Services. Physician Fee Schedule. - on July 19th, 2014
64. Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule. 2013. - on July 19th, 2014
501599-L-bw-van Kempen
248 | Chapter 9
onlIne suppleMent
Study Population
We analyzed 3,736 individuals aged 40 to 85 without a history of CHD or stroke at 
baseline from the 2003 – 2004 NHANES exam, taking into account the sampling weights 
for the U.S. population. We included the following variables: age at the exam visit, sex, 
current smoking, systolic blood pressure, total cholesterol, HDL cholesterol, fasting 
plasma glucose level, anti-diabetic treatment, antihypertensive treatment, ankle-
brachial index, and high-sensitivity C-reactive protein. Because values for CT coronary 
calcium and cIMT were not measured in the NHANES study, we merged the NHANES 
dataset with a subset of the Rotterdam Study cohort (N = 1,915) (1) in which all novel 
markers were measured and estimated these values using a multivariable imputation 
model for each of the individuals in the NHANES data as previously described (2). Only 
NHANES individuals were used for subsequent analyses. 
Imputation of CTCS and cIMT Values
The Rotterdam Study is a population-based cohort study of individuals aged 55 years 
and older living in Rotterdam, the Netherlands. Demographics, traditional risk factors, 
CTCS, cIMT, hs-CRP, ABI, and information on cardioprotective drugs were measured 
during re-examination visits in a subset (N = 1,915) of this cohort. Information on 
baseline risk factors of this cohort can be found in eTable 1. Details on how these novel 
risk markers and the other variables were measured are published elsewhere (1, 3, 4). 
First we imputed missing values of the traditional risk factors in the NHANES individuals 
(N = 16,602), taking into account the according sample weights published by NHANES. 
Then we merged the imputed NHANES set with 1,915 individuals of the Rotterdam Study, 
including the novel risk markers. This extended set was bootstrapped with covariates 
age, sex, traditional risk factors, CVD history, cardioprotective drug information, and 
novel risk markers as input for the imputation algorithm. For the imputation, we used a 
flexible additive imputation model including all other variables using the R ‘aregImpute’ 
function from the ‘Hmisc’ package. After the imputation procedure, we excluded 
NHANES subjects with prior CVD, NHANES subjects younger than 40 years of age and 
the Rotterdam study participants, leaving a study population of 3,736.
Risk stratification
We used the 30-year Framingham CVD model published by Pencina et al as the basis 
for calculating an individual’s CVD risk (5). It uses the 8 traditional risk factors to calculate 
the 30-year cumulative incidence of CVD (defined as myocardial infarction, coronary 
death and stroke), while taking into account the competing risk of non-CVD death 
(mortality due to all causes other than CVD). To resemble currently recommended risk 
assessment, we also calculated 10-year CVD risks without adjustment for the competing 
risk of non-CVD death. Of the 3,736 NHANES individuals aged 40 – 85, we selected a 
total of 618 individuals who had a calculated 10-year risk of CVD of 5% – 7.5% for the 
base case analysis. Baseline characteristics of these 618 individuals can be found in 
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Table 1. In sensitivity analyses we redefined intermediate risk as 2.5 – 7.5% and 5% – 
10% respectively.
eTable 1. Baseline characteristics of 1,915 Rotterdam Study individuals
Variable Median [IQR]
Age 70 [66 – 75]
Sex (%male) 45%
Current Smoking 16%
Systolic blood pressure (mm Hg) 140.0 [124 – 155]
HRX 28%
Total cholesterol (mg/dl) 225 [203 – 250]
HDL cholesterol (mg/dl) 51 [43 – 62]
Glucose (mg/dl) 99 [94 – 110]
Anti diabetic medication 6.2%
CTCS
0 10%
1-100 41%
101-400 23%
400-1000 15%
≥1000 11%
Natural logarithm of (CTCS+1) 4.81 [2.6 – 6.3]
ABI ≤ 0.9 15.6%
CRP (mg/L) 2.4 [1.2 – 4.4]
cIMT (mm) 0.86 [0.76 – 0.95]
Risk reclassification by screening with each of the 4 novel risk markers
For each individual, we used 10-year risk of CVD for risk stratification, and updated 
this Framingham based score for each of the four risk markers. We extended the linear 
predictor based on the 8 traditional risk factors, to which we added each novel risk factor 
as a new variable, together with the corresponding Framingham score adjusted beta-
coefficient from the meta-analysis (6). This yielded 4 updated risk stratification scores (one 
for each four novel risk markers), each of which represents scores that could be used 
in the future. For each of these updated scores, we recalibrated the baseline survival 
probability by assuming no change in the average survival probability compared to the 
old score. For each individual, we calculated four updated 10-year risks of CVD, one for 
each new risk marker. 
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Recalibration of Updated Framingham Risk Scores (FRS)
We developed a state-transition model with three health states: Alive and CVD-free 
(Well), Post-CVD, and Dead (see eFigure 1). One-year transition probabilities of Well  
CVD and Well  Dead were based on the 30-year FRS, which calculates the cumulative 
incidence of CVD and competing non-CVD death. 30-year cumulative CVD incidence 
ICVD is calculated by summing the product of CVD hazard hCVD at failure time ti and the 
survival of competing events S(ti-1) for all failure times up to 30 year follow-up:
∑ICVD(30) =        hCVD(ti )S(ti – 1)
ti<30
eFigure 1. Schematic representation of the microsimulation state-transition model.
We divided the baseline CVD-survival function into 2 survival functions: 1) coronary heart 
disease (CHD) and 2) stroke using the reported number of coronary heart disease and 
stroke events for men and women. The linear predictor of the 30-year FRS was extended 
with adjusted HRs of 4 novel risk markers based on systematic reviews of literature. 
Individual risk profiles including data on traditional and 4 novel risk factors were taken 
from 3,736 asymptomatic subjects of the National Health and Nutrition Examination 
Survey (NHANES) 2003-2004 examination round. To mimic survival selection of NHANES 
subjects at each time interval, we simulated cloned copies of NHANES subjects using 
Monte Carlo microsimulation within the state-transition model.
We followed a 4-step iterative calibration process:
(1) The microsimulation model was run for cycle t, starting at the first year t = 1, using 
the extended linear predictor values of NHANES subjects (uncalibrated simulated 
outcomes for cycle t). 
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(2) The baseline CVD and non-CVD survival function was then recalibrated by a 
fixed term assuming that the average mortality (both due to CVD and non-CVD 
causes) simulated by the model at cycle t, would be equal to the average mortality 
calculated based of the NHANES subjects at time t, based on US life tables from 
2003 and up, adjusted for sex and age of the NHANES subjects population.
(3) The microsimulation model was then updated using the recalibrated CVD function 
and non-CVD mortality function for the next cycle t +1.
(4) NHANES individuals who remained alive and CVD-free after the cycle t were 
selected for the recalibration step for the next period (transition from t = t to 
t = t+1). 
From the ‘Well’ state, one-year cumulative hazards for CHD, stroke, and non-CVD 
mortality were divided by the sum of these cause-specific hazards and subsequently 
multiplied with 1-exp(-cumulative total hazard) to take into account the competing 
risks. This provides unbiased estimates of cumulative incidences assuming constant 
hazards increasing with age but that are constant per over a one year time interval.
For internal validation, we compared the cumulative mortality incidence of the NHANES 
population based on the microsimulation state-transition model at each year t, with the 
cumulative mortality incidence of this population based on US vital statistics (eFigure 
2).
0
0,1
0,2
0,3
0,4
0,5
0,6
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Cumulative mortality US vital statistics                  Simulated cumulative mortality percentage
eFigure 2. Simulated cumulative mortality percentage (red line) and US Vital Sstatistics based 
mortality (blue line) for year 1 – 30.
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Adjusting for efficacy of Treatment
Drug treatment efficacies, in terms of Relative Risks (RR) were obtained from meta 
analyses and considered the relative risk in incidence of CHD or stroke compared to 
placebo. The relative risk of a certain treatment or intervention was assumed to be 
constant over time. Derived annual probabilities of CHD and stroke respectively, were 
multiplied by the RR of the appropriate strategy.
Pafter_treatment = punadjusted • Rstrategy  
Adjusting the treatment efficacies for treatment adherence, baseline 
prevalence and treatment goals
The model incorporates 3 basic drug treatments: statins, anti-hypertensives and aspirin 
(in men). In order to estimate the combined effect, we made the following assumptions:
(1) An individual already on statins at baseline who had not reached the treatment 
goal, i.e. an LDL level >190 (4.92) was assumed to switch to a higher dose or more 
potent statin, and assigned half of the reduction in risk based on a full dose given 
to a non-user. The same holds for an individual using anti-hypertensives at baseline 
and a systolic blood pressure higher than 140 mmhg (or 150 if aged 60 or older). 
(2) When a combination of drugs was assigned, the net effect of the drugs together 
on risk reduction was assumed to be the product of the individual RR’s, times a 
factor for potential (dys)synergy, SF, where .90 < SF < 1.10. This range was chosen 
to make sure that a combination of 2 or 3 drugs was at least as effective as the 
effect of a single drug. For the base case definition of intermediate risk (5% – 7.5%), 
we calculated whether the comparative cost-effectiveness would change if using 
either 0.9 or 1.1. 
Statins, anti-hypertensives and aspirin drug prices
We performed an online search on websites of U.S. pharmacies to estimate current retail 
prices of commonly prescribed statins, anti-hypertensive medication and aspirin. We 
restricted our search to drug retailers with nationwide presence. We assumed that if an 
individual would be prescribed a statin, this would normally be a moderately potent 
statin, we assumed that patients would be prescribed the generic moderate-intensity 
statin Simvastatin. In case an individual would be prescribed a potent statin -in case of 
both diabetes and a 10 year CVD risk over 7.5%, we assumed that Crestor would be the 
statin of choice.
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eTable 2. Model Input Parameters
Parameter Estimate Source
One-year probability of having  
a first CHD event
Depending on cumulative CVD hazard 
function, and updated FRS
Pencina et al (5]) 
Pooled estimates for hazard ratios of 
the four novel risk markers from the 
systematic review
One-year probability of having  
a first stroke event
Depending on cumulative CVD hazard 
function, CHD: stroke event ratio  
104/348 for men and 86/133 for  
women, and updated FRS
Pencina et al (5])
Pooled estimates for hazard ratios of 
the four novel risk markers from the 
systematic review
One-year probability of dying 
from non-cardiovascular 
mortality
Depending on cumulative hazard 
function for non-CVD death and original 
hazard ratios from the Framingham study
Pencina et al (5])
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to a strategy and depicts the percentage of all simulations in which a strategy was cost-effective 
giving all parameter uncertainty in the model, for varying thresholds of willingness to pay values.
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AbstRACt
Objective: To assess the comparative effectiveness and cost-effectiveness of statin 
therapy for the primary prevention of cardiovascular disease in low- and intermediate 
risk individuals. 
Design: Micro-simulation state-transition model to analyze the costs and effectiveness 
from the societal perspective for the United States. Synthesis of best-available evidence 
on risks, benefits, patient preferences, and costs. External validation and modeling of 
parameter uncertainty. Intention-to-treat analysis accounted for non-adherence and 
disutility of daily medication. As-treated analysis assumed individuals were adherent 
and disutility of daily medication was zero. Threshold analysis of lowest risk and highest 
disutility of daily medication at which statin therapy was cost-effective. 
Participants: Population-based sample from the National Health and Nutrition 
Examination Survey, without diabetes mellitus or a prior cardiovascular disease event, 
not on statin therapy and with a 10-year cardiovascular disease risk (based on the Pooled 
Cohort Equations) of <2.5% to 20%. 
Interventions: Initiating generic moderate-intensity statin therapy for primary 
prevention vs withholding statin therapy until the development of disease or disease-
equivalents or >20% risk. 
Main outcomes: Quality-adjusted life years, lifetime costs, incremental cost-
effectiveness ratios, probability of cost-effectiveness at a societal willingness-to-pay of 
$50,000/quality-adjusted life year.
Results: The model produced similar age- and sex-specific life expectancies compared 
to U.S. life tables, demonstrating external validity. In the intention-to-treat analysis, 
prescribing statin therapy resulted in fewer quality adjusted life years and higher costs 
than withholding statin therapy. The as-treated analysis demonstrated that statin 
therapy was cost-effective for 40 – 44 year-old women at ≥10% risk, 45 – 65 year-old 
women at ≥7.5% risk, 40 – 59 year-old men at ≥5% risk, and for all women 65 and older 
and men 60 and older. For individuals at a 5-10% risk, statin therapy is cost-effective 
only if disutility is less than 25 (1 – 50) days.
Conclusion: Statin therapy for primary prevention of cardiovascular disease in 
individuals at low- or intermediate risk is effective and cost-effective but only if the 
individual’s disutility of taking daily medication is justified by the gain in effectiveness. 
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IntRoduCtIon
At least half of major cardiovascular disease (CVD) events occur in people without 
prior CVD, even though many are at low absolute risk (1, 2). This underscores the value 
of primary prevention in reducing the CVD burden to society. Statin therapy can 
substantially reduce CVD events, which makes it a candidate for primary prevention (3, 4). 
The 2013 American Heart Association (AHA) and American College of Cardiologists (ACC) 
guidelines recommend statin therapy for primary prevention if an individual’s 10-year 
risk of a CVD event is 7.5% or higher (4, 5). The 7.5% threshold is supported by randomized 
clinical trials (RCTs), which have shown that individuals at low-risk of CVD benefit 
from preventive statin therapy (6). Findings from a meta-analysis indicate that a lower 
threshold may even be appropriate (3). 
Although primary prevention with statin therapy can reduce CVD events, such an 
approach may be associated with non-adherence, adverse events, disutility associated 
with daily medication, and an impact on healthcare costs (7, 8). Evidence on the 
comparative (cost-)effectiveness, especially in the light of reduced medication costs 
with generic statins, is lacking (9, 10). This lack of information may restrain the primary 
care physician from implementing primary prevention with statins in lower risk patients 
(11).Furthermore, using the 7.5% risk threshold would imply prescribing statin therapy 
to nearly one half of the 40 – 75 year-old United States population (12). Critics see such 
widespread use of statins as over-medicalization. 
The aim of this study was to assess the comparative effectiveness and cost-effectiveness 
of statin therapy for the primary prevention of CVD in asymptomatic U.S. individuals. 
The purpose was to determine the lowest CVD risk threshold and highest disutility 
associated with daily medication for which statin therapy is cost-effective. Two questions 
were addressed: first, whether to prescribe statin therapy, which is the equivalent of 
an intention-to-treat analysis, and second, whether statin therapy is (cost-) effective if 
actually taken, which is the equivalent of an as-treated analysis. 
Methods
We developed a micro-simulation state-transition model (eFigure 1) with 1-year 
cycle length using TreeAge for Health Care (TreeAge Pro 2013 – TreeAge Software 
Williamstown MA) to analyze the costs and effects of prescribing statin therapy to 
U.S individuals at 10-year CVD risk lower than 20%. With this model we studied the 
comparative (cost-)effectiveness of statin therapy in men and women for varying age and 
CVD risk. The model synthesized the best-available evidence on risks, benefits, patient 
preferences, and costs and was developed according to published recommendations 
for such analyses (13, 14). (A detailed description of the modeling assumptions and input 
parameters is available in the online-only data supplement.) 
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The study population consisted of National Health and Nutrition Examination Survey 
(NHANES) individuals aged 40 to 79 years old (Figure 1), without a history of CVD or 
diabetes at baseline, with data on CVD risk factors. We extracted individual characteristics 
and risk factors to represent the heterogeneity of the population (eTable 1).
Figure 1. Flowchart showing the selection of the study population based on NHANES 2001-2002 data 
collection.
Model Structure
Individuals were categorized by age, sex and baseline CVD risk and for each group two 
strategies were compared:
(1) ‘No statin therapy’ (reference strategy): withhold statin therapy for primary 
prevention until the development of CVD or CVD-equivalents or 10-year CVD risk 
of 20% or higher, consistent with current practice and the Adult Treatment Panel 
III (ATPIII) guidelines (8). 
(2) ‘Statin therapy’: prescribe generic moderate-intensity statins (4) for primary 
prevention.
Efficacy of treatment was modelled by reducing the incidence of coronary heart disease 
(CHD) and stroke events in the statin strategy according to evidence from systematic 
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reviews and meta-analyses of RCTs (3, 6). Lifestyle recommendations were assumed to 
be given to all individuals in both strategies. Individuals who developed a CVD event, 
diabetes mellitus, other CVD equivalent, or surpassed the threshold risk of 20% during 
follow-up were prescribed statin therapy. We assumed that statin benefits and costs 
would cease immediately in the case of therapy withdrawal due to non-adherence or 
serious side effects (myopathy, asymptomatic elevation of liver enzymes).
For each cycle, the modeled individuals could stay in one of the following mutually 
exclusive health states: 1) well; 2) post-CHD event; 3) post-stroke event; 4) withdrawal 
from statins; 5) diabetes; 6) diabetes and post-CVD; and 7) dead (eFigure 1). Every person 
started the simulation in the “well” state. The transition to the other states could occur 
once each annual cycle and was determined by age- and sex-specific probabilities. 
The model simulated the remaining lifetime of the individuals and kept track of costs, 
quality of life and time spent in each health state. 
CVD Event Rates
CVD events were defined as nonfatal myocardial infarction (MI) or CHD death, or fatal or 
nonfatal stroke to match the endpoint used in the AHA/ACC Pooled Cohort Equations, 
which were used to estimate the individualized baseline 10-year risk of CVD events (5). 
We modeled the annual increase in CVD risk and estimated age-, sex-, and ethnicity-
specific annual incidence rates (15). Using sex-specific proportions, we estimated the 
annual incidence of CHD vs stroke events and fatal vs nonfatal events (Table 1).
Mortality Rates
We obtained data on mortality from the National Center for Health Statistics (16, 17). 
To model competing mortality risks, we derived life tables that provided sex-specific 
probabilities of dying from all causes eliminating ischemic heart diseases, CVD and 
diabetes mellitus. The probabilities of dying from an MI or stroke were age-dependent 
and based on 30-day case-fatality rates (18). In the years following a nonfatal MI or 
nonfatal stroke, the all-cause mortality rates were modified with a hazard rate ratio for 
manifest CVD (Table 1) (19). 
Diabetes Natural History
The probability of developing diabetes was estimated based on data from the National 
Health Interview Survey (NHIS) and reflects the incidence of diagnosed diabetes in 
the year 2000 (Table 1) (20). Starting at the time of diagnosis, patients with diabetes 
experienced increased rates of CHD events, stroke events, and non-CVD mortality (21, 22). 
After a nonfatal CVD event, all-cause mortality was increased (Table 1) (23). 
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Costs
We estimated costs for the model from the U.S. societal perspective (Table 1). All costs were 
inflated to 2013 U.S. dollars using consumer price indices. Future costs and effectiveness 
were discounted at a rate of 3% (24). Retail prices of generic moderate-intensity statins (4) 
were retrieved from online price lists of pharmacies with nationwide presence in the 
U.S. (eTable4). We assumed that monitoring of therapy cost one additional physician 
visit and lipid panel per year and adverse events induced additional physician visits and 
laboratory costs. 
Costs for MI and stroke events included hospitalization-, procedural-, outpatient-, and 
pharmacy costs (25, 26, 27). The costs for diabetes were estimated from the average annual 
cost per case of type 2 diabetes mellitus, which included physician office and emergency 
visits, ambulance services, hospital outpatient and home health visits, hospital inpatient 
care, nursing/residential facility care, hospice care, podiatry visits, insulin, oral agents, 
and diabetic supplies (28). 
Statin Therapy 
We modeled the effects of moderate-intensity statin therapy using relative risk 
reductions for CVD events reported in a systematic review and meta-analysis of RCTs 
comparing statins with usual care or placebo (Table 1) (6). The increased risk of developing 
diabetes mellitus, myopathy, and asymptomatic elevation of liver enzymes were also 
derived from systematic reviews of RCTs (Table 1) (6, 29, 30). Quality of life penalties of a 
myopathy episode were based on those for mild osteoarthritis of the hip that does not 
impair function (15, 31). We assumed there is no quality of life loss due to the asymptomatic 
elevation of liver enzymes. 
In the intention-to-treat analysis, we accounted for a disutility of daily medication of 
6 months (nocebo effect or loss in quality of life associated with taking medication), 
ranging from 1 to 36 months (7). In addition, we assumed that 60% (50% to 70%) of 
patients would be adherent to therapy (32, 33). With the exception of diabetes, all side-
effects were assumed to cause withdrawal from statin therapy. In the as-treated analysis, 
we modeled 100% adherence and no disutility from daily medication, which assumes 
that patients experiencing significant disutility from daily medication would be non-
adherent and therefore not the target population of the as-treated analysis. 
Analysis
To minimize bias, all authors approved the model structure, the data inputs and 
the validation results, prior to performing the comparative effectiveness and cost-
effectiveness analyses. Internal validity of the model was tested by comparing CVD 
incidence produced by the model to the ACC/AHA Pooled Cohort Equations incidence 
rates. In addition, competing mortality rates produced by the model were compared 
to those from life tables. For external validation, we compared calculated age- and sex-
specific life expectancies to published U.S. life expectancies (16). 
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For all analyses, we first selected a subset of the NHANES population based on age, 
sex, and CVD risk. Only subgroups with documented individuals in NHANES were 
analyzed. We modeled patient heterogeneity by micro-simulating every individual in 
the NHANES subgroup. In addition, one thousand samples were taken from the input 
distributions (Table 1) to model parameter uncertainty. For each set of individuals, we 
calculated mean quality-adjusted life years (QALYs) and mean lifetime costs and their 
95% credibility intervals (95%CI). We calculated incremental cost-effectiveness ratios 
(ICERs) dividing the mean increase in costs by the additional QALYs gained. A societal 
threshold willingness-to-pay of $50,000/QALY was considered (34). Given the parameter 
uncertainty reflected in the input distributions, we calculated the probability that the 
statin therapy strategy was cost-effective for each set of individuals (14). Finally, we 
determined thresholds for change in utility associated with daily medication as function 
of CVD risk. 
Results
Model Validity
Internal validity of the model was demonstrated by consistent CVD incidence rates and 
competing mortality rates (eFigures 2-5). More importantly, the model produced similar 
age- and sex-specific life expectancies compared to U.S. life tables demonstrating 
external validity (Figure 2). 
Figure 2. External validation: life expectancy from published U.S. life tables compared to life expectancy 
as calculated by the model, for men and women aged 45, 55, 65, and 75 years old. 
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Intention-to-treat analysis 
Prescribing statin therapy resulted in lower average quality adjusted life expectancy 
(QALE) in all subgroups analyzed (Table 2). The reduction of QALE was more pronounced 
in younger ages and lower risk categories. For all subgroups except one, average 
lifetime costs were higher for statin therapy which was more pronounced in younger 
ages and lower risk groups (exception was females 70 – 74 years, risk 15% – 19.9%). The 
probability of statin therapy being cost-effective ranged from 0.2% (females 40 – 44 
years, risk <2.5%) to 47.6% (females 70 – 74 years, risk 15%-19.9%).
As-treated analysis
Statin therapy was cost-effective compared to withholding statins (Table 2) for all 
women 65 years and older, regardless of their 10-year CVD risk. For 45 – 65 year-old 
women, statin therapy was cost-effective for those with a risk of 7.5% or higher. In 
40 – 44 year-old females, statins were only cost-effective above a 10% risk threshold. In 
men of all ages with a risk of at least 5% statin therapy was the optimal decision (Table 
2), which included the entire male population of 60 years and older. Statins were less 
effective than no statins for males younger than 55 years old with a predicted 10-year 
risk lower than 2.5%. 
Threshold analysis
The lower the 10-year CVD risk, the lower the disutility associated with daily medication 
needs to be in order to warrant statin therapy (Figure 3). For individuals at a CVD risk of 
15 – 20%, statin therapy is cost-effective if disutility is less than 100 (70 – 300) days. For 
individuals at a CVD risk of 10 – 15%, disutility needs to be less than 70 (25 – 125) days. 
For individuals at a CVD risk of 5 – 10%, statin therapy is cost-effective only if disutility 
is less than 25 (1 – 50) days. For lower risk, statin therapy would need to have a placebo 
effect (a gain in utility from daily medication) in order to make therapy cost-effective. 
dIsCussIon
In this study we analyzed the comparative effectiveness and cost-effectiveness from the 
societal perspective of prescribing statin therapy to United States individuals at low- and 
intermediate risk, synthesizing the best-available evidence on risks, benefits, patient 
preferences, and costs. The intention-to-treat analysis, which addressed the policy-
making decision, demonstrated a decrease in QALE for prescribing statins to individuals 
for primary prevention of CVD, across the full range of risk thresholds analyzed, including 
the current recommendation of 7.5% or higher (4, 5). This decrease can be attributed to a 
modest gain in average life expectancy with statin therapy and a substantial decrease 
in QALE due to the disutility associated with taking daily medication (7). In contrast, the 
as-treated analysis, which addressed the decision for an individual adherent patient 
with no disutility from daily medication, demonstrated that statin therapy was cost-
effective for 40 – 44 year-old women at ≥10% risk, 45 – 65 year-old women at ≥7.5% risk, 
40 – 59 year-old men at ≥5% risk, and for all women 65 and older and men 60 and older. 
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Figure 3. Threshold analysis of change in utility associated with daily medication (expressed in days) 
vs 10-year risk of CVD. The absolute values of negative thresholds (blue dots) indicate the maximum 
nocebo effect (maximum disutility / loss in utility) that would make statin therapy cost-effective. 
Positive threshold values (red dots) indicate the minimum placebo effect (minimum gain in utility) 
that would make statin therapy cost-effective. Note that placebo effects are unlikely in the context of 
primary prevention. 
Furthermore, we demonstrated that the decision to advise an asymptomatic individual 
to take statins depends highly on his or her individual preferences with regard to taking 
daily medication. 
The modest gain in QALYs that we found with statin therapy for primary prevention 
was comparable with that found in previous comparative effectiveness and cost-
effectiveness analyses (8, 15, 35, 36). Previous analyses modelled the ATP III guidelines (8), 
focused on primary prevention of CHD only rather than CVD (35) analyzed statin therapy 
in patients with chronic kidney disease (15), analyzed effectiveness only (36), or used high 
drug prices based on patented statins (37). In contrast, our analysis modelled the recently 
published and highly debated ACC/AHA guideline using the Pooled Cohort Equations 
for CVD risk (4,5), modelled both MI and stroke, analyzed both costs and effectiveness, 
and used generic statin prices. Irrespective of the differences in the models, they all 
showed modest gains in QALYs, a finding inherent to primary prevention which reflects 
the fact that many individuals need to be subjected to the preventive intervention in 
order to avoid events in a few individuals. 
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From a policy-makers perspective, prescribing statin therapy in low- and intermediate 
risk individuals does more harm than good and costs money. For the individual, the 
decision depends on the trade-off between future risk versus the disutility from daily 
medication. Disutility from medical therapy is in part due to symptomatic side-effects 
and in part due to the act of having to take pills every day. Symptomatic side effects 
due to statin therapy are infrequent and only a small minority of symptoms attributed 
to statin therapy are genuinely side effects of statins (6, 29, 30). In particular, muscle 
weakness and muscle aches are frequently attributed to statin therapy but occur just 
as frequently with placebos and may therefore be considered a nocebo effect (30). We 
modelled genuine side effects of statins by assuming that patients would stop taking 
their medication and found that the average loss in QALY’s is very small. The disutility 
associated with taking daily medication, however, can be substantial when considering 
that all individuals may experience some disutility, which includes nocebo effects, and 
is lifelong (7). The disutility of daily medication was a decisive factor in determining 
whether statin therapy was effective and cost-effective. In individuals with very low risk, 
a placebo effect would even be required in order to make statin therapy cost-effective, 
which is unlikely in the context of primary prevention. Disutility of daily medication 
reflects an individual’s preference: patients may experience the act of taking a pill 
every day as disconcerting. It is a small act that is required lifelong on a daily basis in 
order to reduce a future risk of an event that is uncertain to happen. This small act can 
influence experienced quality of life through psychological mechanisms that are poorly 
understood. Most important, our results underscore the importance of taking individual 
patient preferences into account by means of shared decision making prior to advising 
patients to start statin therapy (4,7). 
Limitations
Our results need to be interpreted in the light of the limitations caused by the 
required modeling assumptions and imperfect available evidence. First, the ACC/AHA 
Pooled Cohort Equations that we used to model CVD incidence have been criticized 
for overestimating the risk of CVD (38). Nevertheless, we found that calculated life 
expectancies matched closely with those published, demonstrating external validity. 
Second, we assumed that treatment adherence is independent of an individual’s disutility 
of taking daily medication. In reality individuals who remain adherent are probably less 
affected by taking daily pills. To account for this we chose to use the reported median 
value (rather than the mean) and omitted extremely high disutility values since patients 
with extremely high disutilities are not the target population. Third, the disutility values 
were taken from a UK population sample: US individuals may be more willing to take 
medication for primary prevention. 
Fourth, we assumed that all simulated patients who effectively took statins would 
benefit equally in relative terms from the treatment, justified by studies suggesting 
this is a reasonable assumption (3). Fifth, we modeled the effects of type 2 diabetes 
mellitus (DM2) by increasing the rates of cardiovascular events and non-cardiovascular 
mortality, independent of modifiable risk factors (22). We assumed that the diabetes-
501599-L-bw-van Kempen
Cost-Effectiveness of Statin Therapy: Future Risk vs Disutility | 279
effect is nonreversible and constant over time whereas in reality the risk starts low and 
increases over time (39).  Nevertheless, given the low frequency of statin-induced diabetes, 
this is unlikely to have a major effect on our results. Sixth, we modeled myopathy 
episodes in people taking statins because muscle pain was cited as primary reason for 
discontinuation by 60% of former statin users (30, 40). Even if myopathy is not caused by 
statin therapy, its occurrence still lowers adherence rates of treatment, especially in the 
primary prevention setting, and thus we considered it prudent to model this effect. 
Clinical implications
The widely publicized concerns about over-medicalization and the associated costs of 
statin therapy motivated us to perform this analysis. Our results imply that the current 
recommendation for statin therapy in individuals at 7.5% risk or higher is cost-effective in 
women 45 and older and men 40 and older but only if the disutility of daily medication is 
negligible and patients adhere to therapy. In fact, the results suggest that the threshold 
in men can even be reduced to 5% if the patient has zero disutility from medical therapy. 
Taking the disutility of daily medication into account can, however, potentially change 
the optimal decision for many patients. Our findings demonstrate that the trade-off 
between future CVD risk and the individual disutility of daily medication is decisive in 
the choice whether to advise a patient to initiate statin therapy or not. Shared decision 
making with elicitation of patient preferences is indispensable in this context. 
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suppleMent
Study Population
We selected our study population based on individuals from the National Health and 
Nutrition Examination Survey (NHANES) using the 2001-2002 data collection. To address 
our research questions we selected patients in the age range of 40 to 79 years, without 
a diagnosis of diabetes mellitus, without known cardiovascular disease and who were 
not taking statins at the time of the interview (see Figure 1 of the main paper). There 
were a total of 1755 eligible patients, which formed our study population. The baseline 
characteristics of the selected sample are described in eTable 1.
Cardiovascular Event Rates
We estimated the cardiovascular events incidence using the AHA/ACC Pooled Cohort 
Equations. These sex- and ethnic-specific equations were applied to all individuals in 
the NHANES sample. The Pooled Cohort Equations developed for Whites were applied 
to NHANES individuals classified as Mexican American, Multi-Racial or Other Hispanic, 
following the recommendation of the 2013 ACC/AHA Guideline on the Assessment of 
Cardiovascular Risk (1). 
We estimated an annual increase on modifiable risk factors based on least-squares linear 
regressions performed with the 2001 – 2002 NHANES data. We assumed all patients 
experienced a yearly increase of 0.78 mg/dL in the total cholesterol levels, 0.36 mg/dL 
in the HDL-cholesterol levels and of 0.55 mmHg in the systolic blood pressure levels. For 
all patients, we estimated the 10-year risk of an atherosclerotic cardiovascular disease 
(CVD) event using the Pooled Cohort Equations. The equations were used to estimate 
the risk at baseline and at each following year until all patients turned 79 years old. 
To transform the calculated 10-year risks into annual rates, we used a solver function. As 
the model runs on 1-year cycles, we used a solver function to estimate the individual’s 
age-specific annual incidence rates of CVD events allowing them to increase by year. This 
resulted in smoothed annual incidence rates of CVD for each individual that increased 
with advancing age. The rates were expressed as (2):
Rate of ASCVDAge = α × e 
β × (Age)
For each patient, the solver function calculated the best-fitting Alpha and Beta to 
minimize the difference between the Pooled Cohort 10-year probability and the 10-
year probability resultant from the rate equation. In this way, each patient entered the 
model with a fixed Alpha and Beta that determined the annual increasing incidence 
rates of CVD events until age 89. After this age, we used a constant rate extrapolating 
from age 89. The results from the solver function were compared to the 10-year risk from 
the Pooled Cohort Equations for selected patients (see eFigure 2, eFigure 3, eFigure 4 
and eFigure 5). For this comparison, we assumed that individuals would have their CVD 
risk assessed every 10 years (or when they turn 79 years). We also assumed that the 
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incidence rates from the Pooled Cohort Equations would be constant in the intervals 
between risk assessments.
Competing Mortality Rates
To model competing mortality, we derived the probability of dying of causes not 
related to ischemic heart diseases, cerebrovascular diseases and diabetes mellitus from 
published life tables (3,4). To select the excluding deaths we used the codes I20 to I25, I60 
to I69 and E10 to E14, according to the 10th revision of the International Classification of 
Diseases. We had data on the number of deaths in 5-year age intervals, which provided 
us 5-year probabilities of death (see eTable 2 and eTable 3). To create a smoother 
increase of the mortality rates over the years we applied the same solver function used 
to estimate the increase of cardiovascular risk. We defined the mortality rates as: 
Competing Mortality RateAge = α × e 
β × (Age)
Subsequently, we programmed the solver function to estimate the Alpha and Beta values 
that provided the minimal difference between the 5-year probability of death from the 
life table and the 5-year probability of death from the newly calculated mortality rates. 
The constant rates from the 5-year probabilities and the estimated annual rates from 
the solver function are plotted in eFigure 6 and eFigure 7.
Validation
We compared the life expectancies resultant from the model to published life 
expectancies of the U.S. population (4). For this comparison, we used the same NHANES 
individuals as in the analysis. In order to make the sample comparable to the target 
values, which were from the whole U.S. population, this comparison was performed 
without exclusion of diabetic patients and patients with previous cardiovascular disease. 
We retrieved the prevalence of diabetes mellitus in the year 2000 from the Centers for 
Disease Control and Prevention (CDC) and this value represented the percentage of 
individuals that started the model in the diabetes state (5). A probabilistic sensitivity 
analysis was run with 10000 samples (outer loop) for each group of patients with the 
same age at baseline (inner loop). The life expectancies resultant from the analysis are 
shown in the main paper (Figure 3).
Costs
We estimated costs for the model from the societal perspective for the U.S (see 
manuscript Table 1). All costs were inflated to 2013 U.S. dollars using consumer price 
indices. To include time preference in the model, we discounted future costs and 
effectiveness at a rate of 3% (6). 
The costs of an MI event were averaged from the index-hospitalization costs of patients 
with acute coronary syndrome. For surviving patients, costs for the first year after an MI 
included inpatient, outpatient and pharmacy costs (7). Stroke event costs were based 
on hospitalization costs for a first ischemic stroke in a managed care population. Costs 
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for the first year were allocated to nonfatal stroke events and represented medical and 
pharmacy costs (8). The costs for the subsequent years after a nonfatal MI and after a 
nonfatal stroke were estimated from actual resource utilization of patients in a six-year 
clinical trial (9). We assumed that the costs would accrue for the remaining lifetime of the 
patients.
The costs after a diabetes diagnosis were estimated from the average annual cost per 
case of type 2 diabetes mellitus, which included physician office and emergency visits, 
ambulance services, hospital outpatient and home health visits, hospital inpatient care, 
nursing/residential facility care, hospice care, podiatry visits, insulin, oral agents, and 
diabetic supplies (10).
Statin Drug Prices
We performed an online search on websites of U.S. pharmacies to estimate current retail 
prices of commonly prescribed statins (see eTable 4). We restricted our search to drug 
retailers with nationwide presence. Most of the retailers offered free delivery to any 
address in the United States. In these cases, we assumed that the costs related to filling 
a prescription would be solely the costs of the medication itself. Some grocers charge 
an annual subscription fee for their discount program. This cost was taken into account 
in the price per pill, which was calculated using the prices corresponding to a 3-month 
supply.
For the model, we assumed that patients would be prescribed a generic moderate-
intensity statin. The prices for this drug class ranged from $0.11 to $0.45 per pill in 
our results from the web search. The 2014 prices were deflated to represent 2013 U.S. 
dollars. We created a distribution for Probabilistic Sensitivity Analysis (PSA) to take into 
account the differences in prices found. 
Sensitivity Analysis for Disutility of Taking Daily Medication
To study the impact of varying disutility related to taking a pill daily, we ran a sensitivity 
analysis for selected individuals of the NHANES sample. We selected 145 low- and 
intermediate risk individuals with different risk factors and, for each of them, determined 
from which value of disutility statin therapy would start to be cost-effective at a 
willingness-to-pay of $50,000/QALY. Other model parameters were the same as used 
in the intention-to-treat analysis (Table 1 of the main paper). For 58 individuals, statin 
therapy was not cost-effective irrespective of the value of disutility. For the remaining 
87, disutility thresholds ranging from 0 to 297 days of life traded away would change 
the optimal decision. Figure 3 of the main paper shows the relationship between the 
disutility threshold and the baseline CVD risk of the individuals.
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eTable 1. Baseline characteristics of the study population.
Characteristic Value (N = 1755)
Male sex, no. (%) 877 (49.97%)
Ethnicity
 NonHispanic White, no. (%) 977 (55.67%)
 NonHispanic Black, no. (%) 331 (18.86%)
 Other 447 (25.47%)
Mean age (SD), yr 55.12 (11.08)
Mean total cholesterol (SD), mg/dL 211.93 (39.91)
Mean HDL-cholesterol (SD), mg/dL 53.56 (16.27)
Mean systolic blood pressure (SD), mmHg 128.28 (19.42)
Hypertension treatment, no. (%) 387 (22.05%)
Current smoking, no. (%) 419 (23.87%)
10-year CVD Risk, no. (%)a
 < 2.5% 534 (30.43%)
 2.5% to 4.9% 311 (17.72%)
 5% to 7.4% 207 (11.79%)
 7.5% to 9.9% 143 (8.15%)
 10% to 14.9% 207 (11.79%)
 15% to 19.9% 120 (6.84%)
 >20% 233 (13.28%)
HDL stands for high density lipoprotein; CVD = atherosclerotic cardiovascular disease.
a 10-year CVD risk was estimated using the AHA/ACC Pooled Cohort Equations.
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eFigure 2. Annual incidence rates of CVD events for a 45-year-old male with 3.2% 10-year risk at 
baseline.
Incidence rates estimated for a patient with the following risk factors at baseline: ethinicity = nonHispanic Black; total cholesterol = 
183 mg/dL; HDL-cholesterol = 61 mg/dL; systolic blood pressure = 117 mmHg; smoking = no; diabetes = no; antihypertensives = yes.
eFigure 3. Annual incidence rates of CVD events for a 45-year-old female with 3.2% 10-year risk at 
baseline.
Incidence rates estimated for a patient with the following risk factors at baseline: ethinicity = nonHispanic Black; total cholesterol = 
171 mg/dL; HDL-cholesterol = 53 mg/dL; systolic blood pressure = 139 mmHg; smoking = no; diabetes = no; antihypertensives = yes.
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eFigure 4. Annual incidence rates of CVD events for a 49-year-old female with 10% 10-year risk at 
baseline.
Incidence rates estimated for a patient with the following risk factors at baseline: ethinicity = nonHispanic White; total cholesterol = 
232 mg/dL; HDL-cholesterol = 48 mg/dL; systolic blood pressure = 162 mmHg; smoking = yes; diabetes = no; antihypertensives = yes.
eFigure 5. Annual incidence rates of CVD events for a 49-year-old male with 9% 10-year risk at baseline.
Incidence rates estimated for a patient with the following risk factors at baseline: ethinicity = nonHispanic White; total cholesterol = 
240 mg/dL; HDL-cholesterol = 44 mg/dL; systolic blood pressure = 118 mmHg; smoking = yes; diabetes = no; antihypertensives = no.
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eFigure 6. Comparison between competing mortality rates from abridged life table and estimated 
competing mortality rates from solver function for men.
eFigure 7. Comparison between competing mortality rates from abridged life table and estimated 
competing mortality rates from solver function for women. 
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In this thesis we aimed at contributing to the evidence on the optimal strategy for the 
primary prevention of cardiovascular disease in modern Western populations using 
a risk based approach. More specifically, we constructed models by abstracting and 
deducing data from the cumulative work of others. If one would characterize this thesis 
in an overly simplistic approach, one could argue that we have merely aggregated 
and synthesized data that has already been produced through the extensive efforts of 
others. In fact, that is exactly what we did. Nevertheless, data synthesis is a far more 
daunting task than it may seem. Besides summarizing the main findings in this thesis, 
this chapter will be used to elaborate on the complexity of data synthesis and how 
this process has an important place in assessing the optimal strategy for the primary 
prevention of cardiovascular disease. The limitations and challenges of this approach 
will also be discussed. 
In order to adequately synthesize evidence and evaluate interventions based on 
cardiovascular risk assessment, we have studied 1) the (individualized) underlying truth 
in decision models, based on long-term CVD risk predictions and their improvement 
using novel risk markers; 2) the validity of and critical assumptions underlying decision 
models and their relation to the outcome of such models; and finally 3) the comparative 
effectiveness and cost-effectiveness of guiding preventive (medical) treatment based 
on risk-stratification using both established risk scores and novel risk markers.
We embarked on our journey by looking into the value of screening asymptomatic 
individuals at intermediate risk for coronary heart disease by using the coronary 
calcium score determined with computed tomography. Using observational data 
from the Rotterdam study, which included the CT-coronary calcium score from 1997 
onwards -with a follow-up of a median of 7 years, we calculated -at the population level, 
which percentage of individuals were reclassified to a higher or lower risk category 
when CT calcium was taken into account, compared to the classification using only 
the traditional Framingham risk factors (chapter 2). We explicitly chose not to use the 
original Framingham risk score itself -with the accompanying baseline hazards and 
association strengths found in the Framingham population, as this could have caused 
the reclassification in risk to be due both to recalibration of the original score within 
the Rotterdam Study and the addition of the calcium score. The recalibrated traditional 
risk score included all the original Framingham risk factors, but allowed for different 
accompanying coefficients, so the effect sizes of the individual risk factors and their 
correlations were slightly different than in the Framingham risk score (1), thereby 
isolating the effect of adding CT calcium to the model. If an individual was reclassified 
to the high risk category, (>20%, 10 year risk of coronary heart disease), an individual 
was treated with a statin, anti-hypertensive medication and -in men, also aspirin. 
Compared to current practice, current guidelines and the statin therapy alternative 
(in which individuals were assigned a moderately potent statin regardless of their 
initial LDL levels –considered to be the most ‘aggressive’ strategy), screening with CT 
calcium in men yielded the highest quality adjusted life expectancy, against a lower 
incremental cost-effectiveness ratio (compared to current practice) than the current 
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guidelines strategy did. Part of this result could be explained by the fact that individuals 
targeted and allocated preventive medication in the CT calcium screening strategy, had 
higher predicted risks of CHD compared to the individuals allocated medical treatment 
in the statin therapy and current practice alternative. Arguably, this was inherent to 
the underlying model, but apparently, this mechanism outweighed the higher costs 
of the strategy, and harm of the screening itself. In a sensitivity analysis, CT calcium 
screening was outranked by the statin therapy strategy when the cost of CT increased 
more than 2-fold, or the incidence of radiation induced cancer increased more than 10-
fold. In women CT screening was not found to be cost-effective, even after using a wide 
range of varying assumptions, which included assumptions more favourable to the CT 
calcium screening strategy by treating individuals in the higher end of ‘low risk’ (5 – 10% 
risk) more aggressively, and using more treat-prone LDL thresholds. The difference in 
the optimal decision between men and women can -at least in part, be explained by the 
fact that compared to men, more women were reclassified to the low risk group leading 
to less aggressive treatment. Furthermore, within the low risk group, the observed risk 
of CHD is higher in women than in men, so the foregone benefit with less aggressive 
treatment is higher in women. The benefit of CT screening is obtained in the high-risk 
group, where individuals are treated more aggressively compared to current guidelines 
for treatment of intermediate-risk individuals. Since fewer women were reclassified to 
high-risk, the potential benefit of CT screening is lower than in men. Having said all that, 
the average age in the analysis was 70 for men, and 74 for women (as the requirement 
was for them to be at ‘intermediate risk for CHD’; for which calendar age is the most 
important driver), and residual life expectancy not too much over 10 years. One could 
make a valid argument that primary prevention should take place earlier in life, since at 
the age of 70 atherosclerotic plaque has had ample time to accumulate. Moreover, in 
spite of the availability of a number of novel risk markers, this particular analysis does 
not evaluate these. In chapters 8 and 9 we did analyze these markers and we return to 
these later on in the discussion.
As stated before, we have built on the cumulative work of others, and not all of our 
efforts were put into assessing the value of ‘novelties’, but in the evaluation of current 
recommendations in the prevention of cardiovascular disease as well. More specifically, 
European guidelines on the prevention of CVD have provided clinicians with their world 
famous risk charts (2) in order to individualize decisions on the initiation of statins. The 
rationale behind these charts is that the higher an individuals’ expected risk of CVD, 
the bigger the expected benefit of preventing it (CVD). However, the (traditional) risk 
factors used to estimate CVD risk are also related to ‘competing’ events. For example, an 
individual’s calendar age will affect both the estimated risk of future CVD events, but 
also the risk of developing cancer. By not taking into account competing risks, and by 
possibly ignoring the (indirect) effect of an intervention targeted at lowering the risk of 
CVD on the competing event risk, the net effect of an intervention could be incorrectly 
estimated (3). In order to evaluate these charts at an individual patient level, Chapter 3 
looked into the validity of a previously constructed model: the Rotterdam Ischemic heart 
disease and Stroke Computer simulation (RISC) model. Aside from the traditional risk 
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factors, the model included body mass index, waist-to-hip ratio, ankle-brachial index, 
plasma creatinine; family history of CVD, manifestations of intermittent claudication, 
angina pectoris, atrial fibrillation or transient ischemic attacks; and prevalent CVD. As 
decision models often extrapolate from existing data, we first showed that, by using 
observational data for the period of 5 years -on which the RISC model was originally 
based, the model was able to correctly estimate CVD mortality, non-CVD mortality, CHD 
events and Stroke events up until 13 years (the maximum length of observational data 
available at that time which was used to validate the model). Extrapolation beyond 5 
years was grounded in both the modelling of trends in risk factors over time and their 
effects on the incidence of events, which are jointly modelled in the RISC model. Their 
interplay seemed to have caused a valid basis to extrapolate results, without the need to 
recalibrate the model for the Rotterdam Study population. Extrapolation was also valid 
when we stratified for sex and tertiles of age. As for the external validity, the RISC model 
appeared to be valid for other populations than the Rotterdam Study participants as 
well, after only adjusting for the baseline cumulative hazards of the events and the 
mean values of the risk factors -a method very commonly used when applying models 
to other populations than that for which the model was originally developed in (4, 5). 
The model was able to correctly simulate CVD and non-CVD mortality for the EPIC 
Norfolk population for up until 10 years (again; the maximum length of observational 
data available to us at that moment). However, extrapolating short term to lifetime 
risks -one of the goals we frequently try to achieve when addressing decision problems 
covering the residual life time of an individual, has been shown to be fairly difficult. For 
participants of the QRISK study in England and Wales, of the (arbitrarily chosen) top 10% 
classified at high risk with either the lifetime risk model or the 10 year risk model, only 
14.5% were high risk on both measures (6). Moreover, patients with the high lifetime risk 
were more likely to be younger, male, and much more likely to have a positive family 
history of coronary heart disease than those with a high 10 year risk. This implies –at the 
very least, that extrapolating (far) beyond 10 years by using data from a limited time 
horizon is not without a serious risk of a simulation model producing data that would 
be (far) from reality, in the sense that it would 1) not calibrate well for the long run 
on average, but more importantly: 2) would select individuals for preventive treatment 
based on risk factors that matter for the shorter time horizon, but no so much for the 
long run (i.e. for the QRISK population we should select the younger, male individuals 
with a positive family history). As an alternative, one could ‘wait’ until the long-term 
data has become available (5), but at the cost that recent trends in event rates (7) will 
be inadequately captured; aside from the fact that we have to face a decision now, 
and often do not have time to wait for 30 years. Furthermore, in chapter 3 we ‘only’ 
validated the ‘naturally occurring‘ cardiovascular histories of the participants of the 
Rotterdam Study (and EPIC-Norfolk cohort) as they were observed; that is: without any 
interventions. Although the results with regard to this validity seemed promising, our 
aim was to use the RISC model to evaluate the initiation of statin therapy for the primary 
prevention of CVD –more specifically to evaluate the Score risk charts. The validity of our 
modelling efforts to evaluate these charts (or any intervention more in general) depend 
not only on the validity of the simulated CVD history, but also on the extent to which 
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other structural assumptions are made, such as modeling the treatment effect of an 
intervention (8). 
Besides having covered the validity of the prognostic part of the simulation model in 
chapter 3, chapter 4 focussed on the impact of using different structural assumptions 
about the treatment effect (which is incorporated in every screening strategy evaluated 
in this thesis, which stems from the main concept of targeting high risk individuals and 
treating them), using statin therapy as an example. Three commonly used assumptions 
were analysed: 1) statins lower LDL cholesterol, and being an independent risk factor of 
CVD, the effect of statin therapy was assumed to be equal to the projected decrease in 
predicted CVD risk through the associated hazard rate ratio of LDL on CHD -obtained 
from non-experimental study designs; 2) a fixed reduction in CVD risk based on 
observed risk reductions on CHD and stroke from (meta analyses of ) clinical trials and 3) 
a reduction of CVD risk (again obtained from clinical trials) proportional to the expected 
decrease in LDL-cholesterol levels. All three methods have been identified in existing 
decision models of CVD. We found that for the decision to initiate statins according 
to the ATP-III guidelines, these three different modelling assumptions would lead to 
different conclusions about the cost-effectiveness of initiating statin therapy. A priori, 
there is no ‘superior’ way of modelling the treatment effect. For our statin therapy/
ATP-III guidelines example, if it would have been required that the modeled reduction 
in incident CHD and stroke events corresponded to the same reduction as observed 
in trials (a requirement which could have been validated if we would have simulated 
individual-level trial data (9)), the resulting reduction in fatal total CVD events produced 
by the RISC model would have unlikely matched the observed reduction in fatal total 
CVD events in the same trials if no further adjustments or assumptions would have been 
introduced. In other words, imposing some kind of constraint to force some relationship 
or construct to hold within a decision model, induces additional assumptions and/or 
constructs that can conflict with ‘reality’ as well. It also enables a designer of a decision 
model to ‘prove’ his or her model is valid in some ways -but never in all possible ways. 
How ‘exact’ the process of model building and validating may seem, the modeling of 
complex interrelationships is more of an art than an exact science. For each particular 
decision problem it is important to determine which assumptions drive the results, 
determine the appropriateness of these assumptions, and judge the relevance of the 
model sensitivity to them in the context of the decision problem studied.
In chapter 5 we evaluated the predicted individual gains from initiating statin therapy 
in asymptomatic individuals free of CVD at baseline (without incorporating any form 
of screening), by taking into account the competing risk of non-CVD deaths and use 
of a lifetime time horizon. We found that in 2,428 individuals free of CVD from the total 
of 3,501 Rotterdam Study participants on which the RISC model was originally based, 
statin therapy resulted in robust, small gains in total life expectancy (0.3 years, with 
a range of between 0 and 2 full years) and somewhat larger gains in CHD/stroke-free 
life expectancy. Using baseline levels of risk factors in these individuals, we found that 
a higher systolic blood pressure, higher total cholesterol, lower HDL cholesterol, and 
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larger body mass index considerably increased the expected individual gains in total 
and CHD/stroke-free life expectancy with statin therapy. However, increasing age most 
importantly decreased these gains, as did diabetes mellitus to a lesser extent. With 
advancing age, the risk of death due to other causes than CVD increases rapidly. By 
preventing a (potentially fatal) CVD event at an older age, the prevented CVD event is 
almost immediately exchanged for a non-CVD related death, resulting in a smaller net 
benefit in terms of all cause survival than a CVD event prevented in a younger individual 
-for which the risk of death due to other causes is much lower. As a consequence, 
the expected individual gains of statin therapy for an individual is expected to be 
higher in younger individuals, whereas the current European guidelines on initiating 
statin therapy is purely CVD risk based- of which calendar age is the most important 
determinant; which implies recommending it in older individuals instead –for which we 
have just argued that the expected individual gains are lower. A number of important 
assumptions had to be made for the modelling of the effect of life-long statin therapy. 
First -as mentioned before, although the RISC model adequately reproduced 13 year 
incidences of CHD, Stroke, CVD and non-CVD mortality, the extrapolation beyond 
13 years remains to be established. Second, the relative risk reducing effect of statin 
therapy was kept constant over age and various risk factor levels. Although, a number 
of observational studies found that the protective effect of cholesterol lowering on CVD 
events decreases in individuals aged 70 to 89, this was not confirmed by experimental 
research (10, 11). Moreover, as we will come to discuss later on, we did not impose any 
penalty or disutility for taking daily medication (12, 13). If younger individuals were to be 
allocated statins for longer periods of time, one could easily imagine that such a disutility 
would accumulate to substantial levels, decreasing the net benefit of the intervention. 
In chapter 6 we studied the validity of the long term Framingham CVD risk (combined 
endpoint of myocardial infarction, coronary death and stroke) predictions which take 
into account the competing risk of non-CVD death. As it has become clear, taking into 
account competing risks is a critical asset of CVD predictions if they are to be used in 
long term decision models. We found that the Framingham CVD risk predictions perform 
reasonably well in predicting 15 year risk of CVD in the -on average older, Rotterdam 
population for individuals at low to intermediate risk. This finding is comparable to 
previous studies on the validity of Framingham risk functions in the Rotterdam Study 
using 10-year CHD and stroke as separate outcomes. Recalibration was necessary for the 
apparent overestimation in the higher risk categories. Part of this overestimation could 
be explained by the fact that the Framingham function at the same time underestimated 
the risk of the competing non-CVD death which is of particular importance in the 
older Rotterdam study participants. The most recent guidelines on prevention of CVD 
classify individuals based on their risk of CVD as a combined endpoint -in contrast to 
some older guidelines which merely focused on coronary heart disease. However, we 
demonstrated that estimating the hazards for CHD and stroke separately allows for the 
simultaneous prediction of the risks of these events and found that the weights assigned 
to the risk factors included in the Framingham risk function are different for both 
events. Discrimination increased only very little, but calibration improved substantially 
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compared to predicting CVD as a combined endpoint. The hazard rate ratios of the risk 
factors were sometimes different in magnitude and significance of the effects from 
the ones from Framingham. Our observation that total cholesterol (in the presence of 
other factors) did not appear a significant predictor for CVD in the Rotterdam data was 
supported by earlier analyses in the Rotterdam Study. Whereas serum cholesterol was 
found to have a protective effect on stroke, HDL-cholesterol had no significant effect 
-similar to what we found when we analysed the hazard of stroke separately from CHD. 
Moreover, the major contributor to an individuals’ predicted risk of CVD, (being either 
CHD or stroke), differed between individual risk profiles, as illustrated with a number 
of specific examples in chapter 6. This can have important clinical implications for the 
allocation of preventive interventions. For example, aspirin is currently recommended 
in men with a high risk of CHD, while in women the recommendation is only made for 
those with a high risk of stroke (11). Both reasons (more precise estimation of the total 
CVD risk when estimating CHD and stroke separately and potential different clinical 
implications) illustrate the potential refinement in CVD risk assessment by separate 
prediction of the constituents of the CVD event as a combined endpoint. Similarly, 
in chapter 7 we developed risk functions for the separate prediction of ischemic and 
haemorrhagic stroke, and found that a number of risk factors currently adopted in risk 
scores for stroke as a combined endpoint of ischemic and haemorrhagic stroke, had 
different effect sizes when analyzing subtypes of stroke separately. Again, the subtype 
of a stroke event is clinically relevant for treatment decisions –analogous to the case of 
CVD as a combined endpoint.
In chapter 8 we modeled the predictive value of adding four novel cardiovascular risk 
markers to traditional Framingham risk scores: CT coronary calcium, high sensitivity CRP, 
carotid intima media thickness on ultrasound and the ankle-brachial index. We explicitly 
studied the predictive value of these novel risk markers in individuals representative 
of the U.S. general population by using the NHANES 2003 – 2004 exam data -where 
previous studies focused on the predictive value of (single) novel risk markers in the 
specific observational cohort in which they were measured to design the basic setup 
of evaluating screening strategies by using these novel risk markers later on -as the 
final goal of implementing screening strategies will most likely be their employments 
in a general population rather than a strictly defined study cohort population. Among 
the four novel risk markers, the Framingham risk score updated with CTCS showed the 
most impact on reclassification for both CVD and CHD as endpoint, regardless of the risk 
thresholds used. However, generalizing results on reclassification from specific cohort 
studies to a general population is not without difficulties. The impact of a novel risk 
marker on improving risk classification is determined by the strength of the association 
with the outcome (for which most cohort studies showed consensus in strengths of the 
association), but also depends on the joined distribution of the novel risk marker and 
traditional risk factors within the population one aims to study. The exact distribution 
of the novel risk markers in the U.S. population is unknown and had to be estimated 
by assuming 1) the correlation between the traditional risk factors and hsCRP and the 
ankle-brachial index as observed within the NHANES 2003 – 2004 data also holds for 
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the U.S. general population and 2) – since NHANES did not have data on CTCS and cIMT, 
the correlation between the traditional risk factors and CTCS and cIMT as observed in 
the Rotterdam Study data, would hold for the U.S. general population. Second, having 
constructed the estimated risk profiles of the U.S. population including the 4 novel risk 
markers, we had to come up with event rates to make inferences about the improvement 
of risk classification –since our dataset did not include outcome data on events. We 
therefore constructed a simulation model in which the yearly probabilities of CHD, 
stroke and non-CVD death were based on the 30-year Framingham CVD risk prediction 
model, updated with all four novel risk-markers -under the assumption that the actual 
average risk of the U.S. population as a whole would not change due to the addition of 
the novel risk markers, and used the (not updated) Framingham CVD risk predictions 
as a proxy for the actual average risk (as it has been shown that Framingham-based 
predictions perform fairly well in most U.S. subpopulations) (4). Our conclusion that CTCS 
improves CVD risk classification (in contrast to hsCRP, ABI and cIMT) was congruent with 
MESA and Rotterdam study data. 
As mentioned before, improvement in (correct) CVD risk classification is not 
sufficient for a novel risk marker to be used as a screening tool. In order to analyse 
the comparative effectiveness and cost-effectiveness of screening United States 
individuals at intermediate risk, with either CT calcium, hsCRP, ABI and cIMT, we 
extended the model from chapter 8 in chapter 9 by adding treatment effects of statins, 
anti-hypertensive medication, cost and QALYs of relevant health states, side effects of 
treatment, compliance and a disutility for taking daily medication. The risk thresholds 
in the screening strategies were derived from the latest AHA guidelines -using 7.5% as 
cutoff for 10 year risk of CVD (14). Compared to current practice (the reference strategy) 
and fully adopting current guidelines -and compared to initiating statins instead of 
screening, we found that screening men from the U.S. population with CT calcium was 
cost-effective with an ICER ranging from $22,300 to $49,600. All other novel biomarkers 
were more costly and less effective. This result is in part explained by the observation 
that CT calcium results in the highest percentage of men being allocated any of the 
three cardioprotective drugs compared with the other biomarkers. Only in the case 
of the statin therapy strategy were more men allocated statins, but at the cost of a 
substantial disutility from taking daily medication. Ubiquitously initiating statins results 
in a lower quality adjusted life expectancy in individuals without the need of statins, 
whereas this penalty seems to be outweighed in individuals with an increased risk of 
CVD based on CT calcium testing. In women, screening with hsCRP was found to be 
the optimal strategy with an associated ICER ranging from $15,050 to $185,091. Unlike 
our results in men, the percentage of women being allocated cardio-protective drugs 
was highest in the hsCRP strategy. Moreover, CT calcium is less favorable in women 
due to a higher risk of cancer due to radiation associated with a cardiac CT (15). Both can 
explain the inferiority of CT calcium in women compared to men. For both men and 
women, the disutility of taking daily medication played a pivotal role in the optimal 
decision. When assuming 100% treatment adherence and no disutility, blindly initiating 
statins was superior compared to screening with any of the novel biomarkers. As such, 
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patients with a low tolerance to medication seem to benefit more from screening than 
individuals with high tolerance. 
A similar pattern was observed in chapter 10 in which we analyzed the comparative 
effectiveness and cost-effectiveness of prescribing statin therapy to United States 
individuals at low and intermediate risk (without screening with novel risk markers). This 
analysis revealed a decrease in quality adjusted life expectancy for prescribing statins 
to individuals for primary prevention of CVD, across the full range of risk thresholds 
analysed -including the current recommendation of 7.5% or higher. This decrease 
was fully attributable to a modest gain in average life expectancy with statin therapy 
but a substantial decrease in QALE due to the disutility associated with taking daily 
medication. From a policy-makers perspective, prescribing statin therapy in low-and 
intermediate risk individuals does more harm than good and costs money (assuming 
a policy maker is unable to ethically, legally and objectively differentiate individuals 
based on their disutility-preferences). For the individual, the decision depends on the 
trade-off between future risk versus the disutility from daily medication –a phenomenon 
illustrated in chapter 9 as well. 
Policy implications and Future Directions
After all these elaborative efforts in modelling primary prevention strategies, we remain 
with the question what the clinical and policy implications are of the results and what 
research would be worthwhile pursuing in the future? Can we make policy based on 
our findings or do we need to perform clinical trials? Should we pursue large scale 
multinational multicentre clinical trials using standard frequentist statistical inference 
methods with rejection of the null hypothesis with a 95% level of confidence evaluating 
the CT coronary calcium score in men? More likely than not, statistical power will be 
a major limitation to overcome. In fact, a number of clinical trials using a screening 
modality (functional testing and coronary CT -but not the coronary calcium score as we 
have studied) have been performed in diabetic individuals -considered to be at high 
risk already according to the latest guidelines (14), and were unable to find statistically 
significant differences on hard endpoints (16, 17). Recently, a trial including more than 
50,000 individuals from the general population followed up for 10 years was unable to 
detect a significant difference using similar endpoints, although the screening procedure 
and intervention were slightly different from ours (lifestyle counselling). Looking at the 
parameter uncertainty represented in our results -which are in fact Bayesian derived 
credibility intervals (CI’s), one can deduce from e-tables 3 and 4 in chapter 9 that the 
CI’s of our primary outcome measures tend to overlap quite dramatically. We already 
elaborated on feasibility issues of clinical trials in the setting of our decision problems in 
the introduction of this thesis. So are we right back where we started from?
At the very least, our research has (re-)established the potential role of CT coronary 
calcium screening, without actually ‘experimenting’ with a single patient in real life. 
Although this result is concordant with the current opinions of mastodons in the 
field (18, 19), we came to our conclusions by estimating the effects of screening on long 
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term, hard endpoints (and effects on cost/resource usage as well). Both investigators 
referenced, conclude in their latest expert opinions that demonstrating the value of 
CT coronary calcium screening in a trial setting is unlikely to ever happen given the 
complexity and expense of such an endeavour. 
Rather than trying to replicate what we learned from our decision models in real life 
with an infeasible clinical trial, we could arguably learn more if we use the direction in 
which our results point us and then add something new to it. 
Recent studies have suggested that the results of screening with a novel biomarker – CT 
calcium in this case – influence treatment initiation and continuation downstream (20), 
and -more importantly, seem to improve compliance to statin therapy (21). Although the 
latter observation was made in a non-controlled setting and another study could not 
confirm this finding(22) , there is accumulating evidence that visualizing an individual’s risk 
of CVD by use of coronary CT may motivate individuals to co-operate in the preventive 
efforts being made for their own wellbeing (23). Extrapolating from these findings one 
could expect that visualisation of subclinical disease may change someone’s perception 
of taking medication from being a disutility to being an investment in his or herself.
In conclusion, we have developed an extensive framework to evaluate screening-based 
interventions for the primary prevention of cardiovascular disease. Our approach goes 
beyond establishing improvement of predictive performance of a novel risk marker 
to include benefit in terms of long term survival, quality of life, and cost-savings. 
Furthermore, our results suggest that future research in the field of novel biomarkers 
through trial-based studies should incorporate the interplay between an individual’s 
perceived disutility for taking daily medication, the communicated results of CT 
coronary calcium, the resulting treatment adherence and the extent of potentially 
resulting behavioural changes. 
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Dit proefschrift (en de auteur ervan) zou er niet zijn geweest zonder de inspanningen en 
bijdragen van een groot aantal mensen die mij op meerdere niveaus dierbaar zijn. Wat ik 
hieronder ga schrijven kwalificeert in de regel als het vaakst dan wel enige daadwerkelijk 
(nauwkeurig) gelezen deel van een proefschrift. Het zal ongetwijfeld afbreuk doen 
aan de waarde van de rol die zij die ik expliciet zal benoemen gespeeld hebben, maar 
uiteraard ga ik desalniettemin een poging wagen. En ja, dat gaat persoonlijk worden, 
dus wees gewaarschuwd ;)
Allereerst mijn promotor en supervisor, prof.dr. M.G. Myriam Hunink. Beste Myriam, wat 
heb jij veel geduld met mij gehad. Toen wij elkaar in 2007 ontmoetten was er meteen 
een klik op meerdere fronten. Jij bent degene die in een vroeg stadium in mij geloofde, 
dat bleef doen, en me in een pril stadium de kans gaf om zonder restricties te beginnen 
aan een traject wat uitmondde in deze promotie. Je gaf me je boek en een aantal ideeën, 
maar bovenal de ruimte om zelf een heleboel dingen te leren. Onze gesprekken vingen 
meestal aan met de stand van zaken van mijn wetenschappelijke bezigheden, om het 
binnen enkele minuten vaak te hebben over muziek, psychologie (Influence!) en een 
breed scala aan andere dingen die het leven boeiend en bijzonder maken. Dank ook 
voor het mij –met zachte hand maar doordachte wijze, over obstakels heen te helpen 
die al dan niet door mijzelf waren opgeworpen. De ontspannende wandeling in een 
zonnig park voorafgaand aan ons gezamenlijke interview met de hoofdredacteur van 
JACC zal me altijd bijblijven.
Leden van de kleine commissie, prof.dr. E.W. Steyerberg, beste Ewout, ik heb altijd 
een buitengewone bewondering gehad voor de snelheid waarmee jij in staat bent 
een besliskundig probleem terug te brengen tot de geabstraheerde kern, en wanneer 
normale stervelingen zoals ik nog ‘in awe’ zijn van het gemak waarmee zo’n model 
zich ontspruit aan jouw brein, je reeds geanticipeerd hebt op de met het voorgestelde 
model gepaard gaande validiteits kwesties verderop in het proces. Ook al duurde 
een ontmoeting nooit per se lang gezien de talrijke parallelle processen waarmee je 
tegelijkertijd bezig was, de informatiedichtheid was meer dan genoeg om vol nieuwe 
ideeën richting de 21e verdieping terug te lopen. Beste prof.dr.J.W. Deckers, hartelijk 
dank voor het plaatsnemen binnen de kleine commissie als klinisch expert aangaande 
de primaire preventie van cardiovasculaire ziekten, en meer in het bijzonder voor het 
buitengewoon gastvrije ontvangst op de afdeling cardiologie van het Erasmus MC. 
Dear Kirsten, thank you for the opportunity to share your wisdom with me and keeping 
me in check when needed. Moreover, thank you for giving me the trust to participate in 
the NIH project together with Bart.
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Beste leden van de grote commissie, prof.dr. H.J. de Koning, prof.dr. M. Sturkenboom, 
prof.dr. O.H. Franco: veel dank voor het plaats hebben in mijn commissie. 
Beste Paranimfen, Barry de Goede en Marieke A.’Podiumplaatsje’ Langhout. 
Beste Barry, wat is er in 5 jaar veel gebeurd. Eind 2010 raakte de totstandkoming van 
onze vriendschap in een stroomversnelling in Boston, waar we dagelijks bijna 2 uur in 
de Boston Sports Club te vinden waren, op dezelfde dag ons haar verloren, midden in de 
nacht op een sportveld rondjes aan t rennen waren. Terug in Nederland werkten we het 
merendeel van de nachten die een week gemiddeld telt aan uitermate belangrijke extra-
curriculaire activiteiten in een Jack&Jones V-neck, waarin met een frequentie van 2 maal 
per 15 minuten 2 vingers de lucht in gingen. Onderwijl evolueerde jouw ontwikkeling 
in (onder andere) stijl, mode en vormgeving, waar je me (gelukkig) eea van hebt mee 
gegeven. In een vroeg stadium heb ik de illusie opgegeven ooit jouw niveau daarin te 
benaderen. Op de een of andere manier maakt jouw simpele nabijheid dat ook mijn 
persoonlijkheid ongemerkt wordt geuppergraded. Als een soort onaantastbare twee-
eenheid bewogen we ons voort op de betere feestjes van 010. Zo lang ik je ken ben ik 
jaloers op je drive en doorzettingsvermogen (naast je conditie, symmetrie, morfologie, 
social skills, het gegeven dat je een briljant chirurg gaat zijn en het feit dat ik een van 
de uitverkorenen ben die je vertrouwt, naast nog 100 andere dingen). Het feit dat jij in 
staat bent ver bovengemiddeld succesvol te zijn in zaken waar je niet van nature dol op 
bent –maar die je desalniettemin gewoon doet, is echt bewonderingswaardig. Ik heb 
vaak het idee dat je jezelf niet eens realiseert hoe bijzonder dat wel niet is omdat je ook 
nog eens een niveau van perfectionisme nastreeft op gebieden die je intrinsiek niet 
eens echt aan het hart gaan. Ik ken je kracht dan ook wanneer je die onfeilbare drive en 
skills samenbrengt met iets wat je echt wil, en weet dat je elk bestaand niveau van iets 
wat jij echt wil zal overstijgen, of beter gezegd opnieuw zal definiëren. Daarnaast ben 
je zo inherent geworden aan mijn geschiedenis de afgelopen jaren dat ik je als familie 
beschouw. Maar bovenal ben ik enorm trots dat jij aan m’n zijde staat vandaag. 
Beste Marieke, er zijn een aantal mensen die ik ben tegen gekomen in mijn leven die ik 
echt heel slim vind. Er zijn ook maar een beperkt aantal mensen in staat mij vrijwel altijd 
te laten lachen om hun grapjes. Dat ik je voortdurend pest met je spraak komt slechts 
voort uit n vrij primitieve neiging tot overcompensatie als ik geconfronteerd wordt met 
de manifestatie van je IQ en/of woordenspel. Dank dat je dat al die tijd getolereerd hebt. 
Dank ook dat we op een soms absurdistische wijze een soort van Reviaans gevoel van 
leegte kunnen delen. Als er tijdens de verdediging een vraag wordt gesteld die ik niet 
echt begrijp, kan ik me troosten met de gedachte dat er iemand dicht in de buurt is die 
dat wel doet.
Beste Bart, dank dat je me hebt meegenomen in jouw verbazingwekkend snelle 
ontwikkeling binnen de wetenschap van modelleren en predictie van cardiovasculaire 
ziekten. Zonder jou was dit proefschrift er niet geweest. Dank ook dat je je niet teveel 
stoorde aan dat ik veel te snel was afgeleid en te veelvuldig koffie wilde drinken, dank 
dat je een voorbeeld voor me bent en blijft, en dank ook dat ondanks een buitengewoon 
bijzondere persoonlijkheid waarvan veel mensen slechts een glimp te zien krijgen, ik 
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je ook persoonlijk een beetje heb mogen leren kennen. Ik heb een waanzinnig leuke 
tijd met jou en je familie in Toronto gehad. Meer dan vereerd ben ik nog steeds dat ik 
paranimf op jouw promotie mocht zijn. 
Beste Jan-Willem, er zijn niet veel mensen die me kennen zoals jij. Je hebt je wel eens 
laten ontvallen dat het soms lastig was om vrienden met me te zijn omdat het leek alsof 
ik in veel dingen ‘beter’ zou zijn, maar als ik zo vrij mag zijn geloof ik heilig dat jouw 
invloed in mijn leven groter is geweest dan andersom. Nog steeds heb ik enorm respect 
voor de innerlijke kracht die je hebt waarmee je ooit besloot te kiezen voor wat jij echt 
wilde, de uitdaging die je durfde aan te gaan en de ontwikkeling die je daarna in korte 
tijd hebt doorgemaakt. Op zo’n niveau keuzes durven maken is iets waarvan ik hoop 
dat ik dat ook ooit een beetje kan. Alsof dat nog niet genoeg was komt daar bij dat je in 
staat bent volledig jezelf te blijven en dat soort keuzes kan maken, zonder dat je voorbij 
gaat aan anderen in dat proces. En dat kan je dan ook nog eens op een manier zonder 
ook maar enige vorm van trots en waardigheid te verliezen. Ik benijd je daarom. Ook 
al zien we elkaar weinig zal ik je altijd blind vertrouwen. Ik koester de herinnering aan 
het moment dat Salijn pas geboren was en je haar in mijn armen toevertrouwde om bij 
Roos te gaan kijken. 
Beste Bardia, beste matti: toen wij elkaar voor het eerst ontmoetten dachten we 
ongeveer hetzelfde van elkaar, en diezelfde conclusie kunnen we jaren later nog steeds 
trekken, zij het met een totaal ander substraat. Ik ben bevoorrecht dat ik jou in die 
mate heb mogen leren kennen dat ik een van de mensen ben die jij vertrouwt. Ik heb 
oneindig vaak moeten denken dat het onmenselijk is hoe veel jij aankan op persoonlijk, 
emotioneel en professioneel vlak tegelijkertijd (en er dan nog steeds zo goed uitzien) dat 
ik tenminste in halfgoden ben gaan geloven. Ik bewonder de manier waarop je met een 
gevoel voor stijl en een groter goed –waarmee ik me slechts ten dele kan identificeren 
op het niveau waarop jij dat doet, vaker dan niet een veel lastigere keuze maakt dan 
een louter pragmatisch iemand zou doen. Je adagio ‘stijl voor alles’ omvat een door jou 
nagestreefde levenswijze die eigenlijk ook alleen maar voor iemand van jouw kaliber in 
zijn volledigheid kan worden begrepen en gepoogd na te leven. Dat blijft voor mij een 
voortdurende inspiratie. 
Beste Joost, onze geschiedenis dateert uit een tijd dat er alleen nog maar potentie leek 
te bestaan met een nog niet concreet geduid optimisme, waarin ik altijd tegen jouw 
zelfverzekerdheid, openheid, wil en intelligentie heb opgekeken. Ik heb altijd gevoeld 
dat jij vaak al een paar stappen verder was in de manier waarop jij mensen, relaties en 
de wereld zag, maar je wachtte altijd geduldig op me. Door jou heb ik in een gradueel 
proces onbevooroordeeld leren luisteren, de waarde van autonomie leren kennen en 
een besef van een onbeschrijfelijk aantal zaken van belang gekregen, die ik zonder jou 
niet had gehad of pas veel later wellicht had begrepen. Dat je tegelijkertijd een van 
m’n beste vrienden bent geworden en gebleven is iets waar ik buitengewoon dankbaar 
voor ben. 
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John en Thea, Pappa en Mamma, zoals in de eerste alinea van dit dankwoord valt af te 
leiden wil ik jullie allereerst bedanken voor het verschaffen van alle ingrediënten die 
me hebben gemaakt tot wat ik nu ben, alle liefde, alle ondersteuning, alle ruimte, alle 
hulp. Pap, zelfs nu ik geacht word volwassen te zijn en tal van studies heb afgerond, is 
er één iemand in mijn leven die altijd raad weet wanneer ik op wat voor manier dan 
ook in paniek ben (ook al is dat zelden), en dat ben jij. Al bel ik midden in de nacht, 
slechts een door jou in alle rust uitgesproken ‘ja?’, wanneer mama de telefoon aan 
jou geeft is voldoende om mij meteen het gevoel te geven dat alles goedkomt. Een 
nieuw bed, auto of set winterbanden is vaak al tot in de puntjes georkestreerd zonder 
dat ik de behoefte ooit hardop heb uitgesproken; je weet vaak al voor ik het zelf weet 
wat ik nodig heb. Daarnaast lees je mij als geen anders- zonder iets te zeggen weet 
jij eigenlijk in een oogopslag wat er bij me speelt. Vaak verdenk ik je er ook van dat je 
van te voren al weet hoe zaken gaan lopen, maar je hebt me nooit een strobreed in de 
weg gelegd tot dezelfde conclusie te komen door het me zelf te laten ervaren. Mama, 
voor mij ben jij een onuitputtelijke bron van zorgzaamheid. En hoewel onuitputtelijke 
bronnen misschien normaal zouden overstromen, weet jij die zorgzaamheid vorm te 
geven zonder dat iemand het ooit als een overvloed beleeft. Je hebt een formidabel 
talent jezelf weg te cijferen, en nooit in een strijd te belanden slechts om het uitoefenen 
van macht. Toch -wanneer jou iets aan het hart gaat, zal wat jij wil ook gebeuren, en 
daarmee schuilt in jou een bewonderingswaardig grote kracht, die misschien niet door 
eenieder wordt opgemerkt, maar altijd aanwezig is. Ik zie elke dag uit naar de ochtend 
en welterusten appjes die altijd een glimlach bij me ontlokken, omdat ze me telkens 
herinneren dat je er altijd voor me bent. Ik zal nooit vergeten hoe het voelde toen je me 
voor de deur van de Schaepmanlaan uitzwaaide, toen ik voor het eerst met een grote 
weekendtas vol kleren naar m’n kamer in Tilburg afreisde. 
Babs, m’n grote zusje, ik herinner me nog meer dan goed dat ik bij pa en ma thuis zat 
te wachten tot je belde vanuit het ziekenhuis. Ik beeldde me in dat het krijgen van een 
nichtje – het eerste kindje van m’n zus, me heus niet zoveel zou doen. Laconiek liep ik 
door de schuifdeuren van het Groot Ziekengasthuis, nog wat slaapdronken gezien het 
vroege uur. Ik heb nog nooit ergens zo ver naast gezeten. Toen ik Benthe zag, toen ik 
jou en Aaron met haar zag, toen ik d’r geluidjes hoorde, werd ik geraakt door een gevoel 
van kwetsbaarheid. Het voelde alsof ze ook (een beetje) bij mij hoorde. Ik weet vrij zeker 
dat –hoewel ik daar (zoals het hoort) zelf nooit direct getuige van ben geweest, je tegen 
anderen met veel trots over me spreekt. Ik hoop dan ook dat het je niet zal verbazen 
als ik zeg dat ik over jou aan anderen ook met heel veel trots vertel. Hoe jij in staat bent 
mensen met een volstrekt uniek en verschillend ontwikkelingsniveau, individuele en 
extreme gevoeligheden, handicaps, persoonlijkheden, temperamenten en culturen te 
doorgronden, te weten wat ze voelen en wat ze bedoelen als ze zich op een voor een 
normaal iemand totaal onverklaarbare manier uiten en gedragen, vind ik fenomenaal. 
Het duizelt me helemaal als ik bedenk dat je ook nog in staat bent de groepsdynamiek 
en interacties tussen zulke individuen te managen. Wat me daarom weer niet verbaast 
is dat je samen met Aaron twee zulke heerlijke boefjes hebt gekregen, die met een 
gezonde overdosis aan temperament en persoonlijkheid samen de wereld aan het 
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ontdekken zijn, en waarvoor ik dankbaar ben dat ik daar als oom deelgenoot van mag 
zijn. Aaron, toen ik je voor het eerst ontmoette wist ik (en de rest van de familie) dat het 
goed zat. M’n zusje heeft (gezien haar eigen temperament –dat ik al sinds m’n geboorte 
ken ;)), een evenzo sterke persoonlijkheid als tegenwicht nodig, en het moge duidelijk 
zijn dat ze die in jou gevonden heeft. Ik zou je tekort doen om je slechts als partner/
vader van aan te duiden, dus wil tenminste hebben opgemerkt dat ik een ongekend 
respect heb voor de manier waarop je je werk, gezinsleven en leidende rol als oudste 
zoon van je familie in Cromvoirt weet te combineren. Daarnaast ben je waanzinnig 
sociaal en gevat, en weet je overal -van een lokale kroeg tot de meest pretentieuze 
hipster lounge van Rotterdam, een feestje te bouwen.
Lieve Sanne, hoewel onze ontmoeting vrij exact te duiden is (een kerk!), evenals het 
tijdstip en de omstandigheden, weet ik eigenlijk niet goed waar te beginnen. Beiden 
met torenhoge muren ter bescherming van onze meest kwetsbare gevoelens, beiden 
met een sterk gevoel van trots en eigenwaarde, en elk een vrij extensieve geschiedenis 
in (bijna) totaal verschillende werelden, begon een reis van uitersten. Extreem dichtbij 
en soms extreem veraf, als twee sterk gepolariseerde magneten waarvan de richting van 
het veld soms ineens om kon slaan. In dat proces heb ik dingen met je gedeeld, beleefd 
en ervaren die ik onmogelijk ooit nog met iemand anders op die manier zal kunnen. 
Terugkijkend daarop zijn het niet eens (de intensiteit van) die ervaringen op zich die me 
bijstaan; wel dat ik ze heb mogen beleven met jou. Hoewel de richting van onze velden 
soms maakte dat er momenten zijn geweest waarop we niet bij elkaar waren, is er altijd 
een onzichtbaar lijntje geweest dat ons onlosmakelijk met elkaar verbond. En dat lijntje 
zal voor altijd blijven bestaan. 
Leden en oud leden van de ART groep, Farzin, als twee ‘laatste der Mohikanen’ troffen 
we elkaar vaak op latere uren op de 25e. Er zijn onnoemelijk veel zaken waarmee jij je 
tegelijkertijd bezig kan houden en succesvol in weet te zijn. Daarnaast ken jij op tal 
van terreinen wegen waarvan ik –wanneer je ze niet met me had gedeeld, het bestaan 
nooit had weten te vermoeden. Nathalie, jij hebt me als eerste ooit meegenomen naar 
de Frankborrel, waarmee er een wereld voor me openging. Een vrij omvangrijke wereld 
mag ik wel zeggen ;)
Alle andere leden, collega’s, jaargenoten, teveel om met naam en toenaam op te 
noemen: hartelijk dank!
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